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Chapter I
Introduction 
Welcome to the United Nations International Drug
Control Programme (UNDCP) practical guide for the
planning and implementation of drug abuse treatment
and rehabilitation services. Drug Abuse Treatment and
Rehabilitation: a Practical Planning and Implementation
Guide is designed to be a practical resource for
Governments, policy planners, service commissioners
and treatment providers. The material presented is
intended to be of value in a wide range of national and
cultural contexts. A key audience for this resource is
communities in which there is currently little or no pro-
vision for the treatment of substance abuse problems.
The Guide should also be of interest and value for com-
munities where treatment services are well developed
but need further integration. 
Developing a practical guide in this area is a challenge,
primarily because its target audience is so diverse and at
different stages in developing and delivering treatment
services. There is also considerable international varia-
tion in strategic and practical terms in the way in which
States tackle drug abuse and related problems.
Nevertheless, there is an international trend towards
convergence on key ideas that underpin successful 
treatment and rehabilitation. The Guide is therefore
founded on core principles that are important when
considering, planning and delivering clinically and eco-
nomically effective services.
The Guide has been developed on the basis of interna-
tional experiences in the planning, operation and evalu-
ation of services in different countries. It aims at pro-
viding a broad up-to-date framework to guide planners
and implementers through a number of key steps
required for the initiation and the further development
of treatment and rehabilitation services. It is hoped that
the material will be of particular value to countries that
are interested in developing or enhancing the capacity of
their treatment services.
A.   Cultural settings
The Guide is designed to be applicable to a wide range
of cultural settings where there is substantial variation in
perspectives on addiction and some major economic,
cultural, religious and political dimensions that affect
the ways in which different societies tackle drug abuse.
Such variation adds to the rich and diverse nature of the
responses to drug abuse problems. There is a critical
need for key cultural issues to be respected. The Guide
is based on the principle that treatment programmes
that have been shown to be effective in one cultural set-
ting should be capable of adaptation for use in other
cultural contexts. 
B.   Resource constraints
The resources available in different communities vary
widely and the Guide recognizes that some countries
face major resource constraints in the development of
services. However, drug abuse problems now cause a
substantial burden to almost all societies and, in all set-
tings, it is vital to invest time and energy in responding
to those problems. Such an investment is of particular
importance in resource-poor settings where hidden costs
and burdens related to drug abuse problems (for exam-
ple, costs to the health system, loss of productivity at
work and criminal justice costs) cause substantial
demands on resources that might be directed elsewhere
if comprehensive prevention and appropriate interven-
tion strategies were in place.
C.   Principles underpinning the Guide
The Guide takes a positive philosophical stance to tack-
ling drug abuse and related problems. Such a stance is
based on the emergence in many countries of robust
research evidence indicating that well-organized treat-
ment and trained and supportive treatment personnel
can have a rapid and lasting impact on people affected by
drug abuse. That provides a clear rationale for national
and international policy makers to strive to ensure that
resources are made available to tackle the serious problem
of drugs and drug abuse in a constructive fashion. 
Investing in treatment has been shown to reflect sound
judgement in human and economic terms. As the com-
panion publication to the present Guide, Investing in
Drug Abuse Treatment: a Discussion Paper for Policy
Makers [1], further elaborates, it is possible to identify a
range of effective treatment approaches as well as impor-
tant active ingredients of effective treatments. It will
then be important to adapt those elements within the
context of different sociocultural and economic circum-
stances [2].
The preparation of the material in the Guide was based
on the following 11 guiding considerations:
• People with drug-related problems often have multi-
ple treatment needs across a range of personal, social
and economic areas;
• Drug abuse problems can be treated effectively if
people can access treatment and rehabilitation serv-
ices that are appropriate to their needs and of suffi-
cient quality, intensity and duration;
• The financial support that underpins treatment and
rehabilitation should be directed to those services
that have an impact of proven efficacy; 
• No one single treatment approach is effective for
everyone. People may need different types of treat-
ment, which are integrated and coordinated effec-
tively, at different times and stages in seeking help;
• People should be able to access or be referred to the
treatment that best meets their needs. Treatment
services should take into account specific needs rela-
ted to gender, age, health and risk behaviours;
• The prevention of blood-borne infections, including
the human immunodeficiency virus (HIV) and hep-
atitis B and C, is a key component of a comprehen-
sive treatment approach;
• Treatment services should, as far as possible, build
on, link with and integrate with existing health and
social agencies and provide a continuum of care.
They should also include community-based support
services;
• The coordination of care is an essential task of any
effective and efficient treatment system;
• Effective planning for treatments should involve a
partnership between Government and regional and
local governmental and non-governmental agencies
and providers, service users [3] and the community;
• Treatment and rehabilitation services should play a
key role in reducing the social stigma and discrimi-
nation against drug abusers and supporting their
reintegration into society as healthy and productive
members of the community; 
• Research activities should be geared towards filling
key gaps in knowledge about the effectiveness of
treatment approaches and treating specific groups.
Staff training should follow suit. 
D.   How the Guide was constructed
The Guide has been developed through the partnership
of an international team of experts from Australia,
Thailand and the United Kingdom of Great Britain
and Northern Ireland, engaged by UNDCP, and
United Nations treatment and demand reduction
experts. The emphasis throughout has been on con-
sulting with a wide range of audiences about the mate-
rial. In doing so, the goal has been that no one profes-
sional or country approach should predominate.
Rather, a multidisciplinary perspective has been taken
so that the material contains contributions from the
perspectives of general medicine, psychiatry, psycho-
logy, social welfare and justice. The international team
of experts drafted the initial version of the core sections
of the Guide between October 2000 and January 2001.
A meeting of the core team with international experts
from Colombia, Nigeria, Pakistan and the United
States of America was held in Vienna from 26 to 28
February 2001 to review the draft material and further
consider relevant issues. Practical examples of how dif-
ferent communities have tackled treatment and reha-
bilitation issues were provided by sources from a broad
range of countries in close liaison with UNDCP field
offices. Where possible, the material in the Guide is
supported by key citations from the resource literature,
with an emphasis on materials that can be accessed
using the World Wide Web.
Pilot testing and/or review of the Guide was then con-
ducted in a range of countries in Central America and
South America (Bolivia, Costa Rica, El Salvador,
Guatemala, Guyana, Honduras, Mexico, Nicaragua and
Panama); East Africa (Ethiopia, Kenya, Mauritius,
Seychelles and Uganda); the Middle East (Egypt and
Jordan); and South Asia (Pakistan) and South-East Asia
(Lao People's Democratic Republic and Myanmar). A
draft version of the Guide has also been peer-reviewed
by senior treatment and drug demand experts based in
Canada, the Netherlands, Switzerland, the United
Kingdom and the United States.
E.   Purpose and structure of the Guide
The Guide promotes a systematic approach to thinking
about drug abuse problems and abusers in need of treat-
ment, as well as to planning and implementing services.
It advocates a logical, step-by-step sequence that links
policy to needs assessment and treatment planning and
implementation to monitoring and evaluation. 
In addition to the present introduction, the Guide
includes the following chapters: 
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Chapter II: Developing a strategic framework for
treatment; 
Chapter III: Assessing treatment needs; 
Chapter IV: Effective treatment and rehabilitation
services; 
Chapter V: Developing and implementing treatment
services; 
Chapter VI: Effective integration of treatment services; 
Chapter VII: Monitoring treatment activity and out-
come.
Chapter II describes the core components of a strategic
plan or policy on drug abuse treatment and rehabilita-
tion and how such a plan or policy can be developed
and implemented. The material deals with how treat-
ment fits into the broader policy concerns and legal
framework in a country and how best to judge the
progress of the policy against its goals and objectives.
Chapter III describes how best to conceptualize the
issue of "need for treatment” and how to look at the
population in a country in terms of the sorts of prob-
lems that they might have and the different groups that
may be important to consider. Practical suggestions are
then offered to conduct a needs-assessment exercise that
can be used on a routine basis. 
Chapter IV considers the range of treatment and reha-
bilitative services that have been shown by research
studies to be effective. The material should be of practi-
cal benefit when considering exactly which types of
treatment to develop to tackle specific problems.
Chapter V should be read in conjunction with the com-
panion publication Contemporary Drug Abuse Treatment:
A Review of the Evidence Base [4].
Chapter V offers practical guidance on developing sin-
gle treatment services or more elaborate treatment and
rehabilitation systems. Those responses to assessed needs
incorporate evidence-based treatment services from
chapter IV. Practical step-by-step suggestions for how to
take the planning process forward are dealt with in that
central part of the Guide.
Chapter VI continues the planning and developmental
work of chapter V. The focus is on ensuring that single
services and several types of services work in an inte-
grated and efficient manner and on how best to ensure
that teams work effectively. 
Chapter VII links with all the preceding chapters of the
Guide. It looks at the issue of evaluating or monitoring
the delivery of treatment and assessing its effectiveness.
Practical suggestions are offered on how best to gather
basic or more complex information about how a treat-
ment service works and how well it is meeting its stated
objectives.
The following six chapters of the Guide can be read in
sequence or independently. For countries that are con-
sidering developing their treatment capacity, it is sug-
gested that chapters II to VII of the Guide be followed
in sequence. Countries with developed systems may be
inclined to focus on chapters VI and VII, but may
nonetheless find chapters III and V of interest when
organizing a new assessment of need in a particular
community or for dealing with a newly emerging drug
abuse problem and how best to respond to it. 
The following self-assessment questionnaire may be
helpful in deciding how best to use the Guide.
F.   How to use the Guide
UNDCP recognizes that many readers will approach
the Guide with a specific interest or strategic need. In
order to help the reader to navigate through the mate-
rial, several questions about the context and situation
for each reader are set out below in a self-assessment
questionnaire. Completing it may help the reader to use
the material in the Guide as a practical tool. 
I.3
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Self-assessment questionnaire
Q1. Does your country have a national policy or strategic plan that covers drug abuse treatment and rehabili-
tation?
No Begin at chapter II then go to Q2.
Yes Does that include performance indicators and targets to monitor progress?
Yes - Go to Q2.
No - Begin at chapter II then go to Q2.
Q2. Do you need to work out how to assess which drug problems require treatment and what sort of treatment
may be needed to tackle known drug problems in a particular community or population group?
Yes See chapter III then go to Q3.
No Go to Q3.
Q3. Do you need to review the range of services that have an international research evidence base for their
effectiveness in treating drug abuse?
Yes See chapter IV then go to Q4.
No Go to Q4.
Q4. Is there a need to develop a new treatment and rehabilitation centre or improve existing services in one or
more parts of the country?
Yes See chapter V then go to Q5.
No Go to Q5.
Q5. Is there a desire to review the operation of existing services or enhance the links and effective integration
and coordination between services?
Yes See chapters VI and VII.
No Go to Q6.
Q6. Is there a need to improve the arrangements for monitoring the operation and performance of treatment
and rehabilitation services in one or more areas?
Yes See chapter VII.
II.1
In chapter II of the Guide, the following question is
asked: “How should a strategic framework for treatment
be conceptualized, and what are the key issues that need
to be addressed when developing and implementing a
treatment policy and plan?” 
The benefits of reading and using Chapter II of the
Guide are as follows:
• Placing the development of treatment services into
broader strategic and legal frameworks for drug con-
trol and demand reduction;
• Recognition of the importance of setting measurable
objectives and policy planning priorities;
• Understanding the key elements and guiding princi-
ples of a treatment policy;
• Understanding the need for multisectoral partner-
ships for the development and the effective delivery
of treatment services.
The material in Chapter II deals with the elements of a
strategic framework and how those fit into a wider
national plan on drugs. It is designed to assist in the task
of developing a treatment strategy. The target audience
for Chapter II is policy makers and senior professionals
and their advisers from national and local bodies,
including government departments (health, justice and
social welfare) and regional and state agencies. Other
important stakeholders that need to be committed in
the development of the framework include individual
treatment providers, services users and community
groups and advocacy organizations that will also have a
role to play in the development of the strategy.
Chapter II of the Guide should be read with reference to
the partner document Investing in Drug Abuse
Treatment: A Discussion Paper for Policy Makers. That
concise document considers the expectations that soci-
eties have in treating drug abuse problems and the
nature of return on investment that is likely to be seen
from providing treatment services in terms of improved
health for individuals and reduced social problems for
families and communities. It specifically considers the
impact of various forms of treatment in the light of non-
treatment alternatives—such as no treatment at all and
criminal justice interventions—and argues the case for
treatment being included in the mix of policy options
that form part of the national framework. 
Chapter II is divided into three sections. Section A
introduces the rationale for a strategic framework and
addresses treatment definitions and principles underly-
ing policy and the key features that are usually con-
tained in a strategic plan. Section B addresses the legal
and regulatory background to the strategy and legal
issues concerning treatment provisions, professional
conduct, treatment quality and operational issues, fiscal
and contracting issues, and treatment in the criminal
justice system. Section C looks at developing and
implementing the strategy and considers the importance
of involving different partners; ensuring policy commit-
ment; conducting sound assessment and planning;
building on research evidence; developing an incremen-
tal and step-by-step approach; fostering collaboration
and integration; building on community-based respon-
ses; ensuring service diversification, availability and
accessibility; and monitoring performance.
A.   Strategic definitions and principles 
Today, almost all countries need to consider how best to
respond to the abuse of one or more psychoactive sub-
stances that are causing problems for individuals, fami-
lies and communities. Those drugs include cannabis,
opioids (such as heroin), cocaine, amphetamine-type
stimulants, sedatives/tranquillizers, hallucinogens, sol-
vents/inhalants and alcohol. The response of a country
to drug abuse is best organized and guided by a public
policy and a strategic framework. While it is possible to
develop a single treatment programme or an entire
treatment system without such a framework, there are
substantial benefits in establishing one. The value of the
strategic framework lies in the way in which it commu-
nicates, in a clear and concise document, the nature of
the problem, the actions that the country is taking to
tackle it and what sort of results are expected.
The development of contemporary treatment responses
to drug abuse at the local, regional or national level is
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best guided by a public policy and a planning process to
develop the strategic framework. Such a framework for
treatment should fit within the context of the drug mas-
ter plan of the country concerned or the national drug
policy framework, and should become an important ele-
ment of the demand reduction strategies embedded
within those documents.
1.  Defining treatment
Before working towards a strategic policy of treatment,
a clear conceptualization and definition of treatment
itself is needed.
Treatment can be defined in general terms as the provi-
sion of one or more structured interventions designed to
manage health and other problems as a consequence of
drug abuse and to improve or maximize personal and
social functioning. According to the World Health
Organization (WHO) Expert Committee on Drug
Dependence, the term “treatment” refers to “the process
that begins when psychoactive substance abusers come
into contact with a health provider or any other com-
munity service, and may continue through a succession
of specific interventions until the highest attainable level
of health and well-being is reached [5].”  
The United Nations Office on Drugs and Crime of the
Secretariat (formerly called the Office for Drug Control
and Crime Prevention of the Secretariat) publication
Demand Reduction: A Glossary of Terms adds:
“Essentially, by providing persons, who are experiencing
problems caused by their use of psychoactive substances,
with a range of treatment services and opportunities
which maximize their physical, mental and social abili-
ties, these persons can be assisted to attain the ultimate
goal of freedom from drug dependence and to achieve
full social reintegration. Treatment services and oppor-
tunities can include detoxification, substitution/mainte-
nance therapy and/or psychosocial therapies and coun-
selling. Additionally, treatment aims at reducing the
dependence on psychoactive substances, as well as
reducing the negative health and social consequences
caused by, or associated with, the use of such substances
[6].”
The nature of treatment interventions, including med-
ical, psychosocial, traditional healing and other rehabil-
itative services, can take a different form across different
countries. Those interventions are not static and are
subject to various political, cultural, religious and eco-
nomic factors that influence how they are organized and
delivered and how they evolve over time.
2.  International consensus on treatment 
strategy development
There is now a consensus among the States Members of
the United Nations to invest and develop a range of pre-
vention and treatment activities. The Declaration on the
Guiding Principles of Drug Demand Reduction states
that “Demand reduction programmes should cover all
areas of prevention, from discouraging initial use to
reducing the negative health and social consequences of
drug abuse. They should embrace information, educa-
tion, public awareness, early intervention, counselling,
treatment, rehabilitation, relapse prevention, aftercare
and social reintegration. Early help and access to servi-
ces should be offered to those in need.” The Declaration
also set out specific principles that should underpin
strategy development. Those principles are summarized
in box 1.
Box 1
Declaration on the Guiding Principles of
Drug Demand Reductiona
“8.  … in accordance with the principles of the
Charter of the United Nations and international law,
in particular, respect for the sovereignty and territori-
al integrity of States; human rights and fundamental
freedoms and the principles of the Universal
Declaration of Human Rights; and the principle of
shared responsibility: 
(a) There shall be a balanced approach between
demand reduction and supply reduction, each re-
inforcing the other, in an integrated approach to 
solving the drug problem; 
(b) Demand reduction policies shall:
(i) Aim at preventing the use of drugs and at
reducing the adverse consequences of
drug abuse;
(ii) Provide for and encourage active and coor-
dinated participation of individuals at the
community level, both generally and in sit-
uations of particular risk, by virtue of, for
example, their geographical location, eco-
nomic conditions or relatively large addict
populations; 
(iii) Be sensitive to both culture and gender; 
(iv) Contribute to developing and sustaining
supportive environments.”
“10.   Demand prevention programmes should cover
all areas of prevention, from discouraging initial use to
reducing the negative health and social consequences
of drug abuse. They should embrace information, edu-
cation, public awareness, early intervention, coun-
selling, treatment, rehabilitation, relapse prevention,
aftercare and social reintegration. Early help and
access to services should be offered to those in need.” 
aGeneral Assembly resolution S-20/3, annex.
Most countries have a national drug master plan or a
broader national policy framework designed to organize
and guide how the country is tackling the problem.
Because drug abuse problems can affect many sections
of the population and lead to health, social and legal
problems, those plans are often integrated within exist-
ing law enforcement, justice, education, health, labour,
agriculture, economic and social policy. 
Successful drug abuse treatment strategies must be
placed in that broader policy framework where drug
supply and demand reduction are of central importance.
Treatment and prevention responses are critical dimen-
sions that support the successful implementation of a
balanced demand reduction response. While prevention
policy is not within the remit of the present study, it
must be developed at the same rate as treatment policy
if an overall balanced approach is to be achieved.
Overall, strategic planning is a critical task in which one
or more agencies determine the nature and extent of the
needs of a population and establish a framework to
make the best use of resources to address those needs.
3.  Key features of a strategic framework 
for treatment
There is a growing expectation in many communities
that a range of treatment services should be accessible,
regardless of age, race, gender, sexual preference, social
and economic class and location. The key to successful
responses to drug abuse is partnership and active cooper-
ation between central and local governments, non-gov-
ernmental agencies, service providers and the commu-
nity. Drug abusers are often a stigmatized population and
the community partners may need to take an advocacy
role along with opinion leaders to promote understand-
ing of drug abuse problems and how they can be effec-
tively treated. Support for treatment services in the com-
munity is clearly advantageous. It can foster a positive cli-
mate of drug abuse prevention and can help to ensure
that the interventions receive the necessary resources for
the operation and development of the services.
A treatment framework presents a description of impor-
tant principles that underlie the approaches to treatment
in the country and set out the goals, objectives and activ-
ities for the national treatment system. Resources, agen-
cies and organizations involved in delivering outputs
based on the framework are identified, allowing the activ-
ities to be monitored through achievement indicators. 
In some countries, plans of that nature have evolved to
become detailed and elaborate policy and action state-
ments. However, a strategic framework document does
not have to be long and detailed. It does, however, need
to reflect the cultural and economic context of the
nation and its identified priorities in tackling the prob-
lem. It is important to state the overall principles and
goals clearly in the framework document. It is also
important to set out specific activities that will be
undertaken, together with an agreed set of indicators
that are to be used to judge how well the strategy is
meeting its objectives. Importantly, strategic frame-
works for treatment are best viewed as living documents
that have a fixed lifespan and are subject to regular
review and updates as required. 
Although they vary, strategic plans on drug abuse share
some common features. In particular, most plans: 
• Estimate and describe the populations affected by
drug abuse and the nature and extent of the prob-
lems to be treated;
• Summarize the beliefs, values, goals and objectives of
the national, regional, community and service
provider agencies that are to be involved in tackling
the problem;
• Identify a governing body or individual who will
have responsibility for governance of the policy;
• Describe the general roles of each of the national,
regional and local (governmental and non-govern-
mental) agencies involved and how they will con-
tribute to the various stages of the planning and
implementation of the policy;
• Specify the mechanisms for community involvement
and representation;
• Specify the legislative framework and provisions that
will allow treatment to take place;
• Detail specific types of treatments that are to be
developed or otherwise enhanced, and the activities
that need to be undertaken to do that;
• Specify the levels of financial and human resources
that will be made available;
• Identify realistic outcomes that can be expected from
treatment and the methods to assess the attainment
of those outcomes;
• Specify how the strategy will be monitored and
reviewed and its operation and impact communicat-
ed and considered within the nation.
As examples of national drug abuse policies, the key ele-
ments of the national drug strategic framework of
Australia are described in box 2 and the national treat-
ment service network of the Government of Spain is
described in box 3. 
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Box 3
Services offered by the Spanish treatment and rehabilitation network
At present Spain has a consolidated and diversified network of programmes and resources offered to drug abusers,
including a variety of actions to meet the different needs of the consumers and their families. 
The network depends on the communities and autonomous cities, the local entities and the non-governmental
organizations that deal with drug addiction. 
The majority of people receive care in outpatient treatment services, with methadone prescription and/or dispensa-
tion services being the second type of resource most frequently used. 
In that sense, the substantial increase in the latter type of programme (that of methadone maintenance), and in gen-
eral all those directed towards reducing the harm associated with drug consumption (vaccination programmes,
syringe dispensation and exchange programmes, sanitary kits etc.) in the last few years must be emphasized. 
The objective of other programmes is that of incorporating into society the people who are affected by drug addic-
tion and are under treatment. The programmes include academic and professional training and integration into the
labour force (work in handicraft workshops, specific employment programmes, promotion of self-help cooperatives
etc.), as well as residential support (by means of half-way houses or foster families etc.). 
In relation to the promotion of work incorporation programmes, and in accordance with a collaboration agreement
between the Ministry of the Interior and the Ministry of Labour and Social Matters, five thousand places have been
made available to promote the integration of drug addicts into the labour force via the National Training and
Professional Integration Programme.
In addition, a global intervention programme for drug addicts with legal or penal problems include the following
strategies: alternatives to custodial sentences; programmes in police stations and courts; and intervention pro-
grammes in penitentiary institutions, especially treatment with methadone.
Source: Plan Nacional Sobre Drogas of Spain. For further information, go to http://www.mir.es/pnd/presenta/html/user.htm
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Box 2
National drug strategic framework of Australia, 1998/99 to 2002/03
The Government of Australia has developed a national drug strategic framework for 1998/99 to 2002/03.
Access to treatment, building partnerships, links with other strategies and professional education and training are
four of the eight priority areas identified in the strategic framework.
Under the heading “access to treatment”, the strategic framework sets out the following areas for future develop-
ment of treatment services:
• Improving the range of services available, for example, by developing a range of effective alternative pharma-
cotherapies for the treatment of opioid dependence to better tailor treatment to individual needs;
• Improving the effectiveness and quality of services, for example, by ensuring that service provision is evidence-
based and provided by experienced and appropriately qualified staff;
• Improving access to services and ensuring community acceptance of services, including the development of
services for specific population groups (young people, indigenous people, women with children, people who
live in rural and remote areas, people from culturally and linguistically diverse backgrounds) and improving the
delivery of culturally responsive services from mainstream treatment facilities;
• Increasing the involvement of mainstream service providers, such as general practitioners and hospitals, in early
intervention and relapse prevention;
• Building stronger links between drug treatment services and mental health services, to improve service provi-
sion in both sectors and in mainstream health services for the management of clients with coexisting mental
health and drug problems;
• Improving access to treatment for people in the criminal justice and juvenile justice systems, including expand-
ing the use of diversion programmes to enable those apprehended for minor drug-related offences to be 
diverted to a range of appropriate drug treatment services.
For further details, go to http://www.health.gov.au/pubhlth/publicat/document/ndsf.pdf
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B.  Legal and regulatory background
International drug control treaties provide the legal
foundation for action related to drug control. The
Single Convention on Narcotic Drugs of 1961 [7], the
Convention on Psychotropic Substances of 1971 [8]
and the United Nations Convention against Illicit
Traffic in Narcotic Drugs and Psychotropic Substances
of 1988 [9]  include provisions requesting the States
Members of the United Nations to give special attention
to, and take all practicable measures for, the early iden-
tification, treatment, aftercare, rehabilitation and social
reintegration of individuals with drug abuse problems.
The Member States are also requested to promote the
training of personnel in the treatment, aftercare, reha-
bilitation and social reintegration of drug abusers [10]. 
Responding to drug abuse problems is a complex area
of social intervention that will often include a wide
range of agencies, including social services, criminal
justice agencies such as the police, probation and
prison authorities, as well as other health and social
agencies. 
A range of legal issues and provisions affect the organiza-
tion and delivery of treatment for drug abuse and
dependence. There is a marked variation between coun-
tries in the nature and scope of those legal controls. In
many cases, legal provisions affecting substance abuse
treatment are not found in one single law or legislation,
but are included in different regulations such as drug
laws, consumer rights provisions or regulations concern-
ing medical practice. In all cases, there needs to be a high
degree of consistency between the strategic framework
for treatment and relevant national legislation and regu-
lations. Drug control legislation will frequently precede
the development of treatment strategies. In such cases, it
will be necessary to analyse existing laws for consistency
with the envisaged policies and strategies for national
treatment and modify them if necessary. The remainder
of the present section highlights legal issues in nine areas.
1.  Designation of treatment authority
A key aspect frequently covered by legislation regulating
substance abuse treatment and rehabilitation is the desig-
nation of responsible agencies. Given the personal health,
Box 4
Legal Provisions on drug treatment in Slovenia
The Slovene Law on the Prevention of the Use of Illicit Drugs and Dealing with Consumers of Illicit Drugs (1999) defines,
inter alia, measures for the treatment of drug abuse and dependence. The law determines that the treatment of con-
sumers of illicit drugs should be carried out through hospital-based and outpatient-clinic treatment programmes
approved by the Health Council. 
The minister responsible for health is to appoint a body for the coordination of the centres for the prevention and treat-
ment of addiction to illicit drugs. That body develops the addiction treatment policy, verifies the implementation of the
policy, and coordinates professional cooperation between the centres for the prevention and treatment of addiction to
illicit drugs. In accordance with the act regulating medical activities, treatment includes maintenance with methadone
and with other substitutes approved by the Health Council.
Outpatient centres for the prevention and treatment of addiction to illicit drugs is organized at the primary care level as
part of the public health service network. Services provided in outpatient centres include the methadone maintenance
programme.
In addition, the Government of Slovenia is to establish a public health institution in charge of the implementation of hos-
pital-based and specialist outpatient-clinic treatment—the Centre for the Treatment of Illicit Drug Addicts. Hospital treat-
ment is deemed to include hospital detoxification, psychosocial treatment, extended treatment and health rehabilitation.
According to the Law, resident communities are deemed to be therapeutic communities that carry out professional ther-
apeutic and rehabilitation programmes, communal groups with a programme that is mainly based on mutual help, and
special-care homes with a programme that is mainly based on life and work in groups. 
The Law also addresses the need for the involvement of non-governmental organizations and the coordination of their
activities with the national programme. 
It is foreseen that the funds for co-financing the implementation of prevention and treatment programmes and for moni-
toring consumption will be provided from the national budget. The activities of non-governmental organizations are to be
co-financed from the national budget and other funds. Participants in a programme are to contribute part of the payments.
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social, familial, economic and criminal problems that are
associated with substance abuse, it is common for several
central and local government departments to take an
active role in tackling the issue. Drug abuse strategies are
often drafted as statements of core policy with a broad
partnership and designation of authority within govern-
ment, albeit with a lead department assigned with overall
responsibility for policy analysis and direction. Historical
precedent and the organization of the health-care and
social welfare system in the country typically determine
the balance of responsibility between departments.
Whatever balance is established, the result should be to
ensure effective coordination of treatment services. An
example of how designation of treatment authority and
the overall coordination of services have been established
in Slovenia is shown in box 4. 
2.  Professional standards and conduct
Personnel working in treatment services who have a for-
mal professional qualification should work in the context
of a professional code of conduct and usually a regulatory
and supporting professional body. There may also be an
overarching association of professionals working in a 
particular discipline in the substance abuse area—such as
counselling. Professional standards may include:
• A commitment to ensuring that no professional will
discriminate against clients on the basis of their gen-
der, race, religion, sexual orientation or disability;
• Adherence to the governing regulations and stan-
dards pertaining to the conduct of their work and
the provision of information to clients in relation to
their treatment;
• Specific adherence to the promotion of the rights of
clients, including the right to confidentiality, with
respect to the preparation, storage and communica-
tion of records and clinical information;
• Ensuring that the professional has the required level
of competence to carry out a specific duty and that
routine supervision and continuous education and
training are provided as required;
• A demonstrated commitment to the values and goals
of an organization, as evidenced by participation in
quality assurance and strategies for monitoring per-
formance and outcome on a routine basis.
The elements of a professional code of conduct may
include: the safety of professionals; roles and limitations
of professionals; rules of disclosure; and measures and
sanctions in case of misconduct. The professional body
usually has some statutory powers to investigate and/or
suspend an individual from duty. Most professionals
working with substance abusers are required to have
professional insurance or indemnity coverage. 
3. Rights and duties of treatment 
programme participants
Many countries have enacted general legislation on
individual rights to health and social care with no spe-
cial reference to drug abuse. Under those general pro-
visions, drug abusers have the same rights to receive
treatment as persons with other chronic health disor-
Box 5
Practical application of legislation on consumer rights to drug abuse prevention and treat-
ment
The United States Substance Abuse and Mental Health Services Administration has produced guidelines on the rights
of clients in drug abuse prevention and treatment services. It is a practical application of United States legislation on
consumer rights and considers key issues that have arisen in implementing a Consumer Bill of Rights and
Responsibilities in the contexts of mental health and chemical dependency prevention and treatment. A range of
issues have been addressed along with practical operational guidance and examples of how those rights and respon-
sibilities may be put into practice. The following issues are covered in connection with guidance:
Information disclosure Providers and plans
Emergency services Treatment decisions
Respect and non-discrimination Confidentiality of health information
Complaints and appeals Consumer responsibilities
Access to services Ombudsman programmes
Health literacy Glossary of terms
For further details, go to http://www.samhsa.gov/mc/content/cbr/index.htm
ders. Those rights may be expressed in different ways in
a variety of policies and statements, including: the
individual dignity of the person; the provision of non-
discriminatory services; access to treatment services
that are appropriate to individual needs; and advocacy
and counsel arrangements that relate to criminal justice
proceedings. Users of services are also bound by a state-
ment of their duties in relation to treatment services,
usually concerning their behaviour and appropriate
conduct and participation in the therapeutic pro-
gramme.
In many countries, service users benefit from rights and
charters that provide for the right to complain about
inadequate treatment and the right for a client to see
and obtain a copy of all clinical records kept on them.
Confidentiality regulations are also well established in
many treatment systems. They usually restrict treatment
providers by establishing an absolute minimum legal
requirement for releasing to, or seeking from, a third
party personal and treatment-related information about
an individual without informed written consent.
Detailed consideration of those issues and some practi-
cal guidelines on the rights of clients are highlighted in
box 5.
4.  Service standards and accreditation
There is a growing interest in the development of
accreditation systems for substance abuse treatment
services. Accreditation relates to a system of assurance
that a service provider meets a set of performance stan-
dards and the existing legal regulations relating to the
organization, management and delivery of treatment. 
One of the most developed accreditation systems is that
of the United States. The Centre for Substance Abuse
Treatment oversees the United States accreditation sys-
tem for substance abuse and provides technical assis-
tance to enable service providers to meet the accredita-
tion standards [11]. Box 6 describes the initiative of the
Inter-American Drug Abuse Control Commission
(CICAD) to support the development of standards of
care in the western hemisphere. 
5.  Quality and operational issues
Many countries operate quality control and clinical and
other service standards that are supported by national
and international law. Those standards may cover envi-
ronmental issues and matters such as building safety, the
privacy of clients in residential care, adequate accom-
modation (heating, lighting, food etc.) and related facil-
ities. National clinical governance regulations may also
require certain organizational policies and practices by
law, including:
• Management bodies and committees of a certain size
and composition;
• Client record keeping and data security issues;
• Procedures for risk assessment and professional dis-
closures without consent (for example, in situations
where clients are judged to be a risk to themselves
and/or to others);
• Legal registration, with a government agency, of the
agency providing treatment; 
• Procedures for the storage and disposal of controlled
medications;
• Obligations relating to staff under the employment
law.
Examples of initiatives relating to standards of care are
given in boxes 7 and 8. 
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Box 6
Supported initiative of the Inter-American Drug Abuse Control Commission: 
standards of care in drug abuse treatment
The supported initiative undertaken by CICAD since 1997 is designed to help Governments develop a consensus
within the national health-care community around the desirability of establishing standards of care, and then to
implement practices and guidelines. A long-term objective, recommended by the CICAD Expert Group on Demand
Reduction (March 1998, and again in August 2001), is to develop systems of accreditation for treatment providers.
For further information, go to http://www.cicad.oas.org/en/demandreduction/Projects/Standards.htm
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Box 7
Development of minimum standards of
care for drug abuse and dependence treat-
ment programmes in Nicaragua
The Government of Nicaragua is in the process of devel-
oping minimum standards of care for drug abuse and
dependence treatment centres or programmes, under
the coordination of the Executive Secretary of the
National Council against Drugs and the Ministry of
Health. As part of that process, a workshop aimed at
developing consensus and facilitating the drafting of
the standards was organized in Managua in January
2002, within the framework of a UNDCP-supported
regional project. A total of 31 participants from differ-
ent government sectors in charge of related matters
(health, family, drug control and criminal justice), as well
as from State and non-governmental treatment service
providers, contributed to the workshop. That level of
participation was essential to develop standards of care
that responded to the Nicaraguan reality.
The overall goal of the planned minimum standards of care
was to improve the quality of care at public and private
centres or through programmes offered to people with
problems caused by drug consumption. The identified
immediate objectives of the standards were as follows:
• To serve as reference and guidance for the work of
treatment institutions;
• To establish nationally uniform criteria for the eval-
uation of the quality of care at public and private
institutions;
• To identify the factors that are associated with non-
compliance with the newly established national
standards of care.
The workshop was based on a participatory methodol-
ogy that included working groups, brainstorming ses-
sions, discussions and presentations of participants. The
main outcome of the workshop was a consensus docu-
ment containing a total of 87 standards of care grouped
in the following categories:
• Access, availability and admission criteria;
• Client assessment;
• Nature, services and organization of treatment;
• Treatment discharge, follow-up and case referral;
• Service coverage and rapid intervention;
• Client rights;
• Physical infrastructure of treatment centres;
• Staffing.
The group agreed on an action plan for the design and
implementation of a system to monitor compliance
with the agreed minimum standards of care. The action
plan set specific target dates and established commit-
tees in charge of carrying out the actions agreed upon.
A coordinating committee led by the Department of
Mental Health of the Ministry of Health was to develop
the final document for pilot testing. The monitoring sys-
tem was expected to be in place by the end of 2002.
Box 8
Minimum standards of services in India
In accordance with its mandate for coordinating the
alcohol and drug demand reduction strategy of the
Government of India, the Ministry of Social Justice and
Empowerment, for the last 15 years, has been imple-
menting a wide range of community-based pro-
grammes, through the voluntary sector, for the preven-
tion of alcoholism and drug abuse and the treatment
and rehabilitation of addicts.
The community-based organizations associated with
the programmes have been engaged in a wide variety
of innovative, needs-based, localized interventions,
adapted to the needs of the community in general and
the target groups in particular.
Training programmes, meant for the service providers,
on the principles and practices of care and protection in
substance abuse rehabilitation have, over the years, set
certain minimum standards of services among the reha-
bilitation professionals.
However, considering the size of the country, the wide
variety of sociocultural settings and the varying degrees
of capacity among the implementing agencies, the
need has long been felt to identify the best practices in
the delivery of services and to codify them into a set of
guidelines that could be uniformly applied to all the
implementing agencies as minimum standards.
The Manual on Minimum Standards of Services for the
Programmes under the Scheme for Prevention of
Alcoholism and Substance (Drugs) Abuse is a result of
that effort. With “whole person recovery” as the avowed
objective, the Manual defines the essential components
involved in alcohol and drug demand reduction pro-
grammes under the Scheme, the minimum infrastructu-
ral requirements for each component, the nature and
quality of services, the activities involved in delivery of
different services, the inputs and the anticipated outputs
for each activity, the mandatory records to be maintained
etc. It has also laid down the framework of networking
and linkages between the services and institutions to
ensure holistic interventions and optimum utilization of
resources. Besides standardizing the experiences into
practices, it would also ensure an objective performance-
based evaluation of the programmes.
The Manual has defined a code of ethics for the service
providers, based on recognition of the rights and duties of
the clients. That is intended to ensure a positive, empa-
thetic and caring environment within the institutions.
The Manual, if implemented sincerely by the partners,
the Government and non-governmental organizations,
is expected to usher in a new era of quality-based serv-
ices through voluntary organizations in the social sector.
It would also pave the way for continuous review and
refinement in standards through new experiences and
increasing maturity in the implementation of pro-
grammes.
Source: Foreword to Asha Das, Manual on Minimum Standards of
Services for the Programmes under the Scheme for Prevention of
Alcoholism and Substance (Drugs) Abuse (New Delhi, Ministry of Social
Justice and Empowerment of India, 2001).
6.  Regulation of pharmacotherapies
A specific legal requirement concerns the provision of
medical drug abuse treatments that involve use of a ther-
apeutic drug to treat drug dependence. The most com-
monly prescribed substitute medication is methadone
for opioid dependence. International drug control con-
ventions require that controlled substances that are sup-
plied or dispensed to individuals be done so via medical
prescription only. That prescription can only be made
by an authorized (or licensed) medical practitioner.
There may also be legal controls on various aspects of
pharmacotherapies including:
• Authorized institutions and/or personnel who can
provide different treatment modalities;
• The formulation of the medication allowed (com-
monly only oral form);
• Conditions for dispensation of controlled drugs (for
example, whether the client is able to self-medicate
without supervision);
• Specified maximum dose levels for treatment induc-
tion and subsequent maintenance phases;
• Eligibility criteria for substitution treatment (for
example, minimum age, previous treatment attempt
or minimum length of time dependent);
• A requirement for regular biological testing of clients
for illegal drugs.
7.  Fiscal and contractual issues
There is enormous variation internationally in the
human and financial resources available to support
treatment efforts and the legal provisions that govern
their deployment. No matter how modest those
resources, an effective strategy should describe the level
of investment that can be expected and how it is allo-
cated to support treatment services. That may involve,
for example, national health systems funded through
individual taxation and insurance, mixed economies of
public and privately operated treatment services, or
exclusively privately funded services.
Treatment providers may have legally binding contrac-
tual arrangements with funding or sponsoring bodies
that provide financial resources for the delivery of treat-
ment. Those arrangements may refer to: 
• The provision of a specified volume of service in a
defined period; 
• The duration of any agreement for service and exit
clauses and contractual infringement aspects;
• Specified penalties for failure to provide care of a suf-
ficient volume or quality;
• Obligations on the part of the funding body or payer
concerning the timing of payments for treatment
and other financial arrangements.
There may be reciprocal arrangements in operation
between two or more countries that allow individuals to
be treated in another country. Such arrangements oper-
ate in the European Union for example.
8. Informal and formal pressures to enter
treatment 
The motivation to seek treatment may involve various
forms of pressure, both informal and formal (legally
based). Concerns about damage to family relations and
their financial situation may be in the mind of some
who decide to enter treatment. Others may be con-
cerned about the loss of employment and agree to enter
treatment under a formal referral by their personnel or
medical department. 
Direct coercion into treatment can take place in the
form of legally mandated treatment, although many
jurisdictions require the informed, written consent of
the person concerned. The written consent also provides
an important act of responsibility-taking by that person,
which can be built upon during the programme, while
providing some measure of accountability to help break
through any later obstacles to progress.
Such a measure can be a cost-effective and rehabilitative
alternative to incarceration for drug abuse offenders. In
order for it to be effective, an adequate strengthening of
the treatment system, intensive coordination and team-
work between justice and treatment agencies, and on-
going evaluation must support legal provisions.
Importantly, legal provisions must be carefully drafted,
as they imply restrictions on the basic rights to freedom
and security of the individual.
9.  Treatment in the criminal justice system
Individuals with substance abuse and dependence have
a relatively high likelihood of contact with the criminal
justice system. Referral initiated by the criminal justice
authorities, community treatments and prison-based
rehabilitation programmes can form part of the overall
treatment system. The high prevalence of substance
abusers in the prison system has led to special health
services, as well as drug dependence treatment and reha-
bilitation programmes being established within penal
institutions. 
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In many countries, legislation provides for the diversion
of drug-dependent persons from the criminal justice sys-
tem into treatment and rehabilitation programmes. In
some approaches, the police can allow a detainee access to
a specialist drug abuse referral worker who can undertake
a needs assessment and recommend a specific treatment
programme. The court may take that contact and assess-
ment into account and may itself offer a convicted indi-
vidual the chance to enter a community treatment serv-
ice as an alternative to a custodial sentence. That alterna-
tive to punishment is governed by strict requirements to
attend and comply with a treatment regime. In the event
of non-compliance, the person may be terminated from
the diversion programme, and the case returned for tra-
ditional criminal justice processing. 
Some jurisdictions offer substantial incentives to remain
in treatment and succeed. For example, in Bermuda, if
a participant is drug-free and has not reoffended by the
end of the first 12 months of a drug treatment court
programme, the original offence charged may be can-
celled. If those conditions still hold after two years, the
person's entire criminal record may be expunged. 
In some countries, the prevailing political and legislative
situation means that offending drug abusers are likely to
receive a custodial sentence without referral to treat-
ment. In those situations, arguments for the value of
developing a treatment referral option in the criminal
justice system will need to be couched in terms of the
likely cost-effectiveness of such a policy. 
UNDCP has established an online legal library that pro-
vides details of those and other related legal issues (see
box 9).
C. Developing and implementing an
effective treatment strategy
In the present final section of chapter II, attention is
directed to 11 areas that should be considered as part of
the development and implementation of a treatment
strategy. Those areas are as follows: 
• Involving partner agencies;
• Involving service users and the community;
• Ensuring policy commitment;
• Conducting sound assessment and planning;
• Allocating resources in accordance to needs;
• Building on research evidence;
• Developing an incremental and step-by-step
approach;
• Fostering collaboration, coordination and integra-
tion;
• Building on community-based responses;
• Ensuring service availability and accessibility;
• Monitoring performance.
1.  Involving partner agencies 
In a number of countries, drug abuse treatment is pre-
dominantly provided within the health sector, while, in
other countries, it tends to be provided by social welfare
agencies or predominantly in the criminal justice sys-
tem. While the balance of the contributions of the
health, social and criminal justice sectors may vary over
time, ideally all sectors should be involved. 
In addition to helping people to stop using drugs, treat-
ment services also focus on attaining immediate health
benefits through reducing harmful drug-taking and
associated behaviour that poses a health risk. Specialist
treatment programmes also need to collaborate with
other service providers to resolve the range of health,
behavioural, social and economic problems confronting
individuals and families affected by drug abuse. 
It is important to be aware of the wide array of agencies
that can be involved in modern treatment systems.
There are public sector or government-funded agencies
as well as private sector, non-governmental and other
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Box 9
UNDCP online legal library
The UNDCP online legal library makes available the
full text of laws and regulations promulgated by
States to give effect to the three main international
drug control treaties. Under the treaties, States have
an obligation to communicate their drug control leg-
islation to the United Nations. Most States communi-
cate such legislation to UNDCP on a voluntary basis.
Initially, only legislation adopted since 1990 has been
included online.
The updating of the legal library holdings relies on the
communication by States of their updated legislation.
Therefore, UNDCP cannot guarantee that the user will
always find the latest legislative status of every country.
States having adopted legislation that has been incor-
porated into the database, and that contains specific
provisions on drug treatment, include Austria, Cyprus,
France, Germany, Greece, Italy, Kenya, Nicaragua,
Poland, Portugal, South Africa, Spain, Sweden,
Thailand and the United Kingdom.
For further information, go to
http://www.undcp.org/legislation.html.
community-based, including religious, organizations. In
addition, other forms of traditional healing and social
support can play a role in the overall organization and
delivery of comprehensive treatment systems. Primary
health and social care and community-based interven-
tions are critical components if the treatment system is
to be accessible and a broad public health and popula-
tion-based approach to treatment planning and service
provision is to be used.
2. Involving service users and the 
community
There is increasing recognition that treatment service
users are part of the community and that the process of
service development needs to be accountable to and
shaped by the wide range of community interests.
Service users play an important role in helping to shape
an approach that ensures appropriate accountability and
responsibility of all those involved in providing services.
The involvement of service users in strategy develop-
ment aims at promoting the following:
• Individual behaviour change;
• Improvement of the responsiveness of health services
to user needs;
• Improvement of the utilization of health services;
• Community-oriented interventions;
• Supportive public opinion and health policy.
In the planning process, an effort should be made to
contact and involve those groups that are likely to be
affected by the development of the strategic framework
or system of treatment. That can lead to local support
and advocacy for treatment. The reduction of any local
resistance to the development of a drug abuse treatment
service in a local area should be a key objective.
When planning developments in treatment, it is impor-
tant to consult with a broad range of individuals and
groups in the community, including:
• Local community organizations;
• Clients of existing services;
• Client advocacy and representative groups;
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Box 10
Developing the national drug strategy of Ireland: the power of public consultation
The Government of Ireland developed a drug strategy during 2000 for the period 2001-2008. Part of the process of
development was to engage in a wide consultation process with the public. 
A review of the existing strategy included the extensive consultative process, research focused on international exam-
ples of best practice and an examination of various relevant evaluation reports and other literature. All statutory
authorities and key community stakeholders and professional groups were invited through national newspaper
advertisements to submit views on existing gaps and to recommend new approaches or, if necessary, new arrange-
ments through which to deliver a new drug strategy. 
Eight regional consultation forums were conducted throughout the country. At the forums, the Minister responsible
for the drug strategy presented an overview of the current strategy, followed by presentations from the sectors of
health and education, and from non-governmental organizations and the police. An open forum discussion with
questions and answers was held. That was followed by workshops on the key areas of risk reduction, treatment and
rehabilitation, supply reduction, education approaches and other issues, including emerging drug problems and gaps
in the current strategy. Subsequently, 34 groups representing government departments, agencies, service providers
and other interested parties were invited to meet the Minister and members of the Review Group to discuss their
respective contributions to overcoming the drug problem and to explore how they might address issues emerging
from the forums. 
Written evidence and oral presentations from key stakeholders were also given. The topic was then debated in both
the Senate and the Parliament and, finally, a detailed action plan and a timeline for implementation was published. 
The overall aim of the drug strategy of the Government of Ireland is to provide an effective, integrated response to
the problems posed by drug abuse. Three basic principles underpin the strategy: 
• The response to the drug problem must take into account the different levels of drug abuse being experienced
around the country; 
• All programmes and services that respond to the drug problem should be delivered in a coherent and integrated
manner; 
• Communities experiencing the highest levels of drug abuse should be encouraged to participate in the design
and delivery of the response to the problem in their areas.
For further information, go to http://www.gov.ie/tourism-sport/pressroom/archive/ndstrategy01-08.pdf
• Drug abusers who are not in treatment; 
• Parent groups and other concerned community and
• Representative bodies of professional groups;
• Social welfare and community agencies;
• Clinical staff;
• Existing drug abuse programme managers and
administrators;
• Health-care providers and organizations;
• Official policy makers and strategic planners;
• Government agencies in the areas of health, social
welfare and justice;
• Technical advisers (as required).
The value of extensive consultation to support and give
direction to the strategy is highlighted in the national
drug strategy of Ireland, described in box 10.
3.  Ensuring policy commitment 
At the political level, it may be necessary to seek support
for interventions that might otherwise be seen as inap-
propriate. In some countries, for example, there are
political and community objections to some forms of
pharmacotherapy programmes to alleviate drug depend-
ence. Public policies influence both the adverse conse-
quences of drug abuse as well as the likelihood of devel-
oping effective treatment responses. At the same time,
there is a widespread expectation that the investment of
national resources into treatment will have a beneficial
impact on reducing harms and inequalities.
Governments have a natural inclination to require
arrangements to be put in place to monitor performance
and outcome and to demonstrate a “return on invest-
ment”. In a wider context, a commitment by the
Government to a regular review of the legal framework
concerning substance abuse and treatment provision is
also advantageous, and, in some countries, specialist
professional advisory bodies are employed to inform
that process. 
4. Conducting sound assessment and 
planning
Effective treatment responses are based on sound assess-
ment. The present Guide provides the technical means
for assessing and developing needs-based interventions
associated with substance abuse. Needs-based assess-
ments allow the matching of resources, both human and
technological, to the problems as they manifest them-
selves in the community. They also ensure that services
are located where there is the greatest need. Further
guidance on how to assess the nature and extent of the
need for treatment in a particular locality or country is
provided in chapter III of the Guide.
5. Rationalizing resource allocation in
accordance with needs
In some countries, valuable experience has been gained
in revising and refocusing the current strategy for the
treatment of drug abuse. That process involves an analy-
sis of existing needs and resources and a reallocation of
resources in accordance with a set of predefined need
indicators. The example shown in box 11 reflects such a
process, where the selected indicators for the prioritiza-
tion of health services in the respective catchment areas
were the prevalence of drug abuse, the human develop-
ment index, investment by other sectors and the poten-
tial for treatment expansion.
6.  Building on research evidence
International research has provided a well-established
evidence base for the effectiveness of some types of treat-
ment, and that has done much to make the case for
treatment provision to Governments and service fun-
ders. However, the evidence is far from complete, and
some countries have to rely almost exclusively on treat-
ment outcome and other research that has been con-
ducted in other countries. It may be difficult to judge
whether the findings from other countries can be fully
applied to a particular cultural context, since there are
often marked differences in the types of people who take
part in outcome studies and in the structure and opera-
tion of the services studied. That may have led to an
increasing commitment by Governments to build on
the research evidence, and often a desire to employ and
adapt international studies and experience, as a means of
providing a sure footing for the national strategy.
7. Developing an incremental step-by-step
approach
A systematic approach should be followed to ensure the
best utilization of available resources for the develop-
ment of drug treatment services. The type of services to
be developed will obviously be determined by the
amount of available local and national resources. While,
in all cases, a combination of primary care and special-
ized services will be required, in many situations such
services will need to be developed using a “building-
blocks” approach. Where there is a major resource con-
straint, services will need to rely on the adequate train-
ing of personnel within community and primary care
frameworks. However, as soon as resources become
available, there is a possibility to add specialist services.
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Box 11
Renewed national treatment and rehabilitation programme of Chile
Over the last 10 years, the public health sector in Chile, which covers 70 per cent of the population, has implemented
a range of measures to deal with alcohol and drug problems. The main aspects of the action undertaken are as fol-
lows:
• Increasing human resources in the health services with the greatest need;
• Facilitating the stabilization of therapeutic communities;
• Training professionals in the addiction and rehabilitation field;
• Increasing the early detection of alcohol and drug abuse problems among primary health-care patients;
• Facilitating the reactivation of, and coordination with, self-help groups, especially multifamily groups. 
A 2001 in-depth evaluation of treatment plans has resulted in a decisive course of action involving the collaboration
of the Ministry of Health and the Consejo Nacional para el Control de Estupefacientes (CONACE) in a new strategy
with the following key elements:
• Institutional alliance. The Ministry of Health and CONACE, together with the 28 health services (each responsi-
ble for the health needs of from 50,000 to 1 million people) and the National Health Fund, have established an
alliance under which each party takes responsibility, as appropriate, for particular aspects such as financing, the
establishment of norms, technical support and supervision, in order to ensure more extensive and qualified care
of abusers;
• Adequate use of available information. Strategic decisions are based on objective information (for instance, last-
month prevalence and addiction rates) provided by household surveys carried out by CONACE, which permit an
estimate of potential treatment demand;
• Investment according to a needs hierarchy. Health services are ranked according to the characteristics of their
catchment areas, and more resources go to those with a higher prevalence of consumption, a lower human
development index, a higher potential for expanding treatment and a lower level of investment; 
• Designing diversified services. Six treatment plans have been created and clinical protocols to support and guide
the implementation of each plan are being drawn up. The plans are as follows:
• First-response intervention plan, implemented by the primary health-care units:
• Basic outpatient plan;
• Intensive outpatient plan;
• Residential treatment plan;
• Withdrawal syndrome treatment plan (detoxification);
• Dual diagnosis treatment plan;
• Financial transfers to treatment centres. Transfers are carried out regularly according to a previously estimated
and agreed upon workload for each centre. Funds are received from CONACE through the mediation of the
National Health Fund; 
• Records. Treatment centres keep a standard system of records to allow monitoring of the services provided to
patients, on a local and a national basis; 
• Evaluation. Two studies have been conducted: a comparative study of treatment centres and their capacities and
results; and a cost evaluation of the different treatment plans;
• Capacity-building. Programmes have been established for professionals and technicians working in rehabilitation,
including staff training to ensure the required level of quality of care. Capacity-building also involves initiating a
supervisory mechanism to solve difficulties. 
The first 10-month evaluation demonstrates satisfactory levels of functioning in most of the nearly 200 operating
treatment centres. Approximately 4,000 people have been or are in treatment. Coordination has been a significant
burden to management, but client and staff satisfaction are on the rise. The next step, currently in a preliminary
phase, will be an outcome evaluation based on information provided by regular data collection at each treatment
centre, and on the results of the three- and six-month follow-up periods after discontinuation of treatment.
For further information, go to http://www.conace.cl
8. Fostering collaboration, coordination
and integration
Treatment responses focus on multiple levels, including
individuals, families, the immediate community context
and the wider social environment. Core underlying
principles of an effective intervention response include
the need to encourage engagement at the level of the
individual, families, services, communities, environ-
ments and policies. Treatment provision should also be
seen in the context of a broad, collaborative approach
aimed at the prevention of problems and linking
schools-based and public education and communica-
tion initiatives with community-based advice, informa-
tion and treatment provision.
No single treatment is appropriate for all individuals.
Effective substance abuse responses depend on an inte-
grated response at all levels including the community.
Agencies involved in treatment programmes should not
only work together but also integrate with related pro-
grammes. Integration may include the following dimen-
sions:
• The integration of different types of demand reduc-
tion programmes, of which treatment and rehabili-
tation are a component, with each other;
• The integration of issues relating to illicit drug abuse
with the abuse of other substances and with other
general health issues, in particular HIV and acquired
immunodeficiency syndrome (AIDS);
• The integration of demand reduction and supply
reduction programmes as part of a comprehensive
strategy;
• The integration of programmes related to drug
abuse with those dealing with major social and
humanitarian issues such as poverty, housing
refugees, employment or rural development.
9.  Building on community-based responses
Strategies for community-based treatment intervention
are an effective means of delivering interventions. Many
people affected by the adverse consequences of sub-
stance abuse may have limited contact with existing
organizations. Innovative methods are needed in order
to reach populations most affected by substance abuse.
A community-based response involving local agencies
and organizations, including outreach services, is a nec-
essary component of a strategy that seeks to reach drug
abusers who are not in contact with services. A commu-
nity-based response aims at:
• Encouraging behaviour changes directly in the com-
munity;
• Actively involving local organizations, community
members and target populations;
• Establishing an integrated network of community-
based services.
It is also important to mention the term “community
empowerment”, which implies something more than
just community participation. If communities can
establish a sense of ownership of facilities and services,
the latter are much more likely to be successful and sus-
tainable. 
Being “community-based” in the context of drug treat-
ment is often perceived as involving little more than
placing a residential treatment centre in a community
with a few limited aftercare facilities provided in the
community. Many services are still based on an
approach focused on an in-patient treatment centre,
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Box 12
Community-based treatment in an Afghan
refugee camp in Pakistan
A community-based drug treatment, rehabilitation
and prevention programme was initiated by UNDCP in
the Akora Kattak refugee camp outside Peshawar
with an estimated adult population of 9,000 Afghan
refugees. The programme provided home-based
detoxification and coordinated aftercare and social
reintegration activities through a network of local
non-governmental organizations, other United
Nations agencies, volunteers and community groups.
During 2000, the programme made contact with 800
(male and female) drug abusers in the refugee camp.
Over 300 drug abusers were provided with pre-treat-
ment motivational counselling, and 128 males and
102 females were provided with home detoxification.
In addition, 150 recovering addicts were provided
with work experience, job training or start-up funding
for income-generating activities. Six self-help groups,
three for male addicts and three for female addicts,
were also established in the camp, as well as both
male and female community volunteer groups. 
The experiences from the programme suggest that a
well-resourced community-based treatment pro-
gramme with fully trained and supported staff can
provide a viable and cost-effective home detoxifica-
tion and treatment scheme for both male and female
drug abusers in Afghan communities. Such a scheme,
however, requires the full back-up and support of a
wide range of community-based aftercare and social
reintegration services and facilities, including commu-
nity networking, to be successful and effective and to
prevent relapse.
rather than on a community-based approach that tries
to establish an integrated model of drug abuse treat-
ment. Thus, while obviously both types of approaches
are necessary, and ideally should be complementary, it is
necessary to keep in mind what community-based actu-
ally means. An example of a response that specifically
targeted a community in need is given in box 12. 
As seen in box 12, the key to the success of the pro-
gramme was a radical change in the way staff under-
stood drug abuse treatment services. The new concept
relied heavily on the effective coordination of a wide
range of non-specialist services. The only infrastructure
developed in the previous example, the Community
Drug Treatment Programme Centre, was designed as a
base for outreach activities including detoxification and
family counselling, volunteer training etc. Community
drug treatment meant precisely that-treatment in the
community.
10. Ensuring service diversification, 
availability and accessibility
Key determinants of effective service delivery include
diversification, availability and accessibility. Services
need to be effective in making and retaining contact
with target populations. They need to be able to provide
a variety of services in order to be responsive to the
health and service needs of the target populations. The
key ingredients include:
• Being user-friendly;
• Geographical accessibility;
• Economic affordability;
• Community-based response;
• Provision of an adequate, coordinated mix of
agency-based and non-agency-based services;
• Encouraging client participation and involvement; 
• Providing secondary prevention as well as treatment;
• Services that are flexible and open to improvement
and change.
11.  Monitoring performance
Achieving major goals for any strategy is usually a result
of partnership and combined efforts between different
organizations. In order to monitor progress, a perform-
ance management framework is used by many countries
for each of the elements in a strategy. Two examples of
performance management frameworks are provided in
boxes 13 and 14.
Each goal of a strategy should have a core objective and
a set of indicators and targets in the short, medium and
longer term. Those indicators should, as far as is feasi-
ble, meet certain criteria. In particular, they should:
• Be specific and easily interpretable;
• Be measurable;
• Be time-bound;
• Be sensitive to change and thus capable of reflecting
progress in tackling drug abuse;
• Be feasible and affordable, in terms of a viable, eco-
nomic and sustainable measurement and reporting
system;
• Be informed by international performance indicator
systems and United Nations global reporting sys-
tems (see chapter VII, section B, subsection 1);
• Provide valuable information for strategy evaluation
and local planning.
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Box 13
The performance management framework in the United States
The Office of National Drug Control Policy in the United States has developed a performance management frame-
work based on the following structure: 
The United States approach is to develop a clear diagram called “logic model” that describes how various stake-
holders, including the central and local Government and various non-governmental organizations, contribute to
achieving the strategy.
Strategy
The strategy is to
reduce drug use
(demand), drug
availability (supply)
and consequences
thereof.
Goals
The goals define the
major directives or
directions of the
strategy.
Objectives
The objectives
define major lines of
action to achieve
the desired goals.
Targets
The targets define
desired end states
with which to com-
pare actual perform-
ance.
Measures
The measures repre-
sent means (vari-
ables and events) for
tracking progress
towards targets
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Box 14
Development of performance indicators in Wales
The Welsh National Assembly has set out the strategic plan for Wales, “Tackling Substance Misuse in Wales: a Partnership
Approach”, based on the setting and monitoring of performance indicators as a means of highlighting goals and mon-
itoring progress. Four central strands underpin the national strategy: children, young people and adults; families and
communities; treatment; and availability.
The key performance indicators for the treatment strand and additional and supporting indicators are described below.
The key performance indicators for the treatment strand are designed to increase the number of participant substance mis-
users in substance misuse treatment programmes by 40 per cent in 2002; by 70 per cent by 2005; and by 100 per cent by
2008. Those targets are increases on the estimated baseline of people in treatment before 2002. The additional support-
ing indicators are designed to reduce the health and social damage that substance misusers inflict on themselves. 
Other indicators are designed to:
• Increase the number of problem substance misusers in contact with substance misuse services;
• Increase access to appropriate services for people with dual diagnosis of substance misuse and mental health problems;
• Reduce the time spent by substance misusers waiting for an assessment of their needs;
• Reduce waiting time between assessment of need and availability of treatment;
• Reduce the proportion of drug misusers who inject and the proportion of those sharing injecting equipment over the
previous three months;
• Reduce the number of deaths relating to substance misuse.
Key points
The key points covered in chapter II of the Guide are as follows:
• A strategic framework is a critical element of an integrated and successful treatment response;
• There is a need to see treatment within the context of broader demand reduction policies, which are encom-
passed in the national drug control master plan or the national policy framework; 
• The framework should emphasize the importance of broad community involvement and consultation with a full
range of stakeholders;
• The framework clarifies roles of policy makers, planners and providers of services and reflects key guiding princi-
ples of an effective treatment response;
• The key elements of a strategic framework are:
(i) Description of the population affected by 
drug abuse;
(ii) National statement setting out values, 
principles and goals and objectives; 
(iii) Identification of priority areas with clear goals 
and measurable objectives;
(iv) Specification of the governing body of the 
strategy, as well as of the governmental and 
non-governmental agencies involved and their
shared responsibilities and role expectations;
(v) Mechanisms for community involvement and 
representation;
(vi) The legislative framework;
(vii) Specification of the types of treatments to be 
developed and action to be taken to that end;
(viii) Financial and human resources available;
(ix) Realistic outcomes and methods of assessing 
their attainment;
(x) Monitoring, review and communication 
arrangements to support the strategy;
(i) Involving all partner agencies in strategy 
development;
(ii) Involving service users and the community;
(iii) Ensuring policy commitment by Governments 
and official agencies;
(iv) Conducting sound assessment and planning;
(v) Building on research evidence;
(vi) Rationalizing resource allocation in accordance
with needs;
(vii) Developing an incremental and step-by-step 
approach; 
(viii) Fostering collaboration and integration of 
different programmes;
(ix) Building on community-based responses;
(x) Ensuring service diversification, availability and
accessibility;
(xi) Planning for monitoring performance.
• The guiding principles of an effective treatment strategy are:
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http://www.conace.cl
National Strategy, Spain
http://www.mir.es/pnd/presenta/html/national.htm
Consensus Statement on Drug Treatment, Finland
http://www.aka.fi/users/132/1623.cfm
Three-Year Plan to Fight against Drug Use and to Prevent Dependence, France
http://www.drogues.gouv.fr/uk/index.html
Treatment and Rehabilitation in Hong Kong
http://www.info.gov.hk/ne/text/treat/index.htm
National Drug Strategy, Ireland
http://www.gov.ie/tourism-sport/pressroom/archive/ndstrategy01-08.pdf
Progress Report on the Drug Policy in the Netherlands (1999-2001) 
http://www.minvws.nl/documents/gvm/Rapport/drugs-progress-eng.pdf
National Drug Strategy, Portugal
http://www.ipdt.pt/biblio/LDroga/enlcd_eng/estrategia_eng.pdf 
National Action Plan, Portugal
http://www.ipdt.pt/biblio/LDroga/horizon2004_eng/horizon2004_eng.pdf
Drug Policy, Switzerland
http://www.bag.admin.ch/sucht/politik/drogen/e/drugpol.pdf
Drug Policy, Thailand
http://www.oncb.go.th/e1-frame02.htm
Home Office, Drugs Prevention, United Kingdom
http://www.homeoffice.gov.uk/atoz/drugs.htm
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Government Strategy on Drug Abuse Treatment, United Kingdom
http://www.archive.official-documents.co.uk/document/cm39/3945/3945.htm
http://www.archive.official-documents.co.uk/document/cm39/3945/aim-3.htm
(Aim (iii): Treatment-To Enable People With Drug Problems to Overcome them and Live Healthy and Crime-free Lives)
Office of National Drug Control Policy (ONDCP), United States 
http://www.whitehousedrugpolicy.gov/policy/policy.html
http://www.whitehousedrugpolicy.gov/publications/policy/ndcs01/chap3_2.html
(National Drug Control Strategy 2001, Treating Addicted Individuals)
Changing the Conversation, A National Plan to Improve Substance Abuse Treatment, United States
http://www.natxplan.org
Drug Strategies of European Countries, EMCDDA
http://www.emcdda.org/policy_law/national/strategies/strategies.shtml
Legislation and regulatory issues
Approval and Monitoring of Narcotic Treatment Programs: A Guide on the Roles of Federal and State Agencies, United
States 
http://www.treatment.org/taps/tap12/TAP12toc.html
http://www.treatment.org/taps/tap12/TAP12exhibita.html
(Major federal legislation on addiction treatment in the United States)
http://www.treatment.org/taps/tap12/tap12appe.html
(United States regulations on confidentiality of alcohol and drug abuse patient records)
http://www.treatment.org/taps/tap12/tap12appc.html
(United States regulations on drugs used for treatment of narcotic addicts)
(http://www.treatment.org/taps/tap12/tap12appf.html)
(Definitions used in United States treatment regulations)
Consumer Bill of Rights and Responsibilities: Implications for Mental Illness and Chemical Dependency Programmes and
Practices, Substance Abuse and Mental Health Services Administration (SAMHSA), United States
http://www.samhsa.gov/mc/content/cbr/index.htm
Credentialing Bodies, Certification Requirements for Drug Counsellors, United States
http://www.nattc.org/getCertified.html
Opioid Treatment Programs Accreditation Project: Program Information, United States
http://www.samhsa.gov/centers/csat/content/opat/otpaccr.html
Standards of Care in Drug Abuse Treatment, Inter-American Drug Abuse Control Commission (CICAD)
http://www.cicad.oas.org/en/demandreduction/Projects/Standards.htm
UNDCP Online Legal Library
http://www.undcp.org/legislation.html
UNDCP Expert Working Group report on best practice in planning, establishing and running drug treatment courts 
http://undcp.org/legal_advisory_expert_working_groups.html
UNDCP model drug court legislation 
http://undcp.org/legal_advisory_model_legislation.html
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In chapter II of the Guide, the rationale, structure and
development of national responses to drug abuse and
the place of treatment services within the strategy are
described. In chapter III, the nature and extent of the
need for treatment in a particular locality or country
are examined. The matters covered include the follow-
ing: the nature and content of a needs assessment;
identification of the major problems to be dealt with
and the main services likely to be needed by different
populations affected by drug abuse; and determining
the key steps that should be followed to conduct a
needs assessment.
Detailed methodological guidance on specific techniques
used to carry out assessments is not included in the
Guide. The reader is referred to more specific resources
on that subject, such as the guidelines and workbooks on
treatment evaluation developed by UNDCP, WHO and
the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) (see box 41).
The benefits of reading and using chapter III of the
Guide are as follows:
• Clarification of the rationale for conducting a needs
assessment and what can be expected from it; 
• Understanding of the linked steps that can be fol-
lowed when undertaking and using the results of a
needs assessment;
• Conceptualization of the overall target population of
drug abusers in terms of subgroups that are likely to
have specific treatment needs; 
• Understanding of major problems and the main
services needed for each subgroup of drug abusers
and each priority group.
The target audience for chapter III is policy makers,
technical advisers and treatment service providers 
at national and local levels. The material in chapter III
is designed to assist those partners and their advisers 
in considering how best to assess the needs for treat-
ment of the drug-abusing population as a basis for 
the development of a national strategy or a local treat-
ment initiative. 
The treatment needs of populations with substance
abuse problems vary both within and between coun-
tries, mainly because of the differences between preva-
lent drug problems, target populations, existing service
systems and resources available for the service systems.
Undertaking a needs assessment, however modest and
rapid, should be an essential element in all planned
treatment systems. A needs assessment approach is just
as valuable in the development of new services as it is for
the audit and review of an existing treatment system. 
Chapter III is divided into three sections. Section A
introduces the concepts and rationale for conducting a
needs assessment and summarizes its overall structure.
In section B, a ten-step sequence that can be followed to
implement the exercise is introduced and several impor-
tant points for conducting a needs assessment are dis-
cussed. Section C presents different subgroups in the
population of drug abusers that need to be taken into
account when conducting a needs assessment. 
A.   Nature of a needs assessment
A needs assessment, similar to a rapid situation assess-
ment, is a research methodology using a combination of
several quantitative and qualitative data collection tech-
niques in order to assess the nature and extent of certain
health and social problems such as drug abuse and the
current ability of a community to respond to those
problems. It may not be immediately obvious to all why
a needs assessment should be carried out. 
1.   Concept of need
“Need” may be defined as what an individual might
benefit from by accessing the treatment system. That
concept can also be applied to the total population in
terms of an aggregate level of benefit. The concept of
need may or may not correspond to what an individual
wants from treatment. A needs assessment is therefore a
systematic exploration of the current status of a single
individual or a group with drug abuse problems and of
the changes that they and others consider necessary to
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improve their health and social status. In this part of the
Guide, the assessment of group needs (at local, regional
or national level) rather than individual needs assess-
ment is discussed.
It is important to have a clear conceptualization of the
need for treatment and of the epidemiological aspects of
drug abuse. An example of such a framework has been
used in the United Kingdom for considering major dis-
ease conditions and how they should be best treated (see
box 15).
2. Rationale for conducting a needs 
assessment 
There may be obvious and visible signs of drug abuse in
a particular community and a strong political and pro-
fessional commitment to tackling the problem. On the
other hand, many aspects of drug abuse may be hidden
from view or information about the problem may be
available from many disparate sources. A needs assess-
ment therefore can provide considerable insight into the
problem and can represent a concise exercise in mar-
shalling information to serve as a basis for future plan-
ning. The needs assessment exercise does, however,
require boundaries. It should set out priorities and the
type of learning that is to be acquired, the resources and
methods that are needed (or allocated) and the antici-
pated benefits from undertaking the project.
3.   Components of a needs assessment
The components of a needs assessment may include:
• Contextual assessment: describing those structural,
social and cultural factors that may influence the
overall drug use and abuse situation; 
• Drug use assessment: arriving at a comprehensive
description of the drug use situation and associated
problems using various tools, including reviews of
the literature, interviews, focus group discussions
(see annex IX), questionnaires and reviews of treat-
ment service data; 
• Resource assessment: identifying existing resources,
such as funds, organizations and human resources;
• Intervention and policy assessment: assessing the
nature, appropriateness and adequacy of existing
specific interventions and policies. 
As described in chapter II, many government agencies
and treatment planning bodies undertake formal and
informal needs assessment as part of their public con-
sultation process. The results of a needs assessment can
be used to inform the treatment strategy planning
process, and that can include helping to make specific
decisions about:
• The appropriate strategies that respond to the needs
of various target populations (that is, which services
to develop where);
• The allocation of financial and human resources;
• The mechanisms that are used to finance service
delivery and the controls over those systems;
• How best to establish monitoring and evaluation
arrangements to assess the outcomes of interven-
tions.
Appraisal of the level of care needed by the target popu-
lations and commissioning of strategic service responses
should be flexible and adaptable to changing circum-
stances in each locality, including: 
• Variations and new trends in drug use and con-
sumption patterns; 
• The geographical distribution and concentration of
drug abuse; 
III.2
Drug Abuse Treatment and Rehabilitation A Practical Planning and Implementation Guide
Box 15
Structure of the epidemiologically-based
framework for needs assessment in the
United Kingdom
The Department of Health and National Institute of
Clinical Excellence of the United Kingdom has funded
wide-ranging reviews of the framework for needs
assessment for major disease conditions, including
drug and alcohol abuse, together with several other
conditions, including cancers, diabetes, renal disease,
obesity, hypertension and peripheral vascular disease.
Each framework document uses a standard structure
and presents the best available epidemiological and
treatment-service-related information. The structure is
as follows:
• Statement of the problem;
• Subcategories;
• Prevalence and incidence;
• Services available and their costs;
• Effectiveness and cost-effectiveness of services;
• Quantified models of care and recommenda-
tions;
• Outcome measures, audit methods and targets;
• Information and research requirements.
For further information, go to 
http://hcna.radcliffe-online.com/main.html
• Variations in demand for services;
• The changing relationship between drug use and
other conditions (notably HIV infection and blood-
borne viral hepatitis); 
• Changing policy in response to drug strategy; 
• Changes in the organization of health services; 
• Results of the monitoring of the evidence base for
current and new treatment services.
B. Designing and conducting a needs
assessment
A needs assessment for drug abuse treatment has three
basic elements: assessment of the nature and extent of
drug abuse; appraisal of existing service responses (if
any) and the gaps in provision; and identification of the
necessary services and resources required to implement
them. 
1.  Aims of a needs assessment 
Those involved with the planning of treatment services
should aim at determining:
• The type and likely size of the subpopulations that
are abusing different drugs and that have treatment
needs (see section C, subsection 1, below); 
• The risks and harm conditions that require a specif-
ic intervention (see section C, subsection 2, below); 
• The best options, methods and providers available
for their delivery; 
• The likely service capacity that is required for each
intervention modality; 
• How to choose between different providers of serv-
ices (see section C, subsection 3, below);
• How best to monitor the provision of services and
control expenditure on contracts (see chapter VII).
Detailed guidance in each of the steps involved is provid-
ed in the Evaluation of Psychoactive Substance Use Disorder
Treatment, Workbook 3—Needs Assessment, developed
jointly by WHO, UNDCP and EMCDDA [12].
Guidance can also be found in Drug Abuse Rapid
Situation Assessments and Responses, describing the
method developed by UNDCP [13] and in the method
of rapid assessment and response developed by WHO
[14]. Those resources are highly recommended to anyone
wishing to undertake a needs assessment.
An audit of existing sources of information and the use
of available data should be the starting point for the
assessment of treatment needs. Many countries are
investing in drug information systems that report on
patterns of and trends in the drug abuse situation. It is
therefore important to capitalize on the available infor-
mation before embarking on any new data collection
exercise. 
2. Ten-step process for conducting a needs
assessment
A ten-step process may be helpful in organizing the
needs assessment. It should be noted that some steps can
be done concurrently and that the starting point and
sequencing may vary according to the scale and empha-
sis of the assessment exercise. Detailed guidance on
practical aspects is provided in the above-mentioned
publication Evaluation of Psychoactive Substance Use
Disorder Treatment, Workbook 3—Needs Assessment. The
ten steps involved are indicated below.
Step 1. Allocate resources and establish an agreed plan
and methods for the needs assessment.
Step 2. Estimate the number of people in need of treat-
ment in the target population and identify and profile
subgroups and priority groups.
Step 3. Prepare a resource map of the treatment servi-
ces provided in the locality, together with the services that
are provided by facilities that are located in other areas.
Step 4. Conduct an audit of the demand profile of
treatment services (capacity; number of episodes; and esti-
mated number in need).
Step 5. Hold personal interviews with key informants
across different stakeholder and professional groups to
discuss strengths and weaknesses of current services and
the areas of unmet need.
Step 6. Hold focus groups or other types of open dis-
cussions with key stakeholders to explore what they want
from services. 
Step 7. Compile a report containing an analysis of gaps
in the current and desired profile of service provision,
including the gap between financial and human resources
and services needed or required.
Step 8. Offer recommendations for increasing treat-
ment coverage, purchasing efficiency and service effec-
tiveness based on available evidence.
Step 9. Undertake an assessment of reactions to recom-
mendations from strategists, commissioners, service
providers and service users. 
Step 10.  Develop an implementation plan based on the
identification of activities, resources and timetables (see
chapter V of the Guide).
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The following points should also be noted in conduct-
ing a needs assessment:
• The communication of the key messages and results
from the needs assessment should be considered very
carefully. The format and content of reports will vary
according to the target audience. Concise summaries
will be required for policy makers, and reports on
the technical detail of the needs assessment will be
made available for their advisers as required.
Community groups will want a digestible summary
of the findings of the needs assessment and its impli-
cations;
• A needs assessment should be repeated on a periodic
basis in order to respond to changing needs and cir-
cumstances.
An interesting example of a national needs assessment
exercise that was conducted in Pakistan is summarized
in box 16.
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Box 16
National assessment of drug abuse in Pakistan, 2000
The Pakistan National Assessment Study, conducted by the Anti Narcotics Force Pakistan with the technical and finan-
cial support of UNDCP in 2000, consisted of a set of studies that provided a comprehensive picture of problem drug
use in Pakistan. The objectives of the National Assessment Study included gaining an overview of the patterns of and
trends in drug abuse and of perceived problems associated with the consumption of illicit drugs, as well as review-
ing treatment provision in Pakistan. A brief description of each of the studies conducted as part of the National
Assessment Study is given below.
A national contour mapping exercise using key informants to produce an overview of patterns and trends of drug
use in the country was conducted in 36 urban and rural sampling sites. Those sites were selected to allow a broad-
ly representative national picture of drug abuse in the country. Key informants in those sites were selected on the
grounds that they had an informed understanding of drug abuse patterns and trends in their area. In total, 283 key
informants representing medical professionals, non-governmental organizations, teachers, community leaders, reli-
gious leaders, the police and former drug users were interviewed for the study to elicit their perceptions of the cur-
rent patterns and changing trends of drug use in their locality.
Interviews of addicts, including regular heroin and injecting drug users, were conducted in the four provincial 
capitals of the country—Karachi, Lahore, Peshawar and Quetta. In those cities, a total of 1,049 drug abusers were
recruited and interviewed in almost equal proportions in street settings, treatment facilities and prisons. Through
those interviews, information was elicited on the social and demographic profile of the drug abusers; their history of
drug use; current patterns of drug abuse; injecting risk behaviour; treatment history; and incarceration for drug-
related or other offences. Lifetime treatment contacts, mean age at first treatment contact and the time lag between
regular drug abuse and first treatment contact were also explored in the study.
The third main study as part of the National Assessment Study involved an update of the national treatment register.
In that exercise, the field workers visited 18 major urban centres in the country, updated the previous information on
treatment services, and audited the type of treatment facilities and nature of services provided by each in the urban
centres. They also collected information on the profile of the clientele served, the average occupancy rates within the
treatment facilities and other related services provided by them.
The findings of the National Assessment Study indicated that a majority of the drug users in the study areas were in
need of treatment, although many of them had not been able to access treatment mainly for financial reasons. The
Government, non-governmental organizations and private services provided treatment and rehabilitation for people
with drug problems. Non-governmental organizations appeared to be providing the broadest range of services and
comprehensive care, while the government services were mostly focusing on the provision of detoxification. The
study results suggested the need to expand the provision of community-based rehabilitation and aftercare services
to supplement the inpatient detoxification currently provided predominantly in the government treatment facilities.
There was also a need for affordable treatment services that responded to the needs of different population groups.
C. Estimating the size of the 
population in need
Clearly, it is important to understand the extent of treat-
ment need within a community and the characteristics
of those who are likely to be a priority for service provi-
sion. In many cases, precise estimates are not practical
for the purpose of service development. Valuable infor-
mation can be provided by techniques such as rapid sit-
uation assessment (see annex IX), focus groups and tar-
geted community studies, which can provide insight
into the type and extent of unmet treatment needs.
Those methods have the benefit of being low-cost and
relatively simple to implement, and that they do not
require a large investment in time and other resources.
Generating a more robust estimate of prevalence is
desirable but technically demanding, and it requires a
significant resource investment. A range of epidemio-
logical methods including survey techniques, indirect
statistical estimation methods and the use of data from
ongoing surveillance activities can all be used to that
end. For guidance on those issues, the reader is referred
to the EMCDDA study Estimating the Prevalence of
Problem Drug Use in Europe [15],  and the UNDCP
Toolkit Module 3: Indirect Methods for Prevalence
Estimation. 
1.   Population subgroups
The heterogeneous population of drug abusers across
the world can be divided into different subgroups for
effective needs assessment and strategic planning pur-
poses. At the highest level, the population may be
grouped in terms of gender and age. The following gen-
eral factors are important when considering the charac-
terization of subgroups:
• Age, gender and culture; 
• Socio-economic status;
• Education level;
• Pregnancy; 
• Familial pattern; 
• Type of drugs used, including quantity and fre-
quency of administration; 
• Acute intoxication (overdose liability); 
• Extent of impairment and complications; 
• Route of drug administration (oral, inhalation and
intramuscular and intravenous injection);
• Nature of living situation and social and environ-
mental supports and stressors;
• Available resources and other personal strengths.
Complex cases will usually (but not always) be charac-
terized by drug-related impairment, dependence, regu-
lar injecting, high tolerance levels and concurrent prob-
lems across physical, psychological, personal and social
functioning domains.
2.   People with specific treatment needs
In addition to categorizing subgroups, there are eight
priority groups with specific treatment needs that
require consideration. Special attention should be given
to responding to the needs of each of the following
groups when planning treatment services:
• Young people and children;
• Women;
• Seniors;
• People who have drug problems and other 
psychiatric problems;
• People who are homeless;
• People from racial and ethnic minority populations;
• People who are HIV positive;
• People in the criminal justice system.
Each of the eight above-mentioned priority groups and
their specific needs are described in annex I.
3.   Subpopulation and service matching
People with drug abuse problems have different charac-
teristics, problems and treatment needs. Consequently,
treatment services must offer a range of approaches that
should as far as possible be adapted to individual need.
Although a wide range of services should be available for
all drug users, a significant proportion of the resources
should be allocated to specific target groups. 
Putting aside the complexities of the number and com-
binations of different drugs that may be used, six non-
independent (overlapping) population subgroups can be
identified for the purposes of needs assessment. The
characteristics of those subgroups have specific implica-
tions for the assessment of care needs and the planning
and provision of treatment services. The subgroups are
as follows:
• Non-dependent drug abusers;
• Injecting drug abusers;
• Dependent drug abusers;
• Acutely intoxicated drug abusers;
• Drug abusers in withdrawal;
• Drug abusers in recovery.
Each of the six above-mentioned subgroups is described
in annex II. People in the six subgroups are not all the
same, and each group must be characterized on the basis
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of the severity of the problems to be dealt with (and the
extent of any complications). It is also important to note
that the above subcategories are not mutually exclusive.
Indeed it is likely that a person will occupy more than
one category at any particular point in time (for exam-
ple, the injecting dependent heroin or cocaine user).
The multiple occupations of different categories may
also vary over time. In addition to those groups, a fur-
ther category can be labelled “at risk”. Of particular con-
cern are segments of the younger population thought to
be at risk, and prevention initiatives and general educa-
tional programmes are required.
It should also be stressed that the subgroups are not
meant to convey a hierarchy of problem severity per se.
Appropriate interventions should be based on a com-
prehensive assessment of need, a functional analysis
concerning drug involvement and a programme of brief
counselling and support. Such a process may then trig-
ger the identification of other health and social care
needs. It should also be stressed that some of the sub-
groups may be present in small numbers in a particular
locality or country and that the mix of groups and prob-
lems will vary both within and across countries.
Box 17 summarizes the major problems experienced by
each of the groups and the main types of services
required to meet their needs.
As services for drug abuse are comprehensive and costly,
a treatment setting may not be able to provide all serv-
ices to all subgroups. In a community with many treat-
ment settings providing services for drug abuse, some of
them may be assigned responsibility for particular sub-
groups within the community. For example, while a
drug treatment centre may be responsible for dependent
drug abusers and those in recovery, a general hospital
may be principally responsible for acutely intoxicated
drug abusers and those suffering from overdose compli-
cations.
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Box 17
Subgroups of drug abusers: major problems and main services needed
The Office of National Drug Control Policy in the United States has developed a performance management frame-
work based on the following structure: 
aA variety of services are included in drug abuse treatment programmes, for example, intensive community and residential treatment, aftercare sup-
port and social and legal assistance. 
Subgroups of drug abusers
Non-dependent drug abuser
Injecting drug abuser
Dependent drug abuser
Acutely intoxicated drug abuser
Drug abuser in withdrawal 
Drug abuser in recovery 
Major problems
Negative consequences and risks of
becoming dependent
Drug abuse, at risk for blood-borne
infection and other medical compli-
cations
Drug abuse disorders, health and
other negative consequences
Acute behavioural disorders and
overdose
Withdrawal symptoms 
At risk of relapse to drug use
Main services needed a
Appropriate early interventions
Drug abuse treatment programmes,
HIV/AIDS education and counselling,
needle and syringe exchange pro-
gramme and medical care
Drug abuse treatment programmes
Short-term medical and psychiatric
intensive care
Short-term detoxification pro-
gramme
Rehabilitation and relapse preven-
tion programme
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Key points
The key points covered in chapter III of the Guide are as follows:
• There are two essential aspects of a needs assessment: the assessment of the size and characteristics of the pop-
ulation in need of treatment; and the assessment of the number, capacity, coverage, types, strengths and weak-
nesses of existing treatment resources;
• The nature and extent of substance abuse problems are often hidden from view and needs assessments can
achieve valuable insights into the problem and guide future planning;
• An audit of existing sources of information and the use of available data should be the starting point for the
assessment of treatment needs. Additional data collection can be undertaken, depending on existing data gaps
and available resources;
• A needs assessment can be implemented using a ten-step process. Some of the 10 steps for a needs assess-
ment can be done concurrently and the starting point and sequencing may vary according to the scale and
emphasis of the assessment exercise;
• The needs assessment should investigate the needs of different population groups. Particular attention should
be paid to the identification of the needs of groups of drug abusers frequently underserved by the treatment
system, such as young people and children, women, seniors, people with psychiatric problems, people who are
HIV positive, people who are homeless, offenders and minorities;
• Drug abusers may be classified into six subgroups, including non-dependent drug abusers, injecting drug
abusers, dependent drug abusers, acutely intoxicated drug abusers, drug abusers in withdrawal and drug
abusers in recovery;
• The above-mentioned groupings have important implications for treatment services and the skills needed to
meet the different needs in the population;
• Needs assessment reports need to ensure that key messages are available for different audiences in the format
required;
• Needs assessments should be repeated on a periodic basis.
Chapter III of the Guide outlined the rationale and
methods for conducting a treatment needs assessment.
Assuming that there are identified gaps in service provi-
sion, the next question concerns what sort of treatment
services should be made available. Chapter IV of the
Guide asks the question: “What are the effective
approaches for treating people with drug abuse prob-
lems?” 
The benefits to be gained from reading chapter IV of
the Guide are as follows:
• Clarity about treatments that are effective and sup-
ported by the research evidence;
• Clarity about the purpose of each approach in terms
of the people it is designed to treat and the main
goals and objectives of treatment;
• Understanding of the range of treatment services
available.
Chapter IV of the Guide should be read in conjunction
with the companion documents Investing in Drug Abuse
Treatment: A Discussion Paper for Policy Makers and
Contemporary Drug Abuse Treatment: A Review of the
Evidence Base. Those documents present a summary
international review of research studies that document
the clinical, social and economic effectiveness of specific
forms of treatment. Chapter IV of the Guide places that
evidence in the context of the services that should be
considered when planning a treatment response.
Policy makers and treatment planners are naturally
interested in knowing which treatments for drug abuse
are effective in dealing with the problem. Since there is
no one single treatment that is effective for everyone,
policy makers are also interested in knowing what range
of treatments should be made available as part of a sys-
tem of care and rehabilitation. 
Clearly, providing effective treatment services requires
investment of financial and human resources, and many
countries may be unable to allocate sufficient invest-
ment to develop a fully comprehensive system.
However, several scenarios can be envisaged, ranging
from a basic to a comprehensive response. UNDCP
advocates a building-blocks approach in which the basic
elements of a comprehensive treatment system—the
evidence-based treatments—can be added together over
time, depending on the nature and extent of the prob-
lem, the level of fiscal resources available and the cul-
tural and political context. In that regard, it is important
to note that community-based day treatment is usually
less costly than hospital inpatient and residential care
and may be the best option in contexts where resources
are at a minimum.
Chapter IV is divided into two sections. Section A sum-
marizes the elements of a comprehensive treatment sys-
tem that are supported by research evidence. Section B
briefly highlights how to access information on research
into treatment effectiveness.
A. Elements of a comprehensive 
treatment system
Globally, various terms and labels are used to describe
treatments and referral and support services for drug
abuse. The present Guide uses “open access” services and
“structured treatments” as organizing terms. It is recog-
nized that many countries will use alternative terms to
describe their treatment modalities. Whatever terms or
names are used to describe treatments, it is important
that they are used consistently across the country.
Furthermore, it will be beneficial if those involved in the
treatment system share a common understanding about
the overall purpose and operation of each treatment
modality. 
1.  Open access services
Open access services are important elements of an inte-
grated treatment response. Those services do not pro-
vide formal treatment as such, but act as important
points of first contact for people who have drug-related
problems and for those concerned about the drug use of
another (for example, parents, siblings, spouses and
friends). Open access services are sometimes called
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“street agencies”, reflecting their community location.
They are often managed by non-governmental organi-
zations, involving peer interventions, and can provide
the following services:
• "Drop-in” (that is, non-appointment-based) service
for accessing information and advice (health care,
legal issues, housing, employment, training etc.), as
well as basic survival services;
• Community outreach and advice; blood-borne virus
prevention services, including education, coun-
selling and syringe and needle exchange; and over-
dose prevention education;
• Appointment-based general counselling service;
• Telephone helplines for anonymous, confidential
advice; 
• Onward referral information and advocacy;
• Self-help groups;
• Family support groups; 
• General community aftercare and support services.
An important member of the range of open access serv-
ices is self-help groups for individuals and family mem-
bers (for example, Narcotics Anonymous and Cocaine
Anonymous). They are based on the original principles
of Alcoholics Anonymous and are run by and for people
who are recovering from drug dependence and who
attend a group-based discussion and support session on
a routine basis. Those and other community resources
are also an important source of aftercare and support
following structured treatment.
In some countries with high levels of drug injecting,
policies to reduce the health and social consequences of
drug use have led to the development of syringe
exchange services that have become a central plank of
prevention activities aimed at reducing blood-borne
viral infection and other injection-related physical
harms (abscesses etc.). Those initiatives promote
improved hygiene during intravenous drug use and
encourage the use of new syringes and the safe disposal
of used injection equipment. 
It is hard to overemphasize the importance of open
access services. Some drug abusers may be reluctant to
resort to specialized drug dependence services, and open
access resources can be a critical place of first contact for
them. It is common for someone with a drug abuse
problem to resort to an open access service with a gen-
eral problem—for example, a health problem, relation-
ship difficulty or financial concerns—and their specific
drug abuse difficulties may be disclosed in the course of
their contact with the open access service. Specialized
open access services, in particular those providing infor-
mation and specific services to prevent overdose and the
acquisition and transmission of blood-borne infection,
are also of great importance as part of a community
strategy to minimize the adverse consequences of drug
abuse and as entry points to the treatment system.
2.  Structured treatments
Succinct categorizations of treatments for substance
abuse are surprisingly difficult to develop. In the present
section, a summary of the main types of structured
treatment are offered. Structured treatment character-
izes services that are based on a formal assessment, the
development, monitoring and review of individual
plans for client care and a programme of medical treat-
ment and/or counselling services. Some therapeutic pro-
grammes, in particular those delivered in a residential
setting, are highly structured and involve an intensive
schedule of individual and group-based educational,
therapeutic and training sessions to promote rehabilita-
tion. A schematic description of a care process is shown
in box 18.
(a) Detoxification: stabilization phase 
of treatment
Medical detoxification is the initial and acute stage of
drug treatment. Such programmes provide medically
supervised detoxification to people with a drug depend-
ence. People who are heavy, consistent abusers of certain
drugs (opioids and sedative and hypnotic drugs) and are
likely to experience withdrawal complications require
medically supervised withdrawal (detoxification). A
withdrawal syndrome that can develop after stopping
the use of a drug will vary according to the type of drug
the person was using. Common general features can
include craving for the substance, anxiety, restlessness,
irritability, insomnia and impaired attention.
Dependent users of psychostimulants, in particular
amphetamines and cocaine, may also require medical
supervision during the acute withdrawal phase follow-
ing cessation of use. While there may be no direct phys-
ical withdrawal effects (and no prescribing of an agonist
to minimize discomfort), the individual may have severe
psychological problems (including induced psychosis)
and sleep disturbance that may be managed by prescrib-
ing suitable medication.
The main goal of detoxification programmes is to
achieve withdrawal in as safe and as comfortable a man-
ner as possible. Various medications have been shown to
be effective in opioid detoxification, including true ana-
logues or agonists such as methadone, partial agonists
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such as buprenorphine and other non-opioid drugs that
are called 2-adrenergic agonists (lofexidine or cloni-
dine). Some inpatient programmes use opioid antago-
nists under sedation or general anaesthesia (so-called
ultra-rapid detoxification). In some countries, opiate
products (including tincture of opium) are used as a
detoxification agent. Withdrawal from benzodiazepines
is usually achieved via use of a long-acting benzodi-
azepine (for example, diazepam).
On its own, detoxification is not in itself a rehabilitative
treatment for drug dependence, and it is seldom effec-
tive in helping clients achieve lasting abstinence from
drug use. Detoxification is better seen as a first phase of
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Box 18
Drug treatment and care process
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treatment programmes that are aimed at abstinence and
recovery. 
Outpatient or community-based detoxification 
Persons with a substance-induced disorder who are 
considered likely to be able to withdraw successfully in
the community are suitable for assessment for outpa-
tient or community-based detoxification services.
Detoxification is usually initiated at the programme
facilities or at the home of the client, with a period of
stabilization using substitution agents. Following stabi-
lization, the client is gradually withdrawn over a period
ranging from a few weeks to several months. During
that time, the client can be encouraged to receive coun-
selling, medical treatment and other support services. In
many ways some of those programmes are broadly com-
parable to outpatient or community-based maintenance
programmes. 
Short-term inpatient or residential detoxification 
Persons who have a substance-induced disorder associa-
ted with a withdrawal syndrome or symptoms thereof,
who are unlikely to be able to withdraw successfully in
the community, and who may therefore need a con-
trolled and medically supervised environment, are suit-
able for assessment for a short-term inpatient or resi-
dential programme. Most of those programmes proceed
through a detoxification stage to a fairly brief structured
relapse prevention, counselling and education phase
with the offer of onward referral. It is important to note
that some people in withdrawal will have additional
physical and psychological problems (which may inter-
act with the management of drug or alcohol with-
drawal), and short-term inpatient programmes can pro-
vide an important opportunity for screening or manag-
ing those problems. 
(b) Rehabilitation: relapse prevention phase of
treatment
The rehabilitation or relapse prevention phase of treat-
ment is oriented to the needs of persons who have either
completed a formal detoxification or who have depend-
ence but no formal withdrawal symptoms requiring
access to the previous phase of treatment. Relapse pre-
vention or rehabilitation programmes are designed to
change the behaviour of clients to enable them to regain
control of their urge to use substances. Psychosocial and
pharmacological interventions are involved in that
phase of treatment.
Psychosocial interventions
Community or day programmes. Community or day pro-
grammes offer a programme of psychotherapy or gene-
ral counselling based on a care plan. The programme is
usually individually configured to meet the needs of
each participant using a case management approach.
Case management is based on a comprehensive initial
and ongoing assessment of existing problems, personal
resources, social supports and stressors undertaken by a
specialist clinician or worker. The assessment results in a
set of personal treatment goals for the client, and
progress towards those goals are monitored and
reviewed at regular points over the course of treatment.
Case management functions also include liaison and
referral to other ancillary support services that are 
needed by the client and onward referral to other spe-
cialized programmes as required. 
In many countries, most drug abuse counsellors use a
client-centred, cognitive behavioural and motivational
framework, and offer treatment that varies in duration
from a brief intervention lasting from one to three ses-
sions to a formal structured programme lasting several
months. Structured drug-free day programmes are
found in many countries. In the most intensive pro-
grammes, clients are expected to attend sessions on four
or five days a week, for several hours each day.
Treatment goals are based on helping the client to
increase understanding and awareness of their drug-
using behaviour, so as to reduce the negative conse-
quences of drug use and to avoid drug-taking. In addi-
tion, individual and group counselling and education
sessions may focus on HIV/AIDS issues, family rela-
tionships, vocational training, job integration, housing
support and legal issues.
Planned counselling services offer formal structured
counselling approaches with assessment, clearly defined
treatment plans and goals and regular reviews, in con-
trast to advice and information, drop-in support and
informal counselling. Community-based programmes
may be provided as an alternative to residential rehabil-
itation programmes or as a stage following them. 
Residential rehabilitation programmes. Two types of res-
idential programme are available: short-term residen-
tial rehabilitation and long-term residential rehabilita-
tion. Short-term residential rehabilitation programmes
usually include a detoxification programme as a first
stage and last for between 30 and 90 days. Long-term
residential rehabilitation programmes generally do not
provide medically supervised withdrawal and last for
between six months and one year. The long-term resi-
dential rehabilitation model most commonly used is
the “therapeutic community”. Residential rehabilita-
tion services share several features in common, includ-
ing: communal living with other drug users in recov-
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ery; group and individual counselling on relapse pre-
vention; individual case management; improved skills
for daily living; training and vocational experience;
housing and resettlement services; and aftercare sup-
port. They are usually closely aligned with mutual-help
groups such as Narcotics Anonymous and Cocaine
Anonymous. Some residential programmes have sec-
ond-stage or so-called halfway houses, which are semi-
independent group living environments that are usu-
ally close to the main residential programme. They
offer the client group the opportunity to prepare for
their return to the community, while continuing to
provide formal support as needed.
Pharmacological interventions
Substitution and maintenance programmes. Although
abstinence is the primary goal in the majority of reha-
bilitation treatment programmes, substitution agents
for maintenance purposes, such as methadone and
buprenorphine, may be prescribed for people with opi-
oid dependence. Clients suitable for maintenance
treatment may present a history of failure in absti-
nence-oriented programmes. In a maintenance pre-
scribing programme, a substitute substance is adminis-
tered at a suitable and stable level for a period of seve-
ral months and sometimes years. It is important to
regard community prescribing as a platform for psy-
chosocial counselling interventions to be provided in
combination with maintenance programmes. Most
maintenance programmes offer clients an appoint-
ment-based programme of regular counselling sessions
with a designated key worker, together with access to
self-help groups, primary and other medical care and
social advocacy support. 
There has been some clinical interest in the United
Kingdom and Australia to assess the suitability and
impact of dexamphetamine for certain adult depend-
ent amphetamine abusers who do not have major psy-
chopathology. There is not a sufficient evidence base to
judge the wisdom of that practice and the characteris-
tics of those abusers who can be judged suitable for it
is poorly understood.
Antagonist pharmacotherapy. An opioid dependent per-
son who is now drug-free (that is, fully detoxified) can
be prescribed an antagonist medication (naltrexone) as
part of continuing relapse prevention treatment. That
antagonist blocks the opiate receptors in the brain and
prevents any effect from heroin or other opiates from
occurring should the individual consume them. The
prescription of naltrexone (which has no abuse liabil-
ity) can be a component of continuing outpatient
treatment and may be used in combination with fami-
ly therapy (although it may be initiated in a residential
setting following detoxification). Medication is taken
on a daily basis for several months or longer, blocks the
effects of opiates, and thereby assists in long-term
recovery by helping the person to maintain a drug-free
state. The involvement of the spouse and family of the
person in ensuring compliance with treatment is
important. 
The research evidence points to problems with naltrex-
one compliance and programmes suffer from a high
level of dropout. However, among highly motivated or
compliant patients, naltrexone effectiveness is generally
high, suggesting an assessment and matching effect of
patient and treatment. 
Substantial efforts have been made to develop cocaine
antagonists. However, no cocaine blocking agents have
yet been empirically proven to be effective.
(c)  Aftercare arrangements
Some structured treatment programmes distinguish a
period of less intensive treatment after a client has com-
pleted the main programme, called aftercare. It may be
limited to a month or substantially longer after treat-
ment has finished, but is based on the intention to pro-
vide ongoing support to clients at the level required to
maintain the earlier benefits and goals. Regular phone
contact, scheduled appointments and unscheduled or
drop-in visits may all be available. In addition to after-
care services offered by the structured programme,
clients may also be encouraged to access self-help groups
and other general community support and advice serv-
ices in their home locality as required. The effectiveness
of such services has not been subject to formal evalua-
tion to date, but there is a general commitment to their
value and availability. Clearly, a supportive family and
community environment will also be conducive to help-
ing in the recovery of people who have received drug
abuse treatment. 
(d)  Comprehensive treatment models
In recent years, there have been specific efforts to 
develop comprehensive treatment services. Those ser-
vices represent the integration of different treatment
approaches, such as community-based counselling and
residential rehabilitative services designed to help people
achieve lasting abstinence. See box 19 below for an
example of a model used for abusers of psychostimu-
lants.
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(e) Special setting for treatment: the criminal 
justice system
Large numbers of drug users have contact with the legal
authorities and the criminal justice system. In many coun-
tries, there is interest in developing treatment interven-
tions in criminal justice settings. Several contact points
and stages in the criminal justice system may be used as
intervention opportunities, including the following:
• Arrest. Proactive assessment and referral from work-
ers who work alongside the police can refer individ-
uals to treatment services at arrest;
• Pre-sentence (probation referral). These are schemes
that involve the referral of offenders, whose drug
abuse is identified by a probation officer between the
point of arrest and sentencing, to a treatment service;
• Community sentence. Structured treatment pro-
grammes can be organized as part of a community
sentence and other probation orders using a linked
treatment condition;
• Custodial and post-sentence intervention. A basic
treatment framework can be used to provide detoxi-
fication, counselling while in prison and aftercare
support. Arrangements may be in place to continue
treatment for prisoners who are released before the
full completion of their prison sentence (treatment
on parole);
• Drug treatment courts. A drug treatment court is a
mandated judicial supervision and addiction treat-
ment alternative to incarceration for drug offenders.
Drug treatment courts began in the United States in
1989 as one way of stopping crime by stopping its
underlying drug abuse. They now exist or are planned
in a growing number of countries, including:
Australia and Canada in 1999; Ireland in 2000;
Bermuda, Brazil, Cayman Islands, Jamaica and
United Kingdom (Scotland) in 2001; and Mauritius,
New Zealand and United Kingdom (England, Wales
and Northern Ireland) in 2002 (see box 20).
B. Accessing information about 
effective treatments
Globally, there is a substantial and growing research lit-
erature on the effectiveness of treatments for drug abuse
problems. Traditionally, that material has been available
in three general forms:
• Academic reports published in professional journals;
• Research studies published in the form of reports or
monographs;
• Various book chapters and review articles summariz-
ing a particular type of treatment or body of
research.
Accessing the literature is becoming easier as more pub-
lished reports are available online using the Internet.
Several reference sources can now be accessed on the
Internet, which is a fast-growing resource with new servic-
es constantly becoming available. A highly valuable
resource is the Cochrane Library (see box 49 below), which
contains a listing of reviews that have been compiled on a
variety of health-care topics including drug abuse.
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Box 19
The matrix model
The matrix treatment model for stimulant abusers is a
multicomponent framework treatment for helping
them achieve abstinence and physical and psychologi-
cal well-being. The model addresses the needs of stim-
ulant abusers in a systematic way, separating the prob-
lem areas into distinct categories. The chosen cate-
gories are behavioural, cognitive, emotional and rela-
tionship categories. The treatment focuses on particu-
lar issues emerging in each of those areas during the
“stages of recovery” encountered by recovering clients
during the first year of stimulant abstinence. The
model emphasizes individual contact with a therapist,
education about drug abuse, relapse prevention, social
support, twelve-step participation and issues critical to
addiction and relapse. The programme includes educa-
tion and support for family members. A typical pro-
gramme schedule is given below.
Phase 1 (months 1-6). The therapeutic sessions are
typically scheduled as follows: 
• Weeks 1-2: twice-a-week individual sessions,
weekly twelve-step meeting, family education
group, stabilization group and urine test;
• Weeks 3-16: twice-a-week relapse prevention
group, weekly individual session, twelve-step
meeting, family education group and urine test;
• Weeks 17-26: twice-a-week relapse prevention
group, weekly social support group, twelve-step
meeting and monthly individual session.
Phase 2 (months 7-12). The therapeutic sessions are
typically scheduled as follows: 
Weekly twelve-step meeting, social support group,
counselling for individuals and couples and urine test
as needed.
Sources: A. Huber and others, Integrating treatments for metham-
phetamine abuse: A psychosocial perspective, Journal of Addictive
Diseases, vol. 16 (1997), pp. 41-50; and R. Rawson and others, An
intensive outpatient approach for cocaine abuse: the matrix model.
Journal of Substance Abuse Treatment, vol. 12, No. 2 (1995), pp.
117-127. 
http://www.matrixcentre.com/
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Box 20
Rehabilitation instead of incarceration in Jamaica
Recognition that one has a drug problem is the most important prerequisite for being accepted in the Drug Court
Programme in Jamaica. In two designated Magistrate Courts in Kingston and Montego Bay, it is now possible to avoid
incarceration or a heavy fine for possession of marijuana, cocaine or heroin, or even crimes committed while under
the influence of drugs if an individual is accepted into a court-approved rehabilitation programme.
The programme, which was established with the advisory assistance of UNDCP and the Drug Court in Toronto,
Canada, has already handled dozens of cases. Informal guidelines have been developed in recent months to suit the
local situation. A permanent address, a family connection or a person willing to take responsibility for the client and
regular participation in the counselling sessions are important criteria for acceptance and staying in the programme. 
During its recent visit to the courts, UNDCP saw one participant dropped from the programme for dealing in drugs
and another sent back to jail for one night to impress upon him the importance of consistent attendance in the reha-
bilitation sessions, while three others “graduated” to biweekly visits to the court (otherwise they are required to
return once a week). One participant walks four miles each way to attend the group counselling sessions held three
times per week. In addition to the regular drug testing, peer pressure appears to keep the recovering addicts “clean”
and “honest”.
Most of the clients are cocaine addicts and so there is a high degree of probability that many may relapse. The coun-
sellors know that several of those accepted are “borderline” cases. The biggest problem in Jamaica is finding a suit-
able living and work environment and, for many, there is no alternative to the drug-ridden slums in Kingston and
Montego Bay. The principal debate among the treatment providers is whether to put the participants in a 24-hour
residential care facility, but eventually they must return to life “outside”. Therefore, the attitude of the client is most
important. If the addict is willing to commit to “staying off drugs” to avoid jail, the law in Jamaica provides a person
with a “second chance”. 
Source: ODCCP Update, December 2001.
Key points
The key points in chapter IV of the Guide are as follows:
• The basic elements of a comprehensive treatment approach can be built together in a treatment system depend-
ing on the nature and extent of the problem, the level of fiscal resources available and the cultural and politi-
cal context; 
• Open access services are important elements of an integrated treatment response. Those services act as impor-
tant points of first contact for people who have drug-related problems and for those concerned about the drug
use of another. They are also important strategies for the prevention of the adverse health and social conse-
quences of drug abuse;
• There are a range of treatment services and specific therapeutic interventions for drug abuse. Evaluation stud-
ies conducted in several countries provide support for the delivery of:
— Medically supervised detoxification programmes for management of withdrawal symptoms and stabi-
lization; 
— Rehabilitation programmes for relapse prevention in a community or residential setting;
— Pharmacological interventions including maintenance therapy and antagonist pharmacotherapy;
• Information about the impact of treatment can be accessed from specialist journals and library resources. The
Internet is increasingly the medium of first choice for retrieving information about effectiveness.
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Chapter IV of the Guide presented a summary of the
effective treatments that have been developed to
respond to drug abuse. Chapter V of the Guide takes the
discussion forward and asks the question: “How should
a treatment service or system be developed?”
The benefits to gain from reading chapter V of the
Guide are as follows:
• Appreciation of the value of involving the commu-
nity in a new treatment development;
• Understanding of how to include existing primary
care resources to complement specialist substance
abuse treatment;
• Guidance for a step-by-step approach to planning,
establishing and implementing treatment services or
systems;
• Overview of the key tasks required when setting up
a treatment service;
• Clarity about the value of organizational goals, staff
training, support and supervision.
In such a discussion, justice cannot be done to the detail
of the tasks to be performed in either developing a new
service, or re-energizing treatment services that have
become unresponsive to changing problems in the pop-
ulation. Interestingly, many successful services have
been set up by charismatic individuals who manage to
disregard some of the more conventional aspects of
organizational design and development. Their zeal and
commitment carries the day, but over time such person-
ality-based approaches can run into trouble. Overall, it
is better if the services can have well-developed policies
and procedures and a process for reviewing such policies
so that the system can evolve and mature over time. 
In some countries, central planning has a decisive influ-
ence on new project development, whereas, in other set-
tings, individual and community enterprise may gener-
ate many projects in the absence of any generalized or
systematic strategic development plan. In other places, it
may be that services are developed by non-governmen-
tal organizations. Whatever the detail or the level of
variation, there is always a need to develop a coordina-
ted approach with all the major partners involved if
resources are to be best used.
Treatment systems and services need to reflect the
health, social and community infrastructures into which
they will be introduced. A new treatment programme
should complement and link with existing health, wel-
fare and legal networks. That will maximize efficiency in
the use of limited resources, as well as facilitate the inte-
gration of drug abuse recovery into existing community
services. 
The level of development of health and social care varies
dramatically in different parts of the world. There is a
need to recognize that there may be stark differences in
the amount of financial and human resources available.
The type of services put in place will obviously be
determined by the amount of local or national resources
made available for such purposes. 
However, regardless of scale, UNDCP advocates a sys-
tematic approach to ensure the best utilization of
resources. Such an approach can and in many cases
should be developmental, growing from a basic response
through primary care in resource-limited situations,
through an intermediate solution by the development of
a single treatment service, to a more sophisticated, com-
prehensive approach in the form of a treatment system.
Chapter V is divided into three sections. Section A out-
lines important principles for the involvement of the
community and primary care in the provision of a basic
service. Section B presents information on how to deve-
lop a new treatment service that aims at offering more
specialized services to people with drug problems.
Section C presents some basic guidelines for effective
operation of a treatment service. The information pre-
sented in section C will then be expanded in chapter VI,
devoted to the integration and coordination of the dif-
ferent elements in a treatment system. 
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Chapter V
Developing and implementing 
treatment services
A. Involving the community and 
integrating drug abuse treatment
in primary care
The majority of the material in chapter V of the Guide
relates to a step-by-step approach to developing a treat-
ment service. Before the material is presented, it is
worth considering a situation in which no resources are
available to develop a new treatment service. In that
context, it may be possible to facilitate and build on
community responses and support primary-care person-
nel to offer a basic service. In many areas of the world,
the only treatment resources available are through gen-
eralist primary-care personnel who may be thinly spread
in focusing on a wide range of medical problems.
However, in many systems, primary-care services are
often the first point of contact for drug abusers. In some
communities, the extent of drug abuse problems will
place a heavy burden on primary care services. 
1.  Involving the community
Community resources are important elements to draw
from when developing drug abuse treatment services.
Their importance becomes even more salient in situa-
tions of reduced financial resources. In a community-
driven approach, the family and the community are part
of the treatment system and are actively involved in
planning, implementation and evaluation of the pro-
gramme. Significantly, treatment development must
recognize the cultural context and setting for the service
and may well wish to harness existing, traditional treat-
ments and integrate with the local community, which
may already have taken action. 
Examples of initiatives with the participation of signifi-
cant community, primary care and traditional healers
are given in boxes 21 and 22.
It is crucial to take into consideration the local circum-
stances and cultural values influencing drug abuse and
dependence. For example, serious physical disease and
pain may be medicated using local indigenous products
that give rise to substantial levels of dependence problems
within the community. In such cases, the treatment
response to drug abuse will need to address that underly-
ing factor. In that regard, a case example from the Lao
People's Democratic Republic is given in box 23.
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Box 21
Community mobilization, Chiang Mai,
northern Thailand
In the northern part of Thailand on the border with
Myanmar, there is a well-developed health-care net-
work with a three-tiered approach involving a regio-
nal, a district and a village service, with a primary-care
focus at the district and village level and more special-
ized services at the regional level. Over the past
decade, the problem of methamphetamine has grown
to be a major epidemic, and some of the small districts
have developed local responses in the face of wide-
spread methamphetamine abuse among the village
community. For example, the committee of the
Oonkrang district (north of Chiang Mai) met in a sum-
mit to develop a community response to the metham-
phetamine problem. They developed a community
reinforcement response, designed in particular to pre-
vent drug distribution and selling and to promote sup-
port of treated individuals within the village.
Box 23
Involving community health workers, Lao
People's Democratic Republic
In the Lao People's Democratic Republic, opium was
traditionally used to treat pain and major health prob-
lems and the limited availability of basic health servi-
ces was a major contributor to opium addiction in the
community. The provision and improvement of pri-
mary health-care systems will play an important role in
the prevention of further opium addiction and
relapse. Community-based primary health-care sup-
port is being implemented. Village health volunteers
have been established and supported in order to
improve the health situation. The volunteers provide a
resource to improve health-related development and
support a health promotion strategy designed to
improve the effectiveness, relevance and accessibility
of health information and education available to com-
munities at village level. That approach includes a
demand reduction component with community
involvement by increasing community awareness of
the problem of drug addiction.
Box 22
Involvement of traditional healers 
in Nigeria
In parts of rural Nigeria where the primary health-care
team often consists of one nurse servicing a large
population over a wide area, the primary care team
has formed a partnership with some of the traditional
healers. The aim is to equip the traditional healers
with skills to enable them to participate in the primary
health-care approach. Such approaches are pragmatic
and resource-driven and involve harnessing respected
or elder members of the community in developing a
structured response. Similar approaches could be
developed with a particular focus on drug abuse iden-
tification, short intervention and referral.
2. Key elements for primary care
involvements
In a basic scenario, the objective is to rely on primary
care teams for the identification (screening) of people
who are affected by drug abuse problems and for the
provision of a basic health-care response. A major
advantage of the integration of drug abuse treatment in
primary care is the common use of existing infrastruc-
tures and local resources. To make that possible, ade-
quate training, material support and referral services are
needed. Primary care workers (and also community
health volunteers) in the target area need the following:
to be aware of drug use issues and able to screen their
clients for problems; to know how to provide a minimal
health-care response to those with problems (for exam-
ple, to provide a brief intervention, as defined in the
glossary at the end of the present Guide); and, ideally, to
receive support and assistance to manage complex cases. 
An example of an initiative to train primary care work-
ers in the United Kingdom is given in box 24.
3. Balance between specialist and 
general services
Ideally, there should be a good balance between special-
ist resources and primary health-care resources. Indeed,
where there are major resource constraints, the founda-
tions of services will need to be developed through pri-
mary care frameworks. However, wherever possible,
some form of specialist activity is desirable to facilitate
the development of a core expertise to treat substance
abuse problems in the local area. The specialist resource
can be a valuable source of training and support for gen-
eral primary-care workers.
In practice there may be a transfer of clients across spe-
cialist and general primary-care services. In some
treatment systems, clients who have been successfully
rehabilitated by a specialist service, but still require
medical and other care, may be referred to a primary
health-care team that will continue to provide the
service, with support from the specialist service as
required. The reverse situation can also occur, in
which a client of a primary-care service has needs that
cannot be realistically managed in that setting and a
referral to a specialist agency is undertaken on a tem-
porary or longer-term basis. 
The utilization of primary care personnel in the treat-
ment system in Ireland is summarized in box 25.
B. Developing a new treatment 
service
In this section, general project principles and activities
are applied to the specific context of how best to estab-
lish a dedicated programme for treating substance
abuse. The guidelines do not focus on a specific modal-
ity of treatment. In practice, the majority of key aspects
of a development process are generic issues. Specific
examples in the form of short case summaries are pro-
vided to give examples of how new resources have been
established in different country contexts.
Being clear about the realistic aims and objectives of the
project is essential, no matter how basic or complex the
initiative. The process of developing a treatment service
can be complex and time-consuming. To help to ensure
a successful outcome, it is recommended that one per-
son be appointed (or seconded) to manage the develop-
ment phase. The person appointed to that position
should have organizational, management and commu-
nication skills and the vision to bring the project to
completion. 
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Box 24
Royal College of General Practitioners—
learning objectives for primary care workers
In 2001 in the United Kingdom, the Royal College of
General Practitioners undertook to train some 400
general practitioners and 60 prison doctors as “spe-
cialist generalists” in the treatment of substance
abuse. The training involved a series of pre-class con-
ferences, master classes and continuous assessment
methods. As part of that initiative and the accredita-
tion of competence, a learning portfolio was prepared
setting out the professional competence requirements
and the learning objectives for the training scheme.
The learning objectives included:
• Critically appraising the clinical guidelines of the
United Kingdom on the treatment of substance
abuse;
• Clarifying good practice in relation to prescribing
substitution treatment;
• Understanding of the role of the general practi-
tioner in the care of the drug abuser;
• Developing a broader understanding of “shared
care” arrangements between general practice
and specialist treatment agencies;
• Reviewing the harmful consequences of drug
abuse, including the role of general practitioners
in the prevention of drug-related deaths.
For further information, go to
http://www.smmgp.demon.co.uk 
1. Specifying the needs of the target 
population
As outlined in chapter III, a clear understanding of the
nature of the client groups that the treatment pro-
gramme is intended to serve is required. That can be
done partly by reflecting on the likely referral and treat-
ment access routes that are going to be used and partly
by conducting a needs assessment. That process should
help to identify the likely treatment needs of special
population groups, including young people, women,
injecting drug users, HIV-positive drug abusers, people
with psychiatric co-morbidity, homeless people, people
in the criminal justice system and people from ethnic
minorities. A specific assessment of needs of female drug
abusers in Pakistan is summarized in box 26.
2. Drawing up a project specification 
A written specification should define the scope of the
project and specify what it is intended to do and
achieve. It is also important to state if there are things
that the project will not be expected to do. The docu-
ment should further set out who the key development
personnel are and describe their responsibilities and
what they are expected to do. It should describe the
quality standards and the evidence base to be followed
for the project, and clarify how it will be known when
the project has been completed. Such a clear statement
of all of the project deliverables is extremely valuable.
It will also be necessary to undertake a risk assessment,
even if it is fairly informal. In project management
terms, “risk” is the likelihood of a hazard or undesirable
event happening, and “risk control and management”
involves taking steps to reduce risk, stage contingency
plans and monitor how the project unfolds. Whatever
the level of complexity of the project, a project steering
committee should be established to identify the likeli-
hood of risk for the project. The committee should
address the following questions:
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Box 25
Development of treatment services in
Ireland
In Ireland a series of national reports promoted the
development of services to respond to a major heroin
problem in Dublin. There was major investment in
service development between 1995 and 2000 with
the capacity of the system more than doubling. Much
of that was achieved through the development of a
policy on primary care that laid down clear procedures
for the involvement of general practitioners in the
management of drug dependence, provided training
and also paid general practitioners for the time that
they spent on that complex problem. 
In subsequent policy reviews, it became apparent that
services had developed in Dublin, but the drug prob-
lems were expanding to other parts of the country. A
revised national drug strategy was developed that
took forward the experience of developing services in
one locality and recommended that a regional and
local integrated drug and alcohol service be devel-
oped in all regions. 
A national task force and regional drug coordination
system was also set up as part of the process of facil-
itation and development. The coordination structure
was an important part of the national monitoring and
implementation process.
Box 26
Developing services for female drug
abusers in Pakistan
In Pakistan, female drug abuse has a substantially
lower prevalence than male drug abuse and is a more
hidden behaviour. Prescription drugs, followed by
heroin, are the substances most commonly reported
to be used by women. Unlike the male pattern of use,
hashish, or charas, is not commonly reported as the
main drug type used by women.
In the country, there was a perception that many
drug-abusing women do not seek treatment because
of concerns that their children will be taken into State
care. They also fear reprisals from their spouses and
punishment from authorities in the community. In that
context, it seemed essential to provide a confidential
service that female drug abusers could trust and have
easy access to.
Keeping in view the limited facilities available for
women drug abusers in Pakistan, UNDCP, in collabo-
ration with a local non-governmental organization,
established a telephone hotline service in the city of
Lahore. The objective of that one-year pilot project
was to provide realistic information to women about
drugs and how to handle the problem if drug abuse
exists within a family. The non-governmental organi-
zation assigned counsellors and psychologists, who
were trained in drug demand reduction, to answer
questions from women drug abusers or their families
and to provide support. The non-governmental organ-
ization also established a system for the referral of
women drug abusers to public and private treatment
facilities. Success factors for the project included the
availability of well-trained counsellors around the
clock and a high degree of perceived confidentiality.
• Is the project likely to be effective and feasible from
a technical viewpoint?
— Will it achieve the desired results?
— Will it achieve other benefits?
— When will the benefit be realized?
— Is the project sustainable?
• Is the project politically acceptable?
• Is there community support for the project?
• Is there likely to be demand for the project among
the target service users?
• To what extent are the benefits assured?
• Is the project affordable?
3.  Mobilizing funds and getting started
In the early project planning phases, fundamental ques-
tions about the budget and available resources need to
be addressed. Early discussions should also be held with
representatives of government agencies and staff of other
services (as provided) to identify existing gaps in provi-
sion. Examples of how finance was secured for a devel-
opment in Africa and how a modest initiative has grown
in Mauritius are shown in boxes 27 and 28.
4.  Project timetable
Several useful techniques have been developed by pro-
ject management specialists to help to ensure that pro-
jects are delivered on time and according to specifica-
tions. One such technique is a Gantt chart. For project
management purposes, it is a diagram with activities
represented by a bar that is positioned along a horizon-
tal timescale, with the length of the bar indicating the
duration of each activity. The chart compares the base-
line to the current schedule, with one of the bars run-
ning from start to finish and the second bar running
from the currently scheduled start to finish. If the two
bars for a task run on top of one another, the task is on
schedule. The extent of non-overlapping indicates the
amount of delay or slippage that has occurred for the
task area. There are several commercial project manage-
ment software products that can be used and will enable
such a chart to be drawn and managed.
5. Defining therapeutic services to be 
provided 
An initial appraisal or needs assessment of the nature
and extent of drug abuse problems in the locality will
inform discussions of which types of therapeutic servi-
ces are required. In addition to a core outpatient and
day-care programme, it is usual to include direct provi-
sion or access to some form of residential setting treat-
ment. It is not uncommon for a treatment service to
evolve over time from an initial core service-perhaps a
community counselling service with referral to inpatient
care as required-to the direct provision of outpatient and
residential services that are linked together and form a
logical programme.
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Box 27
Identifying sources of funding in Kenya
Kenya has very limited services for the rehabilitation of
persons with a substance abuse disorder. In 1996, a
group of four mental health experts, three psychia-
trists and a clinical social worker decided to build a
centre of excellence dedicated to the treatment of the
problem. At the time, the concept of borrowing
money for a project of that nature was novel in the
Kenyan banking system. No bank would consider
lending any money to the four promoters, as they saw
the project as being uncertain and of too great a risk.
The African Project Development Facility (APDF) is an
affiliate of the World Bank and was approached to
formally evaluate the project concept on behalf of the
mental health experts. Following a favourable review,
APDF facilitated the financial structuring of the project
by the local banking sector. The project was devel-
oped and has made a substantial contribution to the
setting of standards of rehabilitation in the East
African region. 
Box 28
Community and professional mobilization
to develop a treatment centre in Mauritius
The Dr. Idrice Goomany Centre in Mauritius offers an
example of how a treatment and rehabilitation centre
can be developed as the result of a community initia-
tive. The Mayor of Port Louis, concerned about a sud-
den increase in drug abuse, convened a number of
social workers and professionals to a meeting to dis-
cuss how to address the problem. The outcome was a
decision to initiate a treatment centre on an outpatient
basis, using the premises of a municipal kindergarten.
A volunteer team started operations without financial
support. The team gradually matured, services were
improved and eventually the Government started to
provide funds for the recruitment of a small full-time
staff. A new building was built on a plot of land leased
to the centre by the municipality and a full-time staff
team was created. The programme still operates on a
modest budget and is very well regarded and much
used by the community.
An example of a range of services that has been devel-
oped in the Middle East is shown in box 29. In the
example, a range of therapeutic elements were designed
for delivery to the new centre. However, those elements
were not brought into operation immediately. The mix
of services was delivered according to the needs and vol-
ume of referrals received in the early months of the serv-
ice. A flexible and developmental approach was there-
fore used as an efficient means of managing resources
and the staff team.
6.  Establishing the policies and procedures
of the treatment centre
A key task in the development process of the treatment
centre will be to write a protocol specifying the aims and
objectives of the service, as well as its operational proce-
dures. The type of staff employed will depend upon the
programme type, the components and the resources
available. An assessment should be undertaken to iden-
tify what staff levels and competences and expertise are
required. 
An early identification is clearly needed of the financial
resources that will be available for capital and revenue
aspects of the service. There are many examples of treat-
ment programmes that have floundered because prepa-
rations have not been sufficient to clarify or agree on
work service contracts, operational revenue and pay-
ment mechanisms with funding organizations. A speci-
fic business function devoted to funding management
issues is almost always needed. 
In terms of sustaining the service over time, it is worth
noting that the scale and nature of problems to be
addressed will change. The vision of the service should
recognize that adaptations will be needed to ensure that
the services continue to be responsive. Services ideally
would be supported by a coherent national plan that
allows for long-term planning and implementation and
does not change too readily.
A summary of the general specifications of a treatment
programme is shown in the table below. When develop-
ing a new treatment, or reviewing an existing service, the
table can be used as a checklist of components. There are,
naturally, considerable differences across countries in
how treatments are specified, but the table captures the
core elements that are common in most contexts. 
An illustrative example of a residential rehabilitation pro-
gramme is provided in annex III to the present Guide to
help clarify how the principles listed above can be
applied. While the components outlined above (except
accommodation and food) apply to any type of treatment
V.6
Drug Abuse Treatment and Rehabilitation A Practical Planning and Implementation Guide
Box 29
Development of a National Treatment 
and Rehabilitation Centre in the United
Arab Emirates
In 2000, the Government of the United Arab Emirates
initiated a development plan to create a new National
Treatment and Rehabilitation Centre in Abu Dhabi.
Available data suggested that the country has a low
prevalence of drug abuse problems, but the project is
seen with long-term prevention goals in mind. In close
consultation with the officials of the United Arab
Emirates, an international team of experts in the field
initiated a needs assessment and developed a project
implementation plan. Problems of opioid, cannabis and
benzodiazepine dependence were identified and a
small but rising treatment population was being man-
aged by several existing services in the country, with
the prison and criminal justice systems also closely
involved. The view taken by the Government was to
establish a temporary facility with a core developmen-
tal staff team to launch the new service pending the
design and construction of a permanent facility. The
initial resource contains five separate elements: pro-
gramme administration and business management;
client assessment and treatment planning; an out-
patient counselling unit; a detoxification unit; and a
rehabilitation unit.
The programme has nine functional components: a
referral and assessment service; detoxification and
basic physical assessment; an outpatient programme
and a day programme; a residential programme; after-
care follow-up; community development and outreach;
overall integrated care coordination; a telephone
helpline and advice centre; and research and develop-
ment.
Following refurbishment of an existing building in a
central location in the city, the treatment centre began
operations in 2002 with a mixed team of nationals and
substance abuse treatment professionals from several
countries. Concurrently, work is under way to config-
ure and construct the new permanent, dedicated facil-
ity on the outskirts of the city. It is possible that the ini-
tial treatment centre may remain as a “satellite” 
service. 
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Specifications of a treatment programme
Element
Description of client
groups served
Philosophy
Standards governance
Strategic management
Staffing
Access and referral
information
Assessment criteria
Care planning and
review
Completing treatment
Human resource 
management and
development
Physical environment
Accommodation 
and food
Performance 
monitoring and quality
Operational policies
Content
A description should be developed to characterize the client group that is served by the pro-
gramme.
The operational philosophy should be outlined, together with the specific approach that is used
by the service and accounts for why the programme is successful.
A description is needed of the executive and operational management structure of the pro-
gramme and how that is regulated.
The programme should be able to outline an overall mission statement and a strategic plan.
The composition and size of the staff team should be described.
A clear description should be developed to show how referrals are made to the programme;
what are the minimum and maximum timescales for response; which staff are involved and how
the referral will be managed; and how the referral process will be documented and referral out-
comes monitored and communicated back to the referring agency.
A method for how clients are to be assessed is clearly required and that needs to include what
specific complaints will be screened for and assessed.
A care plan is a written description of the treatment to be provided and its anticipated course.
Care plans set out the specific needs of individual clients and the ways in which they are going
to be addressed by the service (and by other service providers as required). The care planning
process needs to be carefully monitored, evaluated and revised as necessary.
Departure from the programme and onward referral should be a planned event, and should be
overseen by a key worker responsible for clients.
The programme will need to have a management, staff and volunteer team (if used) that have
the skills and abilities to meet the objectives of the service. A policy sets out the staff recruit-
ment and selection and employment policies and they comply with equal opportunities and
employment rights legislation; a human resource, management policy and supervision and
appraisal system should be described that monitors, motivates and supports performance; and
an annual training plan should also be developed with sufficient financial resources to support
it, subject to periodic review.
The premises and other environmental resources will need to meet the requirements of appro-
priate regulatory bodies.
The accommodation provided in the programme will be comfortable and should meet the
needs of the resident in terms of his/her right to privacy, dignity, respect and personal inde-
pendence. Food and drink provided to the users should be nutritious and healthy.
The programme will develop and maintain criteria and procedures for documenting and report-
ing service outputs and outcomes. Criteria should be agreed with commissioners and other rel-
evant external bodies. Output and outcome monitoring reports will be provided to the man-
agement body and to relevant external audiences as specified in the contracts.
The core policies and procedures can encompass the following:
• Admission and discharge criteria;
• Statement of rights;
• Confidentiality (record-keeping etc.);
• Complaints procedure;
• Service users involvement procedures;
• Service users privacy policy;
• Equal opportunities policy;
• Programme environment and personnel;
• Policy on visitors to the programme.
centre, a community-based service may need to develop
protocols for additional components. For example, in
addition to seeing individuals with substance depend-
ence, a community-based service may also manage peo-
ple with substance abuse problems relating to intoxica-
tion and earlier stages of abuse of those substances. In
consequence, protocols for early interventions, including
brief interventions, to treat those drug-related problems
or low levels of dependency will most likely be needed.
Community-based programmes are also more likely to
participate in community development and other health
promotion activities, and policies and procedures to gov-
ern their participation will be needed. 
An effective community-based programme will have
written protocols for the following components:
• Assessment, treatment and care;
• Early identification and intervention (unique to
community-based programmes);
• Health promotion and prevention of health and
social consequences (unique to community-based
programmes);
• Community liaison and participation (unique to
community-based programmes);
• Family interventions;
• Vocational training;
• Social reintegration;
• Client rights and responsibilities;
• Client and programme records;
• Staff education, training and development;
• Planning, evaluation and quality improvement;
• Management.
Key questions to be addressed in the conceptualization
of a treatment centre are summarized in box 30.
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Box 30
Treatment centre development and management: key questions to address
Treatment protocol development
• What will be the service style, content and coordination mechanisms?
• Do they reflect current research evidence?
• Do they respond to consumer demand?
• What will be the assessment and treatment protocols?
• Who will be involved in the phases of treatment (see chapter VI of the present Guide)?
• Are there clear written statements of service regarding philosophy, policies, procedures and the target population?
• In case a variety of treatment modalities are offered, criteria and consistent algorithms to place or match patients
to different modalities should be made explicit.
Staff team a
What type of staff team is needed? Staff members can include:
• Programme director, manager and administrator;
• Secretaries and office support;
• Physician and psychiatrist; 
• General and psychiatric nurse;
• Social workers and family liaison worker;
• Psychologist and psychotherapist;
• Occupational therapist;
• Other support staff.
Overall management
• What will be the management structure?
• Will staff and management and the broader community exchange ideas on service style and content?
• Are the areas of responsibility clearly defined?
C. Treatment programme 
operation
1. Organizational climate
A drug abuse treatment service requires an accountable,
efficient, effective method of management that facili-
tates the achievement of its goals. That requires an orga-
nizational structure with clear lines of responsibility. An
important priority is to ensure that staff and manage-
ment facilitate a positive working environment. Aspects
that contribute to such an environment include the fol-
lowing:
• The value of the contribution of each staff member
to the success of the programme is acknowledged;
• There are opportunities for open discussion between
team members;
• There are mechanisms for conflict resolution;
• There is a regular assessment of team member satis-
faction;
• Appropriate staff incentives and rewards are offered.
2. Staff training 
It is self-evident that one of the main determinants of a
successful drug abuse treatment programme is a compe-
tent and appropriately trained staff team that is adequate-
ly resourced. There should be shared understanding about
the collective and individual role and responsibilities of
the team. It is the role of management to ensure that the
staff is supported in carrying out its tasks. In that regard,
a policy that is properly resourced for staff training and
support should be based on the following: 
• Training and other non-formal learning opportuni-
ties are offered in accordance with the needs of the
staff in fulfilling its roles;
• All staff members have access to supervision and
regular feedback;
• There is an allocated budget for training;
• Networking with other treatment agency staff is
encouraged.
In recent years, developed treatment systems in many
countries have been reviewing the training and profes-
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Box 30 (continued)
Treatment centre development and management: key questions to address
Financial management
• What are the implications for human and capital resource requirements that are needed to provide the service?
• What will be the accountability mechanisms?
• Is there a budgeting process that includes a mechanism for performance monitoring?
Monitoring system management
• Are there mechanisms for monitoring, evaluation and feedback on service and system performance?
• What record systems exist for clients, human resources management and the payroll?
Staff management
• Are staff appraisal mechanisms in place?
• Are there opportunities for orientation, education, training and support of staff?
Quality management
• What will be the quality improvement systems?
• Are there special licensing conditions associated with the service?
• What are the information management and information technology requirements?
• What external data, including demographic and epidemiological data, are available for planning? 
• What internal data are available for monitoring and evaluation?
aThe composition of a staff team in terms of medical/nursing and social work/occupational therapy professions will vary. In some contexts, a predom-
inantly medical structure will be common; other programmes will be more oriented towards social work.
sional competencies of workers in the field of substance
abuse treatment. It is important to review the profes-
sional competencies that each worker should possess in
their role in a programme. Areas of required compe-
tence can include:
• Screening and assessment procedures for each pro-
gramme;
• Detailed knowledge of eligibility criteria for client
treatment;
• Methods of establishing personal goals for clients
and reviewing and managing progress;
• Counselling skills and specific psychotherapeutic
approaches.
3.   Staff supervision
At the heart of staff supervision is the provision of ade-
quate support and feedback to staff members in order to
improve the quality of care, increase staff satisfaction
and prevent staff burnout. Staff supervision is defined as
the process of ensuring that personnel involved in the
operation of a treatment centre are able to undertake
their responsibilities appropriately and effectively and
with regard to the core competencies required. Staff
supervision issues and the elements of a supervision sys-
tem are summarized in box 31.
4.  Financial and budgetary management
Almost all treatment services require policies and proce-
dures to manage the flow of financial resources into and
out of the programme. Providers are responsible for
ensuring that resources are appropriately used and mon-
itored. 
In an ideal situation, service providers would develop a
medium- to long-term financial strategy that considers
financial planning over a three- to five-year period. The
plan would also take into account what action would be
taken and the impact upon services etc. if there were to
be a loss of current funding, as well as the opportunities
that may arise with regard to alternative funding sources. 
A good-quality provider must be able to: 
• Establish systems for authorizing the payment of
bills, signing cheques, managing petty cash etc., with
sufficient safeguards;
• Prepare an annual budget (clearly identifying pro-
jected income and expenditure) to Guide service
delivery; 
• Produce a monthly cash flow and financial operating
statement that compares projected and actual expen-
diture;
• Prepare an annual, independent, audited financial
report showing compliance with the applicable tax
regulations. 
A good-quality provider should be able to cost the vari-
ous components of their programmes. An important
concept in that regard is that of “unit cost”, which is cal-
culated by listing all the “inputs” to the programme (for
example, staff, equipment, medications, supplies, office
space and accommodation, utilities and other supports)
and the units of service (number of therapy sessions etc.)
that are used for a specific period of time, such as a 24-
hour period, in the operation of an inpatient unit. The
unit cost figure can then be used to arrive at the overall
cost of a programme or system for a number of persons
over a specific reporting period, such as a financial year. 
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Box 31
Staff supervision system
The structure for clinical supervision is usually on a per-
sonal interview basis between staff members and a sen-
ior staff officer, although a group discussion format may
be used. Various methods are employed as part of
supervision, including reviews of the current caseload of
the staff member, as well as issues-based discussions of
problems recently encountered and resolved. 
The supervision system for staff should:
• Offer support, feedback, problem-solving and
instruction;
• Use successes and mistakes as learning opportuni-
ties;
• Provide regular planned supervision sessions;
• Use an action cycle of performance feedback to
staff members to help their development.
The supervision should be undertaken by someone who
is more experienced than those who receive it.
The benefits expected from the supervision system will
be to:
• Improve the quality of care;
• Increase staff confidence and job satisfaction;
• Create a workplace that values open reflection;
• Identify staff educational needs.
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Key points
The key points covered in chapter V of the Guide are as follows:
• Treatment service development has to be pragmatically based within the network of available health and social serv-
ices;
• The size and scale of the response depends on the patterns and extent of the drug abuse problems, as well as on
the resources available;
• Globally, the type and scale of services will vary enormously in accordance with differing needs, resources and soci-
ocultural conditions;
• Key components of services relevant to the local circumstances should be identified and put in place. An overall plan
should ensure that the different components are logically and practically linked. In that context:
— Community-based primary care responses should be the foundation of services and could be supported
through more specialized district or regional services;
— Dedicated treatment services constitute the next stage of development;
— Comprehensive, diversified and coordinated treatment systems will be required in situations of high
demand for services;
• Good planning, organization and coordination is critical to good service development. In particular:
— Clear objectives and clearly defined approaches to achieving those objectives will set the foundation for a
good treatment service to be developed over time;
— A written timetable with clear outcomes and development tasks that are time-framed and that identify
who is responsible for action will help to keep the project on track;
— Rational management and good staff management will facilitate high-quality services;
• Long-term approaches should include strategies for training and staff development and for broader research and
development.

It is fair to say that all treatment systems, however well
developed and resourced, can be better integrated. In
many countries with long-standing and developed sys-
tems, current efforts concentrate on encouraging treat-
ment services and agencies to work together in a more sys-
tematic way. The need for better integration and coordi-
nation has been highlighted at several points in the pre-
ceding chapters of the Guide and reflect the fact that many
people with substance abuse problems need a combina-
tion-or a sequence-of treatment services that are delivered
according to a care plan for each client. The need for a
number of linked treatments generally reflects the chroni-
city and severity of the problems faced by a client. 
Chapter VI of the Guide asks the question: “How can
individual treatment programmes and systems be most
effectively coordinated?”
The benefits to be derived from reading chapter VI are
as follows:
• Conceptual clarification of the structure and ele-
ments of a treatment system;
• Understanding of how the treatment system is likely
to operate;
• Understanding of how to identify and achieve out-
comes desired by individual clients in the treatment
system.
Depending on the size of the target population and the
nature and extent of drug-related problems, a compre-
hensive treatment response may include the provision of
each of the main types of open access and structured
treatment that were outlined in chapter II. Those
responses should be seen as part of the broader health,
social and legal response to drug use and, as such,
should be integrated into those systems. Some types of
treatment—usually residential rehabilitation pro-
grammes—are often accessed on a regional basis. That
involves a referral to a programme at a distant location
and the need to link to community-based services for
aftercare and social reintegration.
Chapter VI is divided into two sections. Section A looks
at the definition and general characteristics of a treat-
ment system and how it must respond to changing con-
ditions in the population. Referral routes and an exam-
ple of an integrated system in operation are then
described. Section B turns to operational issues and dis-
cusses client screening and assessment, treatment plan-
ning and care coordination issues. Section B also pres-
ents an approach to planning the development and
implementation of a whole treatment system, or com-
ponents of that system. 
A. Definition and characteristics of an
integrated treatment system
People with drug problems tend to have a wide range of
additional problems, are often significantly involved
with the criminal justice system, and are homeless or
without welfare and other support. It is important
therefore that the treatment system is holistic and brings
key local agencies into working partnerships in order to
maximize the overall effectiveness of the service
response. 
1. Definition of a treatment system
A treatment system is a group of interrelated, or inter-
dependent treatment and rehabilitative “elements” that
form a combined response to substance abuse problems
in a defined region or country. If the evolution from a
single treatment service to an array of multiple providers
of treatment is considered, the forces for expansion are
driven by increases in the nature and volume of demand
for treatment in the population that outstrips the capac-
ity or competence of any one provider. 
2. Elements of an integrated 
treatment system
Many individuals may require the provision of several
different types of treatment service over time (that is, a
continuum of care). It is quite common for an individ-
ual receiving treatment from one provider to receive
additional welfare support and other social inclusion
services provided by other agencies (for example, hous-
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ing support and legal advice). It is also frequent that
treatment services provided by different agencies are
provided in sequence (for example, detoxification, resi-
dential care and outpatient counselling). Those supports
are important elements in an effective package of care
services that can evolve over the course of treatment of
an individual. An example of the basic structure of a
treatment system integrating different types of services
is shown in box 32. Box 33 presents an example of a
more sophisticated integrated treatment system.
In an integrated care system all agencies have a role to
play in staging a coordinated response. Individuals in
need of treatment for drug abuse may resort to any one
of the mainly identification and referral services shown
at the bottom of box 32. The precise nature of formal
linkages will need to be determined by the system and
the prevailing contractual and partnership arrangements
that exist.
A fully integrated system is characterized by good coor-
dination, linkage and integration of the various special-
ist and generic treatment and support elements. In
large-scale treatment systems, that involves a range of
agencies and supporting strategic and funding organiza-
tions, working in conjunction. It is also sometimes the
case that there is a single specialist provider agency for a
locality that operates a wide range of treatment units
and administrative support functions including
research. However, it is more common for several
providers to be in operation. Those single or multiple
providers are likely to link with an array of non-
substance-abuse specialist and generic services in the
course of their work. It is important to stress that effec-
tive coordination is also advantageous in relatively small
treatment systems. For example, in the context of a pri-
mary care team, a specialist agency, a general social wel-
fare support service, effective linkages and cross-referral
of clients according to their treatment and rehabilitation
needs is advantageous.
Linkages to education, employment and welfare agen-
cies, as well as to the criminal justice system, are impor-
tant components of the system, if integrated care is to be
developed. Box 34 illustrates the process of diversifying
and linking treatment services.
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Box 32
Example of the elements of a treatment system
Below is an example of a treatment system that could be delivered for areas with a population of between 300,000
and 500,000.
Nature of service
Specialist residential
Specialist community
Generic and specialist community services
Generic open access services
Screening and referral
Provider/organization
Inpatient/residential programmes 
Residential rehabilitation programmes
Counselling programmes/day programmes 
Specialist community treatment programmes
Social services/welfare agencies 
Community mental health services
Primary health care
Hospital emergency services
Other hospital care services
Criminal justice agencies
Youth services
Education and employment organizations
Community organizations
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Box 33
Example of an integrated treatment system in operation: the models-of-care framework in the
United Kingdom
The following description shows how a treatment system could be conceptualized in terms of levels or “tiers” of ser-
vice. The ideas behind the example have been developed by several organizations and projects and are presented for
illustrative purposes. In the following description, a tiered system has been advocated in the United Kingdom, which
reflects how the system is designed to operate.
The system contains an array of generic and specialist providers, together with agencies and services that may come
into contact with drug users during the course of their work (for example, voluntary agencies and telephone
helplines). The latter services are important, since they can provide brief advice for individuals and referral into the
treatment system, as appropriate. 
The elements of the system are not presented in a fixed vertical way, and referrals can be made to one of the 
services depicted in each tier from any one of the generic or specialist services in a tier above or below.
A.  Non-drug-abuse-specific generic services
Non-drug-abuse-specific generic services can contain a broad array of generic services that may come into contact
with large numbers of individuals with drug abuse problems with a full range of problem severity. Probation, parole,
social welfare agencies and primary health care are all examples of services that can provide a screening service and
provide opportunistic intervention for problematic drug use. They also provide a point of entry into the formal drug
treatment system.
B.  Open access services
The second tier contains specialist agencies (often provided by non-governmental organizations) that target drug
abusers. The set of services responds to the basic needs of people with drug problems as well as the harms associa-
ted with drug use, without necessarily focusing on attempts to cease drug use. Examples of such services include
advice and information, drop-in services, motivational interviewing and brief interventions, street outreach services,
needle exchange (through pharmacies, agencies and outreach), low threshold prescribing and assessment and care
management specific to substance abuse.
C.  Structured community-based drug services 
Structured community-based drug services contain specialist (usually multidisciplinary) services that are resourced to
offer specialist treatment and referral. Services in this tier include planned counselling and psychotherapy, structured
day programmes, structured community-based detoxification, structured prescribing and methadone maintenance
and structured aftercare programme.
D.  Specialized residential drug services
The fourth tier essentially comprises specialist services that offer intensive and structured programmes that are deliv-
ered in residential, hospital inpatient or other controlled environments. Some crisis intervention services in this tier
may have open access and others require formal referral via a health or social care agency. Examples of services with-
in this tier are inpatient drug-dependence units and designated psychiatric beds, residential rehabilitation, mother and
child rehabilitation services, dependency units for young people, specialized crisis centres and residential co-
morbidity services.
At any one time, the model advocates that a client should be able simultaneously to attend services that are in the
same or a different tier according to need. The model can be accessed at: 
http://www.doh.gov.uk/nta/modelsofcarefull.pdf.
3. Referral routes into the treatment 
system
It is important to specify the main referral routes into
the treatment system. In practice, there may be quite
complex referral and assessment decision-making
processes that operate when individuals resort to the
treatment system. Assessment and appropriate place-
ment of a client within the system is crucial and will be
influenced by immediate needs and those emerging over
the course of a treatment episode and aftercare. 
A treatment system should be able to receive referrals
from the following: self-referral; family and friends;
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Box 34
Diversifying and linking services for injecting drug users: opiate substitution treatment in
Lithuania
In 1995, two Lithuanian experts participated in a study tour of programmes for drug users in London and Amsterdam,
supported by the Phare Programme of the European Commission. Thereafter, the Ministry of Health held a series of
meetings to discuss the possibility of introducing pilot substitution treatment programmes in Lithuania. The Ministry
organized training on substitution treatment in Sweden; and furthermore elaborated the first national guidelines on
substitution treatment in May 1995. 
Substitution treatment and outreach needle exchange were introduced as additional services to the existing pro-
grammes of the narcology centre. Existing resources (staff and facilities) were used, and substitution treatment cur-
rently constitutes, together with inpatient detoxification and drug-free rehabilitation, a main treatment option in
Lithuania. The existing wider spectrum of services and links with other community-based institutions and organiza-
tions provides better opportunities to meet the needs of clients at different stages of the treatment process. With the
introduction of new modalities, a larger number of injecting drug users can be reached and HIV prevention activities
can be carried out among the group.
When a drug user applies for treatment, the physician assesses the user. Clients are referred to relevant services
according to their motivation and needs. If the client meets the clinical criteria for substitution treatment, he or she
is referred to a substitution treatment commission, which examines whether the client will be admitted into the pro-
gramme. The client is then assigned to a physician, who takes care of the treatment plan and its implementation. The
treatment plan includes screening for HIV, sexually transmitted diseases and tuberculosis, as well as routine medical
examinations and consultations with an internist as needed. The plan also includes an assessment by a social worker
in order to draw up recommendations for social rehabilitation. Social workers encourage and assist clients in regis-
tering at the unemployment agency, which has a possibility to offer vocational training and assistance in finding a job.
Furthermore, the Lithuanian AIDS Centre, the Vilnius Municipal Social Care Centre and several charitable institutions
assist clients in their respective areas of work. 
New substitution treatment clients usually initiate treatment at the specialized narcology clinic, and after the physical
and social status of the client becomes stable, he or she can be transferred to a primary health-care centre under the
care of a general practitioner. Three primary health-care centres cooperate with the Vilnius Substance Abuse
Treatment Centre in the substitution programme, whereas other primary health-care centres provide general health
care at the request of staff of the Vilnius Substance Abuse Treatment Centre. Primary health-care centres offer a non-
stigmatizing setting for the treatment of injecting drug users. The two-phase programme of initiation of substitution
treatment at a specialized clinic, combined with referral of stable clients to a non-specialized institution involving gen-
eral practitioners, is considered to provide an increased level of individualized care.
The evaluations of the substitution treatment programme, based on treatment statistics, are annually presented to the
Ministry of Health. Currently, 2,000 injecting drug users are registered in Vilnius, while there is an estimated 4,500 to
5,000 injecting drug users. In 2001, 525 outpatient clients were in substitution treatment and 3,600 injecting drug
users were reached through outreach, including 360 regular clients, who used outreach services several times per
month. Thus, the substitution treatment programme, together with the outreach needle exchange, reached about
50-60 per cent of the estimated number of injecting drug users in Vilnius. The retention rate in treatment in 2000-
2001 was around 75 per cent, which was considered satisfactory, with a dropout rate of 4-6 per cent per year. 
Source: Drug Abuse and HIV/AIDS: Lessons Learned, Case Studies Booklet—Central and Eastern Europe and the Central Asian States (United Nations,
2001), pp. 26-30.
primary care physicians (and primary health-care
teams); community services; specialist service
providers; criminal justice agencies; cross referral with-
in a treatment system.
4.  Integrated care pathways
In many areas of health and social care, an integrated-
care-pathway approach is increasingly being used to
identify and achieve outcomes desired by individual
clients. Integrated care pathways are known by various
names, including critical care pathways, treatment pro-
tocols, anticipated recovery pathways, treatment algo-
rithms, care standards and benchmarks. All of those are
designed to create professional consensus and standard-
ize elements of care to improve efficiency, effectiveness
and value for money.
Essentially, an integrated care pathway describes the
nature and course of treatment for a particular client, a
pre-determined plan of treatment and the anticipated
outcomes. The components of care available in the dif-
ferent levels of treatment should provide for a coordi-
nated care approach where there is both horizontal and
vertical integration and linkage of services. That requires
appropriate referral mechanisms as well as feedback on
outcome to the referral source. The development of
integrated care pathways in the drug abuse field is rec-
ommended for several reasons: 
• People with drug problems may have multiple diffi-
culties that require effective coordination of treat-
ment;
• Several specialist and generic service providers may
be involved for an optimum treatment and rehabili-
tation response;
• A person may have continuing care needs requiring
referral to a different level of service over time.
Integrated care pathways resemble a detailed flow chart
showing how patients move through the treatment
programme. Importantly, integrated care pathways can
also show how patients can move from one treatment
service to another in cases of continuing treatment
need. For example, an integrated care pathway for a
methadone programme might show how patients flow
across the following stages: intake and methadone dose
induction; stabilization/maintenance; reduction/with-
drawal; and community aftercare support. A special
feature of integrated care pathways is called variance
tracking. Variance tracking involves monitoring depar-
tures from the expected course of treatment and exam-
ining the causes for the departures and thus improving
the pathway of care. In that regard, integrated-care-
pathway initiatives are similar to audit activities. As an
example, a simplified pathway for a community opioid
substitution programme is shown in box 35. That
example represents a model pathway for illustrative
purposes only.
5.  Responding to local conditions
However complex and integrated a treatment is, it
should be flexible and able to respond to changing con-
ditions in the nature of drug abuse nationally and in
local communities. For example, new drugs may appear
in the drug use market in a country as a result of illegal
distribution channels, and there may be a rise in the
prevalence of using certain drugs in combination. There
may be also a change in the configuration of services
that are able to respond to drug use. A good example is
the growth of criminal justice interventions in several
countries in recent years, requiring careful integration
into the existing treatment system. A good example of
changes in drug problems has been seen in Thailand (see
box 36). 
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Box 35
Example of integrated care pathways for
community opiate substitution 
programmes
Step 1: Screening and triage

Step 2: Comprehensive assessment 
(waiting list support)

Step 3: Intake: dose induction and treatment 
planning

Step 4: Stabilization (maintenance) 
Counselling and support services

Step 5: Monitoring and review (every 90 days)
(cycling through step 4)

Step 6: Medically supervised withdrawal 
(inpatient or community)

Step 7: Departure planning: 
(continuing care/relapse prevention)

Step 8: Community-based support programme or 
residential rehabilitation programme

Step 9: Periodic follow-up
B. Operating the system: 
client assessment processes
An integrated treatment system should be able to screen
people for problems, undertake a suitable brief triage
assessment and then stage a comprehensive and continu-
ing care assessment as one or more treatment and support
services are provided. Those aspects are described below.
1. Screening
Screening involves the use of a rapid procedure designed
to detect individuals who have a health disorder. In gen-
eral medicine, that normally involves the identification
of a risk factor, a marker of the condition, or some
symptomatic early stage. A cost-effective screening test
should be simple, precise and validated. It should also be
acceptable to the population being tested and it should
link with further procedures for diagnostic assessment. 
Screening is not a sufficient condition for the diagnosis
of disorders related to substance use, but it alerts those
involved to assess the person's needs. Screening should
involve the use of a rapid detection procedure to: (a)
identify individuals who are likely to have a substance-
related disorder; and (b) refer the screened individual to
an appropriate service for any immediate treatment that
may be required and further triage assessment. It is
important to note that the person being screened may
well have immediate independent or indirectly linked
personal or social problems that need attention by non-
specialist services. 
In the context of a substitution treatment programme,
screening involves detecting the presence of the signs and
symptoms of dependence. For example, in opioid substi-
tution, the critical procedure of screening ensures that
opioid-naïve individuals (that is, those with no opioid
tolerance) are exited from the assessment procedure for
substitution prescribing. Screening can involve either
self-reporting or biological investigations, or both. 
There is a growing expectation that generic health and
social care professionals (that is, non-substance abuse
specialist service providers including general practition-
ers, accident and emergency departments, children and
families social services) should be able to conduct a basic
drug abuse screening. 
The Alcohol, Smoking and Substance Involvement
Screening Test has recently been published and it is the
first generalized screening questionnaire to look at all
psychoactive substances [13]. The items in the Test are
summarized in box 37 and a further example of a short
screening form is given in annex IV.
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Box 36
From heroin to methamphetamine: the
changing profile of drug problems in
Thailand
Until recently, opioids were the most serious drug
problem in Thailand. In the first half of the 1990s,
more than 90 per cent of those seeking treatment
were opioid users. Most clients were unemployed or
labourers in early to middle adulthood and many were
polysubstance users. Since a number of them injected
heroin, HIV infection caused by intravenous drug use
was an issue of concern. Inpatient detoxification and
short-term rehabilitation programmes in large treat-
ment settings were the main treatment approaches
provided. 
Since the mid-1990s, illicit drug problems in Thailand
have changed drastically, with methamphetamine
users having surpassed the numbers of heroin users.
While the numbers of cases involving heroin seizures
decreased from 40,904 in 1995 to 6,571 in 1999, the
numbers of cases involving methamphetamine
seizures significantly increased from 20,379 to
129,204 during the same period. Methamphetamine-
related admissions rose from a negligible 0.2 per cent
of overall treatment demand in 1990 to 9 per cent by
1996 and 33 per cent in 1999. The characteristics of
methamphetamine users are very different from opi-
oid users. There has been a notable trend of increased
methamphetamine use among youth, especially in
students. The overall drug use among high-school and
college students doubled between 1994 and 1998
(from 72,000 cases to 190,000 cases) and it appears
to have doubled again in 1999 (463,000 cases). Many
of them use methamphetamine only. Because
methamphetamine users in Thailand rarely use that
drug by injection, HIV infection caused by intravenous
drug use is not of particular concern. However, risk of
infection via unsafe sex may be high. Another prob-
lem is that most methamphetamine users do not rec-
ognize their use as problematic. 
To cope with the emerging problem of methamphet-
amine, the psychosocial treatment programmes pro-
vided for the treatment of opioid abuse have been
adapted for the treatment of methamphetamine
users. Two major approaches for the treatment of illi-
cit drugs (mainly methamphetamine) problems have
recently been launched. Under the guidance and
training of United States consultants, hundreds of
health professionals across the country have been
trained to provide a psychosocial treatment pro-
gramme adapted from the Matrix Model programme
developed for psychostimulant users in the United
States.
2.  Triage 
Substance abuse triage assessment is conducted by special-
ist services providing treatment for substance abuse prob-
lems. The purpose here is to identify, at the point of first
contact with the service, which type of treatment is best
matched to the needs and preferences of the individual,
together with the level of urgency of the case that relates to
the response needed. That process involves a diagnosis of
the nature and severity of the problem. An example of a
triage assessment form is provided in annex V and a sum-
mary of the basic assessment process is shown in box 38.
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Box 37
Alcohol, Smoking and Substance Involvement Screening Test
Q1. In your life, which of the following substances have you ever used? (tobacco products, alcoholic beverages,
cannabis, cocaine, stimulants, inhalants, sedatives/hypnotics, hallucinogens, opioids and “other” drugs; non-
medical use only)? 0 = No; 1 = Yes.
Q2. In the past three months have you used the substances you mentioned? 0 = Never; 1 = Once or twice; 2 =
Monthly; 3 = Weekly; 4 = Daily or almost daily.
Q3. During the past three months, how often have you had a strong desire or urge to use (first drug etc.)? 0 = Never;
1 = Once or twice; 2 = Monthly; 3 = Weekly; 4 = Daily or almost daily.
Q4. During the past three months, how often has your use of (first drug etc.) led to health, social, legal or financial
problems? 0 = Never; 1 = Once or twice; 2 = Monthly; 3 = Weekly; 4 = Daily or almost daily.
Q5. During the past three months, have you failed to do what was normally expected of you because of your use
of (first drug, second drug etc.)? 0 = Never; 1 = Once or twice; 2 = Monthly; 3 = Weekly; 4 = Daily or almost
daily.
Q6. Has a friend or relative or anyone else ever expressed concern about your use of (first drug etc.)? 0 = No, never;
2 = Yes, in the past three months; 1 = Yes, but not in the past three months.
Q7. Have you ever tried to control, cut down, or stop using (first drug etc.)? 0 = No, never; 2 = Yes, in the past three
months; 1 = Yes, but not in the past three months.
Q8. Have you ever used any drug by injection (non-medical use only)? 0 = No, never; 2 = Yes, in the past three
months; 1 = Yes, but not in the past three months.
Box 38
Simple structure of an assessment process
Substance involvement and problems Treatment history, readiness and preferences

Treatment modality eligibility criteria
 
Prescribing interventions Psychosocial interventions
   
Withdrawal Stabilization Managed care Residential
management and maintenance and counselling rehabilitation
 
Inpatient Community
Risk and case priority assessment

Referral and case coordination
3. Comprehensive assessment 
The third type of assessment can be labelled a compre-
hensive substance abuse assessment. That is an assess-
ment undertaken by trained substance abuse service
professionals and is appropriate for those individuals
who have problems in several areas and whose complex
needs are likely to require more structured and intensive
treatment interventions. Six core measurement domains
that describe the personal and social functioning of a
client are usually addressed in comprehensive assess-
ments: (a) medical status; (b) employment and support
status; (c) drug and alcohol consumption and problems;
(d) legal status and crime involvement; (e) family and
social relationships; and (f ) psychiatric status.
The primary purpose of assessment is to carry out a
functional analysis and determine the best type of
response. That involves a detailed analysis of the
antecedents, context, expectations and consequences of
an individual's drug use. Since many people are heavy
and problematic users of more than one drug, assess-
ment should profile the consequences arising from a
range of substances. Assessment of the route of drug
administration is also of clinical importance, since
injecting drug use may lead to specific medical prob-
lems, including viral hepatitis, HIV, septicaemia, sub-
cutaneous abscesses and endocarditis.
In addition to assessing the consequences arising from
drug use, the threat of HIV infection and other commu-
nicable diseases has made it important to assess certain
drug use and sexual risk behaviours (for example, sharing
injection equipment and unsafe sexual behaviour). An
important task during assessment is the identification of
barriers to change and the maintenance of change. They
may include psychological problems (for example, anxi-
ety, negative mood states and psychiatric co-morbidity),
social and relationship issues (for example, living with a
drug-using or addicted sexual partner), and environmen-
tal issues (for example, physical access to drugs). 
Several comprehensive assessment tools have been devel-
oped. One of the most widely used is the Addiction
Severity Index and its short version known as the
Addiction Severity Index Lite. The Addiction Severity
Index assesses the extent of a client's problems in seven
areas: medical status; employment and support; drug
use; alcohol use; legal status; family/social status; and
psychiatric status. A trained interviewer can gather a
range of valuable information about a client's areas of
need. The Addiction Severity Index Lite is shown in
annex VI. Another example of a very detailed, multidi-
mensional assessment tool, developed in Chicago, is
known as the Global Assessment of Individual Needs.
That tool combines assessments of clinical and social
problems with research scales and behavioural measures
that record current and follow-up problems for outcome
monitoring and evaluation applications (see
http://www.chestnut.org/LI/gain/index.html). 
4. Characteristics and eligibility criteria 
A client usually needs to satisfy eligibility criteria for
admission to a structured treatment programme. An
example of eligibility criteria that might be considered
as part of the client-treatment assignment process is
shown in box 39 below. It is presented for illustrative
purposes only, and should not be used for clinical man-
agement of clients without necessary adaptations to the
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Box 39a
Eligibility criteria for community setting detoxification
The client must meet the following criteria (a)-(d) and either (e) or (f):
(a) Over the past six months, criteria for substance dependence (with physiological dependence) is met and current,
objectively verified use is confirmed; 
(b) The client is currently tolerant to one or more substance classes such that an abrupt cessation of use will lead
to the onset of withdrawal symptoms;
(c) The client expresses a preference for a community detoxification programme or is willing to receive that type of
treatment;
(d) There is a reasonable expectation that the client will be able to comply with and complete a community detox-
ification programme;
(e) Withdrawal symptoms following cessation of the main substance(s) used are likely to be relatively uncomplicated;
(f) The client's living environment is characterized by reasonable levels of family and/or social supports. 
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Box 39c
Eligibility criteria for community counselling (drug-free)
The client must meet the following criteria (a)-(d):
(a) Client meets diagnostic criteria for past six months substance dependence or abuse;
(b) The client expresses a preference for treatment in a community counselling programme or will accept an assess-
ment for that type of treatment;
(c) The client has sufficient motivation to address harm reduction behavioural changes (safer drug use) or absti-
nence from their main problem substance(s) (according to the required orientation/approach of the counselling
programme);
(d) There are reasonable grounds to assume that the client will be able to attend treatment and comply with the
rules and regulations operating in the counselling programme;
(e) There are reasonable levels of family, relationship or friendship supports that do not represent substantial risk of
sustained drug abuse or relapse to further drug abuse that will prevent attendance at the programme.
Box 39b
Eligibility criteria for inpatient 
detoxification
The client must meet the following criteria (a)-(d) and either (e) or (f)
(a) Over the past six months, criteria for substance dependence (with physiological dependence) is met and current,
objectively verified use is confirmed; 
(b) The client is currently tolerant to one or more substance classes such that an abrupt cessation of use will lead
to the onset of withdrawal symptoms;
(c) The client expresses a clear preference to withdraw from substances in an inpatient programme, or is willing to
receive that type of treatment;
(d) Previous treatment or detoxification experience situation and/or the client's drug use involvement, or personal
resources suggest that he/she will be unlikely to complete a community setting detoxification; 
(e) Withdrawal symptoms of a severe and/or complex nature are likely to follow cessation of the main substance(s)
used; 
(f) The client's social environment contains one or more people (for example, a partner or friends/acquaintances)
who are current substance users and who are likely to hinder the client's resolve or ability to participate in an
outpatient programme and present an immediate risk of relapse.
Box 39d
Eligibility criteria for substitution prescribing 
The client must meet the following criteria (a)-(c) and either (d) or (e):
(a) Over the past six months, diagnostic criteria for substance dependence (with physiological dependence) is met
for the opioid or amphetamine class;
(b) The client expresses a preference for a substitute prescription or will accept an assessment for a community sta-
bilization/maintenance programme;
(c) The client is currently tolerant to opioid or amphetamines (having demonstrated that via objective verification)
and abrupt cessation of use will lead to the onset of a characteristic withdrawal syndrome;
(d) There are reasonable grounds to assume that the client will be able to attend treatment and comply with the
rules and regulations operating in the prescribing programme;
(e) Due to the nature of the client's substance dependence, he/she is not able to make an immediate commitment
to abstinence and requires a period of stabilization/maintenance and monitoring based on appropriate substi-
tution and other adjunctive pharmacotherapy pending further assessment of treatment goals.
particular treatment system in question. In that regard,
the reader should consult resource materials listed at the
end of chapter VI of the Guide.
5.  Treatment plan
All structured treatments should be delivered according
to a written, individual treatment plan for each client.
That should be a collaborative process and involve an
assessment with the client, not of the client. It should
take into account the views and motivations of the
clients and their personal and social supports and prob-
lems. The treatment plan document should: 
• Describe the clients and their personal, social, eco-
nomic and legal situation;
• Show sensitivity and awareness of the clients' cul-
ture, ethnic background and religious affiliation, as
well as their gender and sexuality;
• Describe the client's current problems (as known at
intake);
• Specify authorized sharing of information (what
information will be sought and/or given to other
professionals/agencies, and under which circum-
stances);
• Describe the specific interventions that are planned;
• Set out the goals of treatment and progress “mile-
stones” that can be achieved;
• Describe how the care plan will be reviewed over
time.
When building an individual plan, it is necessary to
address the client's movements both within and
between treatment modalities. Within-treatment move-
ments refer to screening, assessment, intake and pro-
gramme and discharge planning. Between-treatment
movements refer to the potential for sharing the care of
the client between two or more services. 
The care plan concept reflects the fact that many people
have continuing care needs even when a treatment
episode has been completed. It also acknowledges that
individuals can enter the treatment system at different
points and can travel across the treatment system over
time. That movement can occur both within an episode
of care as well as in subsequent care episodes. For exam-
ple, someone completing an inpatient detoxification
programme may well benefit from a short- or long-term
residential rehabilitation placement to maintain and
build on the immediate outcomes achieved by the inpa-
tient programme. They may subsequently be followed
up in a community programme. Relapse into drug use
may lead them to seek the so-called open access services.
Therefore, a particular inter-agency pathway may
involve moving across the treatment system as the client
progresses (or relapses) over time. An example of how
treatments may be linked for an individual client—for
illustrative purposes only—is shown in box 40.
6.  Care coordination
Care coordination is the process of assessment, treatment
planning and management of a client who is receiving
treatment. It is similar to case management but is a wider
concept that can involve the facilitation of treatment across
more than one provider. The function of care coordination
is a key role in an integrated, effective treatment pro-
gramme. A care coordinator's responsibilities would be: 
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Box 39e
Eligibility criteria for residential rehabilitation (drug-free)
The client must meet the following criteria (a)-(e) and either (f) or (g).
(a) Over the past six months, the client has met diagnostic criteria for substance dependence;
(b) The client expresses a desire to maintain abstinence from previously dependent drugs and expresses a prefer-
ence for admission to a residential rehabilitation programme or agrees to enter that type of treatment;
(c) The client has completed detoxification and is not experiencing marked withdrawal discomfort;
(d) The client is likely to have substantial problems maintaining abstinence due to the severity of his/her substance
dependence;
(e) The client requires a programme of psychosocial counselling and rehabilitation that is most suitably delivered in
a 24-hour residential environment;
(f) The client's living environment is characterized by social deprivation, including accommodation problems or
accommodation instability, and that represents a threat to relapse;
(g) The client's social environment contains one or more people (for example, a partner; friends/acquaintances) who
are substance users and who are likely to hinder his/her resolve or ability to maintain abstinence
Box 40
Example of a treatment link for an individual client
• To develop, manage and review documented care
plans based on ongoing assessment (including risk
assessment);
• To ensure that the care plan takes account of the
client's ethnicity, gender and sexuality;
• To advise other professionals also involved in the
treatment plan of any known changes in circum-
stances of the client that may require a review or
change of the care arrangements;
• To carry out an early follow-up of discharged clients
(where feasible);
• To aim at re-engaging people who have dropped out
of the treatment system.
The level or intensity of care coordination required will
reflect the nature of the client's current problem. A
“standard care coordination” response would be envis-
aged for clients who:
• Require treatment from a single treatment modality; 
• Are relatively stable;
• Pose little danger to themselves or others.
In contrast, a “multifaceted care coordination” model, of
higher support and intensity of care, would be more
appropriate for clients who have:
• Multiple needs that cannot be provided successfully
by one service provider;
• Multiple needs but are only willing to engage with
one agency;
• Contact with a number of agencies at referral;
• A severe co-morbidity;
• The potential for harm to themselves or others.
When a client is transferred from one treatment pro-
gramme to another (for example, from a residential pro-
gramme to a community-based counselling programme),
the day-to-day coordination of treatment is passed to the
new service with the intention that a new caseworker in
the receiving service will assume that responsibility.
However, the overall care coordination of the client's
continuing needs can remain with the original agency,
and that is particularly relevant in cases where the person
is returning to the local area following treatment in
another locality and may require aftercare support. 
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Initial treatment required Then possible additional treatments needed (care pathway)
→ Aftercare/support
→ Community drug-free counselling → Aftercare/support
→ Residential rehabilitation → Aftercare/support
→ Residential rehabilitation → Community drug-free counselling →
Aftercare/support
→ Aftercare/support
→ Community drug-free counselling → Aftercare/support
→ Residential rehabilitation → Community drug-free counselling →
Aftercare/support
→ Aftercare/support
→ Residential rehabilitation → Aftercare/support
→ Community detoxification → Aftercare/support
→ Community detoxification → Community drug-free counselling →
Aftercare/support
→ Community detoxification → Residential rehabilitation → Aftercare/support
→ Inpatient detoxification → Community drug-free counselling →
Aftercare/support
→ Aftercare/support
→ Community drug-free counselling → Aftercare/support
Community 
detoxification
Inpatient 
detoxification
Community drug-free
counselling
Community 
prescribing
Residential 
rehabilitation
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Key points
The key points covered in chapter VI of the Guide are as follows:
• A comprehensive treatment response includes the provision of several types of structured treatments in a spe-
cific area according to needs;
• Responses should be seen as part of the broader health, social and legal response;
• It is important to specify the main referral routes into the treatment system;
• Clarifying and formalizing the referral and linkages procedures between treatment services is a key part in the
development of treatment systems;
• The integrated care pathway approach is increasingly being used to identify and achieve individual client desired
outcomes. Elements of such pathways are:
— Client assessment: screening, triage and comprehensive assessment;
— Care planning: structured treatments should be delivered according to a written, individual care plan;
— Care coordination: coordination of care should be a central function of a treatment response.
Almost all treatment services record information about
their clients, their problems and the services to be pro-
vided, and usually store narrative information and other
notes about treatment progress in the client's file.
However, many treatment services struggle to find ways
to practically use the information they gather to assess
the impact of their treatment and to provide an
overview of how they are performing as a service.
Today, there is concern about that situation in many
countries. In almost all developed and developing coun-
tries, treatment systems place emphasis on improving
the day-to-day recording of service delivery and assess-
ing the impact and outcome of treatment. The value
and importance of gathering and applying information
about the effectiveness of services is highlighted in the
Declaration on the Guiding Principles of Drug Demand
Reduction and the Action Plan for the Implementation
of the Declaration on the Guiding Principles of Drug
Demand Reduction. 
Chapter VII of the Guide asks the question: “How can the
performance of treatment services be assessed?” That ques-
tion is approached first from the perspective of a basic set
of information and recording procedures that can be
included in the day-to-day operation of a treatment serv-
ice. More complex and sophisticated monitoring and
research activities are then described. Ways of accessing
summaries of the research literature are also discussed.
The benefits to be gained from reading this section are
as follows:
• Guidance on how to ensure that information can be
collected to show that services meet their stated
objectives and other general outcomes;
• Clarification of the key outcome measures that can
be used;
• Understanding of how to establish an incremental
model to gather outcome information and commu-
nicate results to key audiences.
The material in chapter VII is intended to be relevant to
new treatment developments as well as existing treat-
ments and systems. As with earlier chapters of the
Guide, the coverage and sophistication of monitoring
activities can range at all points from basic to complex.
Chapter VII is divided into three sections. Section A
presents the case for establishing a performance moni-
toring system and discusses definitional and conceptual
issues. Section B presents a summary of the elements of
a performance and outcome monitoring system and
offers guidance for a basic, intermediate and formal sys-
tem. Section C considers information management and
communication issues and how to access evaluation and
outcome research information.
A. Purpose of monitoring treatment
activity
In general, the purpose of activity monitoring is to assess
whether (and to what extent) the services are actually
doing what they originally aimed to do. Monitoring can
range from basic types to more sophisticated forms that
will require considerable resources to run. Guidance is
offered for implementation of a basic form of monitor-
ing first. From that base, more complex and expensive
outcome monitoring systems can be built if resources
permit. Monitoring systems also evolve over time, with
expanding depth and coverage as required.
As described in the two companion documents to the
Guide, there is good research evidence about the effec-
tiveness of treatment of people with substance-related
problems. However, that evidence needs to be validated
in different sociocultural circumstances and day-to-day
practice. To do so, collection and documentation of
actual practices are essential. The key message of chap-
ter VII is that a basic set of information about services
can and should be subject to routine collection, as part
of the day-to-day running of each programme.
1. Resources on monitoring and 
evaluation
Step-by-step guidance on how to plan and carry out
evaluations is not included in this Guide. The reader is
referred to more specific resources on that subject. For
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Monitoring treatment activity and
outcome
example, guidelines and workbooks on treatment evalu-
ation have been developed by WHO, UNDCP and
EMCDDA (see box 41).
2. Audiences for activity and outcome
assessment information
There are three audiences with an interest in activity and
outcome information: 
• The individual client and his or her family may well
be interested in learning about the activity of a service; 
• Both clinical and managerial staff will have an interest
in charting the progress of the service over time; 
• Government service planners and funding organiza-
tions will be interested in learning about the overall
performance of the service. 
3. Evaluation and treatment monitoring
concepts
Several terms are used in the evaluation and monitoring
field that characterize how treatments are viewed and
their impact is assessed.
(a) Inputs
An input is a measure of the resources used to provide a
particular treatment or service. Inputs can refer to capi-
tal and revenue monies; human resources (that is, peo-
ple required to deliver treatment); buildings; equipment
and supplies and materials. The total cost of programme
inputs provides an indicator of the economy of the serv-
ice. Inputs enable staff to run the services in order to
meet the aims and objectives of the programme.
(b) Output
Output measures are an indicator of the level, amount
or volume of activities undertaken by the treatment pro-
gramme, such as the number of new clients seen and the
actual number of consultations. Output measures usu-
ally reflect workload expressed in terms of time or cost.
It is important to note that outputs do not necessarily
indicate whether the objectives of a treatment pro-
gramme have been met or the extent to which they are
effective or of acceptable quality. 
The conversion of inputs to outputs provides an indica-
tor of the efficiency of the programme. In addition,
resource inputs also enable the service to be provided to
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Box 41
WHO/UNDCP/EMCDDA international guidelines and workbooks for the evaluation of treat-
ment services and systems for psychoactive substance use disorders
In 2000, joint publications from WHO, UNDCP and EMCDDA presented guidelines and a series of workbooks on
treatment evaluation. The publications are part of a strategy by WHO, UNDCP and EMCDDA to develop tools for pro-
gramme managers to carry out evaluations of their services and to assist in decisions concerning the allocation of
treatment resources. 
The guidelines focus on formal research studies and seek to characterize the main components of a well-conducted
evaluation and how results can be best communicated.
For further information, go to:
http://www.undcp.org/drug_demand_treatment_and_rehabilitation.html
http://www.who.int/substance_abuse/PDFfiles/guideevaloftreatment.pdf
The series of workbooks is intended to guide programme planners, managers, staff and other decision makers
through the process of planning and implementing evaluations. It also provides a valuable training resource for peo-
ple interested in evaluation as well as service planners and providers.
The following main types of evaluation are described in the series of workbooks: needs assessment; process evalua-
tion; evaluation of client satisfaction; outcome evaluation; naturalistic and observation studies; experimental and con-
trolled designs; economic evaluations (cost analysis and cost-effectiveness).
For further information, go to 
http://www.undcp.org/drug_demand_treatment_and_rehabilitation.html
http://www.who.int/substance_abuse/topic_treatment.htm
a certain level of quality. Measures of quality reflect the
extent to which the service meets the desired standards
set for the programme and the expectations of the
clients and other key audiences and stakeholders.
Quality measures can be used across the programme
environment to measure the competences of the staff
and the timeliness and appropriateness of the services
received. 
(c)   Outcome
An outcome may be defined as the results or the effects
from therapeutic activities and can be either positive or
negative. Outcome measures need to be relevant to indi-
vidual treatments and sensitive to the desired goals of
clients. In some programmes, there may be few
resources available to assess true outcomes (that is, those
measured using a scientifically reliable instrument or
procedure), and often proxy outcome measures are used
as an alternative. For example, in outcome research, a
measure of change in the frequency of substance use is
often assessed by means of a standardized instrument.
That requires measurement of the frequency of using
the drug at intake to treatment and again when the
client leaves treatment. Some agencies that are unable to
take those measurements may relay their assessment in
reporting the status of the clients when they leave (for
example, improved, stayed the same or deteriorated).
B. Elements of a performance and
outcome monitoring system
A performance and outcome monitoring system is a core
element of a treatment service that wishes to understand
how well it is serving the needs of its clients on a day-to-
day basis. The information collected can be used to: 
• Improve the client assessment and care coordination
process;
• Help treatment providers explore ways of improving
their services (for example, for particular types of
clients who may not achieve the outcomes of the
majority);
• Provide knowledge about the overall impact of the
treatment system and to help treatment planners and
government agencies judge the investment return on
funding treatment;
• Help identify gaps in effective provision of treatment
and the need for additional or new types of care pro-
gramme.
It can be undertaken at several levels and may involve a
single agency, a consortium of agencies in a specified
geographic area, or a regional or national initiative.
The initiative can be conducted by a treatment agency
itself or by some external service provider. The external
service provider model can be of value when several
treatment agencies are involved in a locality.
Effective outcome monitoring systems are characterized
by the following “success factors”:
• Staff commitment and enthusiasm to gather infor-
mation as part of routine service delivery;
• Integration of data collection for outcome monitor-
ing as part of routine assessment and care coordina-
tion arrangements;
• Use of minimum data sets (that is, using a small
number of critical or essential indicators of outcome
only);
• Sustainable scope of the initiative (for example,
focus on outcome assessment during treatment);
• Government-level financial support of costs of train-
ing, data management and the communication of
results; 
• Partnership and mutual learning values;
• Rapid feedback of information to guide further
development of services.
It may be helpful to think of the nature and volume of
data gathered in a performance and outcome monitor-
ing system as a pyramid. The greatest volume of infor-
mation is collected as part of the routine, day-to-day
clinical work and operation of a treatment system. A
small volume of key performance indicators are then
transmitted to treatment funders and other external
audiences. Finally, a core set of key performance indica-
tors are reported to governmental and other organiza-
tions, as part of a public accountability and national
treatment reporting approach.
Guidance on three levels of treatment monitoring is pre-
sented below. Those levels are additive and increase in
complexity from a basic approach through to a more
complex (and resource-intensive) performance and out-
come monitoring system.
1. Basic monitoring system (level one)
The purpose of level one is to collect a basic set of key
information about the delivery of treatment with which
to infer something about its impact. All providers of
services-no matter how limited their financial, technical
and human resources-should be capable of collecting
and reporting on a basic set of activities and outcome
information for any type of treatment. For a basic level
VII.3
Chapter VII Monitoring treatment activity and outcome
of reporting, there are seven types of descriptive infor-
mation required:
• Summary information about referrals and assess-
ment activities;
• Basic sociodemographic characteristics and drug use
profile of the client;
• Previous treatment information and whether the
first-ever treatment episode is involved;
• The setting and general nature of the treatment pro-
gramme;
• The total amount of treatment (that is, the number
of individual, group and other therapeutic sessions
and their duration);
• The total time spent in treatment;
• The status of the client at the end of treatment
under the programme (or the stage completed, such
as detoxification).
All services should record a basic set of information
about the client referral, assessment and treatment activ-
ity of the programme for a specified reporting period
(for example, per annum). That information should
include the number of people: referred to the pro-
gramme for assessment; referred to another service; who
commence treatment; and who complete treatment. It is
recommended that that information be presented by
referral source and gender as a minimum.
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Box 42
Example of a minimum data set required for each client
Area covered
Client
Sociodemographics
Primary drug problem
Risk behaviour
Treatment experience
Treatment
Programme type
Setting
Duration of stay 
Result
Status of clients leaving 
treatment within the 
reporting period
Relevant factor or component
Gender
Age (at last birthday/year of birth)
Cannabis type, heroin, other opioids, cocaine type, amphetamine, metham-
phetamine, Ecstasy type, sedatives/tranquillizers, hallucinogens,
solvents/inhalants, other
Injecting drug use
First time in treatment
Low threshold/drop-in
Withdrawal (detoxification)
Counselling/psychotherapy
Agonist maintenance prescribing 
Antagonist relapse prevention prescribing
Rehabilitation (drug free)
Hospital inpatient
Outpatient treatment centre
General practitioner
Community residential
Prison/detention
Days/weeks/months in treatment under that programme on discharge
Planned departures (that is, successfully completed treatment)
Unplanned departures (that is, client dropped out or otherwise stopped
treatment)
Transferred to another treatment (described)
Administrative/disciplinary discharge (non-compliance with treatment plan
or rules of the service)
At that basic level, no attempt is made to report per se
on changes in the problem behaviours of clients.
Instead, the status of each client is recorded at the point
of departure from the service. But it does not involve a
quantitative description of changes in drug use and
other problem behaviours. Box 42 shows an example of
a minimum set of data required for each client who
leaves or completes treatment during a reporting period
(for example, yearly).
An informative picture of the results of treatment can be
obtained from such information. The aggregation and
presentation of the information can be approached in
several ways. Box 43 presents some fictitious example
data for a sample of 220 female clients who left treat-
ment from a community programme.
The row at the bottom of box 43 shows the overall out-
come from the programme and indicates that 63.6 per
cent of the clients completed treatment. The row per-
centages by age group also show the relative impact of
the programme for the three age groups. The data pre-
sented in the example suggest that increasing age is asso-
ciated with a better outcome. Naturally, other ways of
presenting the data are possible.
International reporting-country indicators
In addition to local outcome monitoring initiatives, it is
important to note the requirements for country-level
reporting to international bodies.
For example, part II of the UNDCP annual reports
questionnaire concerns the extent, patterns and trends
in drug abuse. It is the primary regular reporting mech-
anism for the demand side of drug abuse data from the
Member States. The data are recorded under the
UNDCP international drug abuse assessment system. 
The Commission on Narcotic Drugs sends the annual
reports questionnaire each year to the Governments of
Member States for completion. The annual reports
questionnaire, inter alia, collects information on treat-
ment demand in each country. One of the aims of the
Global Assessment Programme on Drug Abuse coordi-
nated by UNDCP is to support Member States in their
data collection efforts. The activities of the Global
Assessment Programme include the development of a
protocol for the collection of data from treatment cen-
tres. The proposed protocol is designed to facilitate the
collection of data reported through the annual reports
questionnaire. The structure of part II of the annual
reports questionnaire is shown in box 44.
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Box 43
Community programme: twelve-month outcome report for female clients by age group
(Number of clients: assessed for treatment—310; commencing treatment—250;a leaving treatment in reporting 
period—220)
Outcome status of clients leaving treatment during year by age group (n = 220)
Age group
18-24
25-35
36+
Total
a The number of individual episodes of treatment may also need to be shown for the reporting period, since a client may have been treated under the
programme on two (or more) occasions.
30 (50.0)
50 (62.5)
60 (75.0)
140 (63.6)
20 (33.3)
20 (25.0)
15 (18.8)
55 (25.0)
Unplanned 
departures 
(percentage in 
parentheses)
Outcome status
Administrative 
discharge 
(percentage in 
parentheses) Total
60
80
80
220
Planned departures
(percentage in 
parentheses)
10 (16.7)
10 (12.5)
5 (6.3)
25 (11.4)
Another example of international reporting is shown in
annex VII. It has been developed for use in Europe and
can be adapted for use elsewhere as required.
2. Intermediate monitoring system 
(level two)
The next level of reporting carries the features of level
one forward and incorporates additional information to
document and describe treatment activities. The pur-
pose of level two is to add further details to the client
and treatment description and gather a basic measure of
behavioural change as a direct measure of outcome. 
In addition to reporting under level one, the following
can also be recorded:
• Sociodemographic information (nationality and eth-
nic description, relationship and living status, labour
status and educational level);
• Drug-related information (routes of administration,
frequency of use, age of first use of main problem
drug, drug injecting status and frequency);
• Treatment referral information;
• Average waiting time to commence treatment (from
assessment);
• A description of the specific types of services
received by the client.
The information should also be presented by the main
problem drug used by the clients under the following
categories: cannabis-type; opioids; cocaine-type;
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Box 44
Annual reports questionnaire—Part II (drug abuse)
Part II of the annual reports questionnaire comprises nine sections. Section 8 concerns treatment.
Drug treatment
Q48. Have people received treatment for drug problems in the past year? (Any drugs, cannabis type, heroin, other
opioids, cocaine type, amphetamine, methamphetamine, Ecstasy type, other drugs)
Q49. How are drugs ranked in order of the primary cause of receiving treatment? (Cannabis type, heroin, other opi-
oids, cocaine type, amphetamine, methamphetamine, Ecstasy type)
Q50. What has been the trend over the past year in the numbers of people receiving treatment? (Any drugs,
cannabis type, heroin, other opioids, cocaine type, amphetamine, methamphetamine, Ecstasy type, other
drugs)
Q51. Do you have an estimate of the number of people receiving treatment for drug problems? (No, Yes—an 
estimate for the country as a whole, Yes—an estimate for a part of the country for a selection of treatment
facilities) If No, proceed to Q 59
Q52. For which year does the estimate apply? Which part of the country or selection of treatment facilities is cov-
ered by the estimate? (Year of the national estimate, year of the partial estimate, part of the country for which
the estimate applies, types of treatment facilities included and/or excluded in the estimate)
Q53. What is the estimated number of people receiving treatment for drug problems? (Any drugs, cannabis type,
heroin, other opioids, cocaine type, amphetamine, methamphetamine, Ecstasy type, other drugs)
Q54. What is the estimated percentage of people receiving treatment for the first time ever among people in treat-
ment? (Any drugs, cannabis type, heroin, other opioids, cocaine type, amphetamine, methamphetamine,
Ecstasy type, other drugs)
Q55. What is the estimated percentage of females among people in treatment? (Any drugs, cannabis type, heroin,
other opioids, cocaine type, amphetamine, methamphetamine, Ecstasy type, other drugs)
Q56. What is the estimated mean age of people in treatment? (Any drugs, cannabis type, heroin, other opioids,
cocaine type, amphetamine, methamphetamine, Ecstasy type, other drugs)
Q57. What is the estimated percentage of drug injectors among people in treatment? (Any drugs, cannabis type,
heroin, other opioids, cocaine type, amphetamine, methamphetamine, Ecstasy type, other drugs)
Q58. Which definition of “people treated for drug problems” applies to the figures in the columns of Q53-Q57
above? (All people receiving treatment during the year, people starting treatment during the year, people in
treatment at census date in the year, people discharged from treatment during the year, other)
amphetamine-type; sedatives and tranquillizers; hallu-
cinogens; solvents and inhalants; and other drugs.
In addition to describing the status of clients at their
departure from the programme, it would be informative
to report on some basic behavioural changes. Stopping
or reducing problem drug use is the obvious behaviour-
al change and outcome objective, but improvement in
personal and social problems is also important. As an
example, the basic information outlined in box 45 could
be reported from a short interview with each client at
intake and prior to departure (if feasible).
3.   Formal monitoring system (level three)
The third level represents a formal performance and
outcome monitoring system. Its purpose is to operate a
formal and sustainable system of recording how well the
treatment service is operating and meeting the needs of
its clients. Using a structured approach to outcome
monitoring also has benefits for clinical practice, since
staff can feed the information back to clients at the
beginning of treatment and at follow-up as a means of
building and sustaining motivation for change.
Level three contains the features and records described
for the previous two levels, but also provides greater
characterization of the client and a wider range of
behavioural and other changes with which to describe
their outcome. Readers interested in establishing such a
system should also review the material in chapter VI
relating to comprehensive assessment processes and to
integrated care pathways and the importance of describ-
ing continuing treatment episodes for clients who
require several linked treatment services. An informative
picture of outcome can be obtained from looking at
treatment from that perspective. 
It is important to caution against devising a level-three
system without a careful feasibility assessment. That
assessment should examine the following:
• The specific questions to be addressed;
• The size and scope of the monitoring system
required;
• The human resources that will be needed;
• The skills needed by the personnel involved;
• The financial resources needed;
• The implementation and reporting timetable.
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Box 45
Basic description of drug use, employment and crime
(last 30 days before intake and before departure from treatment)
Patient recall can be assisted by showing the prompt below.
None
0
1 day
only
1
2 days
only
2
3 days
only
3
1 day 
a week
4
2 days 
a week
9
3 days 
a week
13
4 days 
a week
17
5 days 
a week
21
6 days 
a week
26
Every
day
30
Measure
Drug use
Used main problem drug
Employment
Had paid work
Crime
Committed illegal activity
Number of days during 
the past month before
treatment
Number of days during 
the past month before 
discharge
The most logical and practical means of assessing treat-
ment outcome is to gather a set of measures from a
client and his or her family at intake to a programme
(baseline) and then collect the same measures again
from the client at one or more points during and ideal-
ly following treatment. In that way, outcome monitor-
ing is conceptualized as reassessment and can be incor-
porated as part of routine clinical practice (please refer
to material on client assessment in chapter VI). It is
most desirable that outcome assessments involve an
active appraisal of the client from a face-to-face or tele-
phone interview or a self-completion of an assessment
questionnaire by the client. Other methods, such as esti-
mating outcome from case notes, are unlikely to be valid
or accurate and are not recommended.
(a) Characterizing outcomes
When considering which outcomes to report, it is valu-
able to follow a consensus from formal research studies
about key measures. Researchers have focused on three
core problem domains: substance use behaviour; physi-
cal and psychological health problems; and personal and
social functioning (a broad set of problems spanning
family and relationships, accommodation, employment,
crime involvement and other public safety issues). The
risk of exposure to HIV and other infections, including
hepatitis C, has led to the assessment of injection-rela-
ted and sexual risk behaviours for contagion and trans-
mission of blood-borne infections. It is important to
recognize that outcome expectations can differ across
individual, family, community, service-related and crim-
inal justice perspectives.
(b Choosing appropriate assessment points 
For outcome monitoring, client changes can be assessed
at one or more points during treatment. Unlike research
studies, most treatment outcome monitoring initiatives
do not attempt to evaluate outcome after a client has left
treatment, largely because of the resources required in
organizing face-to-face interviews (although telephone
or mail-based assessments may be considered). 
(c) Using treatment objectives for monitoring
purposes
The WHO/UNDCP/EMCDDA guidelines on treat-
ment evaluation mentioned in box 41 advocate the use of
the programme-logic-model approach to help clarify the
objectives of a treatment programme. A logic model is a
diagram that sets out the different components of a pro-
gramme, the purpose of each component (implementa-
tion objectives) and short- and long-term outcomes.
Logic models are useful when setting objectives and tar-
gets for each component and for outcome and can be
powerful communication aids when describing the pro-
gramme to professional audiences. A theoretical example
of a logic model, prepared to characterize the operation of
a residential rehabilitation service, is shown in box 46. 
4. Assessment instruments for outcome
monitoring
The majority of variables suitable for repeated assess-
ment will be continuous, or scale measures, which are
sensitive to assessing change over time. A satisfactory
assessment of outcome requires status measures to be
recorded at intake, at some point during treatment, at
treatment completion and possibly at follow-up. 
There are a variety of assessment instruments and tech-
niques such as face-to-face interviews, behavioural
observation, questionnaires and psychological tests.
Although substantial training is required in order to uti-
lize the data collection methods properly and effectively,
well-constructed questionnaires can collect useful data
even when administered by less trained staff members.
Choice of suitable outcome questionnaires should be
guided by the following principles: 
• Relevance to the target population and treatment
programme; 
• Relevance to the programme philosophy and capabil-
ity to direct reporting against targets and priorities;
• Suitability for face-to-face interviewing with a client
or self-completion by the client;
• The instrument must have established psychometric
properties (validity and reliability); 
• The measures must be sensitive to change over time; 
• Administration of the questionnaire must be as brief
as possible;
• The client and other non-professional audiences
should be able to understand assessment methodolo-
gies and reports without marked difficulty. 
There are several instrument banks available that con-
tain information about research questionnaires and
instruments. An example resource is shown in box 47. 
In annexes VI and VIII of the present Guide, examples
are shown of the structure of two established instru-
ments for outcome monitoring, the Addiction Severity
Index and the Maudsley Addiction Profile. Both instru-
ments can be used free of charge for non-commercial
research and outcome monitoring purposes. They are
similar in several respects, and the Addiction Severity
Index Lite version contains a more comprehensive set of
background and client functioning measures for indi-
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vidual treatment planning. The Maudsley Addiction
Profile is a brief instrument that has been designed for
outcome purposes and takes approximately 12 minutes
for completion.
C. Managing information and com-
municating results
A computerized database management application is
almost always needed to manage the information set
from the performance and outcome monitoring system
at each of the three levels. The computerized database
represents an efficient means of validating, storing and
analysing the information and producing reports for dif-
ferent audiences. Developing a database application
would be reasonably straightforward for level-one appli-
cations, but is likely to require the support of a specialist
developer for levels two or three. In the past, much
money has been wasted by agencies that are uncertain
about either their information or their reporting require-
ments. That results in a database that is unsatisfactory
and sometimes never actually implemented. Today, many
computer database developers use a core application that
has already been written, adapting it to the specific (and
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Box 47
Evaluation Instruments Bank of the
European Monitoring Centre for Drugs and
Drug Addiction
The EMCDDA Evaluation Instruments Bank is a docu-
ment archive of tools created to encourage evaluation
using reliable methods and to help to standardize
those tools at the European level. The Evaluation
Instruments Bank contains tools for evaluating both
prevention and treatment programmes. By entering
the specific criteria of the intervention to be evaluat-
ed, the database provides the user with suitable eval-
uation tools, together with comments on its use and
references to related studies. The Evaluation
Instruments Bank is a flexible and living tool that has
expanded since its launch in June 2000; it now
includes all 12 EMCDDA languages. The Evaluation
Instruments Bank is regularly updated and currently
holds 150 evaluation instruments from the treatment
field and 35 from the prevention field. It has keyword,
category and full text search facilities.
For further information, go to 
http://eibdata.emcdda.org/databases_eib.shtml
Box 48
Electronic treatment data collection in the United States
The Drug Evaluation Network System (DENS) is an ongoing, multi-site, electronic data collection and reporting sys-
tem providing standardized, automated, timely data via modem, on patients entering addiction treatment and on
treatment programmes in the United States.
Sponsored by the White House Office of National Drug Control Policy, and the Center for Substance Abuse Treatment,
the goal of the project is to provide practical and current clinical and administrative information on patients entering
into substance abuse treatment throughout the country. Ultimately, the system will include alcohol and drug treat-
ment programmes representatively sampled from all areas of the country, and from different treatment modalities and
facility types, including the criminal justice system.
DENS collects real-time information on the nature, number and severity of patients' problems at the time of treat-
ment admission, their length of stay and type of discharge. The collection of such data aims at providing policy mak-
ers at the federal and state levels with the information necessary to recognize important trends occurring that may
be relevant in planning and administering systems that deal with substance abuse problems. 
To serve such needs, DENS information is relevant to the multiple clinical, administrative, fiscal, evaluative and policy
questions that so regularly arise; it is also available rapidly and continuously to enable observation of changes over
time.
In addition, DENS offers a framework for a future, ongoing, nationwide system for monitoring treatment outcomes.
As such, the DENS system can be utilized as a starting point for specific, targeted outcome studies, or for large,
regional, or state-level outcome projects. 
For further information, go to: 
http://www.whitehousedrugpolicy.gov/ctac/dens.html
http://www.densonline.org
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Box 49
Cochrane Database of Systematic Reviews
The Cochrane Database of Systematic Reviews contains articles that review the impact of health-care treatments and
procedures. The reviews are highly structured and systematic and published research is included on the basis of explic-
it quality criteria to ensure the reliability of the conclusions reached and to minimize bias. Information from studies
are usually combined statistically using a technique called meta-analysis. 
As part of the Cochrane Collaboration, a Cochrane Drug and Alcohol Group has been established and has published
a range of reviews and evidence-based practice guidelines in the form of full reviews, technical abstracts and brief
summaries. The latter are written in a plain language style and constitute a valuable tool for those who have respon-
sibility for the funding or planning of treatment services.
For further information, go to http://www.cochranelibrary.com
Key points
The key points covered in chapter VII of the Guide are as follows:
• There is increasing emphasis on improving the day-to-day recording of service delivery and communicating
essential information about outcome;
• Outcome monitoring is an initiative designed to gather information on the impact of services provided in order
to understand how a service operates and to identify gaps in effective provision and ways of improving treat-
ment effectiveness. The scope and depth of such an initiative can vary from a basic system (level one) to more
comprehensive solutions (levels two and three);
• Successful outcome monitoring systems are characterized by staff commitment, the integration of outcome
information as part of routine assessment and care coordination arrangements; partnership and mutual learn-
ing values; and rapid feedback of information to guide further development of services;
• Performance and outcome monitoring initiatives can be tailored in terms of the range and depth of reporting
according to resources;
• Most service providers should be able to implement a basic performance and outcome monitoring system to
report on during-treatment outcomes; 
• Attention to the evidence for treatment outcomes, as reported by formal research studies, is critical, and sys-
tematic reviews can be valuable sources of summary information about a particular treatment or approach.
future) needs of the specific treatment provider. Most
current applications are based on the entry of data for a
client to a secure database programme operating on com-
puters in the treatment centre. Some agencies also use
secure Intranet or web-based applications, and that is
likely to become more common in the future. 
Box 48 illustrates an example of a data collection and
monitoring system that is electronically based and that
evolved from the Addiction Severity Index, a clinical and
evaluation tool developed in the United States and used
in a wide range of countries.
Regardless of the complexity of the information to be
collected, the key requirement is to be clear about what
types of report are needed and their format. Most reports
from an outcome monitoring database can be in a stan-
dard format and can, for example, summarize the client
group and its main outcomes for a particular time peri-
od. The key audiences for the reports include the client
(through personalized feedback); provider staff and man-
agement; and funding bodies and government bodies.
1. Accessing information about treatment
outcome
One of the most important reasons for gathering infor-
mation about the impact of services is to help to optimize
treatment for specific groups of people and to ensure that
the more effective and affordable treatment alternatives
are given priority. In recent years, there has been an
increasing interest in using the published findings of for-
mal evaluation studies together with clinical expertise
and clients' preferences as a means of guiding resource
allocation and decisions relating to health and social wel-
fare services and systems. Treatment planners are increas-
ingly motivated to direct resources to treatment services
that have an evidence base for their effectiveness.
Evidence-based practice relies on a systematic appraisal of
the research literature for the impact of a particular treat-
ment. The appraisal can then lead to the preparation of
guidelines and protocols for a particular treatment.
Naturally, there are limitations to the body of evidence.
Knowledge of all treatments, with all the various popu-
lation groups and individual priority needs, is far from
complete. Moreover, most robust studies of treatment
outcome have been conducted in a relatively small num-
ber of countries with developed treatment systems.
There are natural limits in the way that findings from a
treatment study in one part of the world can be applied
to treatment services in another country. In part, that
has led to investment in research studies and other mon-
itoring activities that assess the same questions in differ-
ent cultural and economic contexts. Nevertheless, much
can be learned from reviews that aggregate the findings
from different countries (see box 49). 
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Young people and children
Drugs strategies need to consider how best to provide
services to young people and children who may have, or
who are at risk of developing, drug-related problems. It
may be helpful to distinguish the following priority
subgroups: children (aged 12 or less); young people
(aged 13 to 17) and young adults (aged 18 to 24).
Among young people and children, the following high-
risk groups have been identified:
• Young people who have a poor attendance record at
school or who are excluded;
• Young people who are looked after by welfare
authorities;
• The young homeless, especially street children;
• Young people and children in conflict and post-
conflict situations;
• Under-age children in a labour market;
• Young people living in environments with high 
levels of drug abuse;
• Young offenders.
It is important to recognize that there are substantial
challenges for the appropriate assessment of multiple
risks and problems that may be experienced by young
people and children. There are also real challenges in
designing appropriately matched treatments and sup-
ports for young people and children, and there is little
experience of service delivery. 
Effective solutions lie in the integration of general serv-
ices for young people and children with specialist
expertise in the treatment of drug abuse, together with
the involvement of supportive family and community
structures.
Women
In most treatment systems, the incidence of females
resorting to treatment services is markedly lower than
that of males. That partly reflects greater numbers of
men developing serious drug problems at the overall
population level, as well as a reluctance of female users
to go to treatment services. There are different reasons
for that situation. Some women may feel or fear that
there is considerable stigma towards them and may be
reluctant to seek help. Because of the higher level of
referrals of men, some services may be less sensitive to
women's needs and less able to respond appropriately.
Pregnant drug users should be specially targeted by serv-
ices at an early stage. Levels of support for pregnant
users vary quite widely between specialist services in
most countries. That situation, coupled with a fear of
the consequences if drug abuse is disclosed, may deter
many pregnant users from going to maternity and treat-
ment services at an early point, and that may increase
the risk of obstetric and neonatal complications. Since
some pregnant users go to treatment precisely because of
their pregnancy, that should be seen as an important
opportunity to offer treatment and support. The impor-
tance of meeting the needs of young people also extends
to issues of childcare. For example, nursery scheme facil-
ities for drug users attending treatment services may not
be commonly available. Treatment agencies need to
respond to that situation by encouraging pregnant drug
users to seek help and remain in contact with specialist
and generalist support agencies.
Seniors
The prevalence of drug abuse varies with age. While vul-
nerability to drug use is highest among young people,
older people who either have a late onset of drug abuse
or have experienced a long using history, should not be
ignored. Seniors with drug abuse problems are a fairly
hidden population and their needs are generally not well
understood. 
People who have drug problems and other
psychiatric problems
There is widespread concern about improving services
and outcomes for people who have co-morbid psychi-
atric and substance abuse disorders. Both the research
and the clinical evidence base are limited with regard to
the effective management and care of people who have
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psychoactive substance abuse co-morbidity. There is
some evidence that people with substance use problems
and co-morbid psychiatric disorders appear to have a
relatively high contact with medical services and may
require more intensive treatment. However, it would
appear that substance abuse among people admitted for
psychiatric treatment is of a less severe nature than
among those entering treatment for primary substance
abuse problems. It is also important to consider and
plan for the possibility that people with drug abuse and
severe mental illness will not respond well or comply
with traditional care plans and arrangements.
People who are homeless 
There is major concern in many regions and countries
about drug and mental health problems among home-
less populations. There is also some evidence that drug
abuse is a risk factor for accommodation instability.
Homeless people encompass those who use night shel-
ters and temporary hostels and rely on the accommoda-
tion of friends and acquaintances, as well as those sleep-
ing rough on the streets. The most common health-
related problems cited by people who sleep rough con-
cern psychological issues, alcohol consumption and
drug use. 
People from racial and ethnic minority
populations
Many minority people live far away from urban areas
and may differ from majority people in numerous ways,
for example, ethnicity, language, culture and beliefs. In
some areas, the prevalence of drug use among minorities
may be considerably higher than among the rest of the
population. The services needed by those minority
people may also differ from others. For example,
minority people may prefer community-based outreach
programmes to hospital or other residential treatment
programmes.
People who are HIV-positive
People in drug treatment services who are known to be
HIV-positive need primary attention to their drug
addiction while maintaining appropriate care for their
HIV status. HIV-positive clients have specific issues to
deal with in treatment, many of which fall under the
heading of grief work. They will need to deal with mul-
tiple current and anticipated losses associated with the
diagnosis—longevity, health, career and family plans,
including relationships and children. 
The double stigma and shame associated with drug
abuse and HIV/AIDS require extensive therapeutic
work, as do fears of progression to AIDS, disability and
death. The counsellor working with HIV-positive
clients requires preparation and supervision in meeting
their needs. In addition, the clients may be under treat-
ment with antiretroviral agents as well as prophylactic
agents against a variety of opportunistic infections.
Possible interactions with pharmacological treatment of
their substance dependence need to be taken into
account. Close links and coordination between sub-
stance abuse treatment and HIV/AIDS care services
need to be established.
People in the criminal justice system
Many people in contact with the criminal justice system
have drug abuse problems and histories. Detention
without treatment frequently leads to the relapse into
drug abuse after an offender returns to his or her com-
munity. Treatment programmes will help to reduce not
only drug abuse but also drug-related crimes. The coop-
eration between treatment providers and criminal jus-
tice systems is an important part of the treatment pro-
grammes for those individuals. There are issues involv-
ing the detection and management of drug abusers in
police custody, in prison and within probation services.
Drug abuse problems present a major problem for crim-
inal justice authorities in virtually all countries.
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Non-dependent drug abusers
The group of non-dependent drug abusers comprises
individuals who are experiencing drug-related problems
but who do not meet the criteria for dependence. That
group may include large numbers of younger users who
have begun to use drugs relatively recently. Many young
people abusing drugs, in particular for recreational pur-
poses, do not perceive it as a problem and do not active-
ly seek help. Since members of that group (both adults
and, in particular, young people) are at risk of advancing
their drug involvement to more serious levels, they may
be ideal clients for early intervention services, especially
community-based early identification and intervention.
Injecting drug abusers
The group of injecting drug abusers comprises individu-
als who are injecting drugs and who may be at risk of
acquiring and transmitting blood-borne diseases.
Individuals who inject drugs are much more likely to be
dependent and experience drug-related harms. They con-
stitute a subgroup to be attracted to outreach programmes
aimed at reducing the health consequence of drug abuse,
and to structured treatment programmes, as appropriate.
Dependent drug abusers
The group of dependent drug abusers comprises indi-
viduals who have drug-related problems and meet a set
of criteria for drug dependence. The majority of people
going to specialist drug abuse services are in that group.
They may require intensive community and/or residen-
tial treatment and aftercare support together with social
inclusion services to mitigate problems of housing,
employment and training. Two examples of the criteria
for dependence are given below.
Opioid dependence (International Classification of
Diseases (ICD)-10 code, F11.2; Diagnostic and
Statistical Manual of Mental Disorders (DSM)-IV code,
304.00) is defined under DSM in the following manner:
most individuals with opioid dependence have significant
levels of tolerance and will experience withdrawal on
abrupt discontinuation of opioid substances. Opioid
dependence includes signs and symptoms that reflect
compulsive, prolonged self-administration of opioid sub-
stances. Clinical features may include: a subjective aware-
ness of compulsion to use; a diminished capacity to con-
trol use; and salience of drug-seeking behaviour.
Cocaine dependence (ICD-10 code, F14.2; DSM-IV
code, 304.20) is characterized by the following features:
substantial impairment in the ability to control amounts
used; high dose, usually episodic consumption pattern;
increased anxiety, depression; paranoid-type ideation (in
some users); and weight loss. The existence of a defined
withdrawal syndrome following termination of heavy
and prolonged cocaine use has been somewhat contro-
versial. No coherent syndrome is usually seen and there
are marked intra- and inter-individual variations in the
type and severity of problems experienced.
Acutely intoxicated drug abusers
The specific needs of acutely intoxicated drug abusers are
identified because of the morbidity and mortality risks
due to adverse reactions and drug overdose. There is evi-
dence that some two thirds of heroin users have experi-
enced an overdose and, in addition, intoxicated stimulant
users with psychotic symptoms can be classified in that
subgroup. Acute intoxication is a discrete event, although
an individual's needs may advance to those associated
with dependence, co-morbidity and withdrawal manage-
ment and support. Most services provided to the intoxi-
cated drug user will be found outside specialist drug or
mental health services (for example, accident and emer-
gency departments and police custody). 
Drug abusers in withdrawal
The group of drug abusers in withdrawal comprises peo-
ple who are undergoing withdrawal after stopping the use
of one or more classes of drug. For example, cessation of
opiate use produces a withdrawal syndrome characterized
by observable physiological and subjective effects, includ-
ing somatic flu-like symptoms of varying severity, toge-
ther with sleep disturbance and anxiety. Drug abusers in
that category may require acute medical attention and
planned detoxification support in an inpatient or a com-
munity treatment programme according to need.
Drug abusers in recovery
The group of drug abusers in recovery comprises indi-
viduals who have achieved a state of abstinence from
their main problem drug (or all drugs), usually through
successful completion of a treatment episode. They may
require residential rehabilitation services, vocational
training or community-based aftercare programmes and
other supports. 
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The present annex describes, for illustrative purposes, a
residential programme that has been prepared for poten-
tial referring and funding agencies. It is a concise
description of the purpose of the programme, who it is
intended for, and how it operates. Such a document is
intended for professional audiences. A separate informa-
tion pack for clients would also be needed.
Introduction
The programme involves a 20-bed facility for adult
males who are recovering from substance dependence.
More information about the programme is available in
the client information pack. The programme is organ-
ized in two stages. The first (primary) stage lasts for
three months. Those wishing, and given support, to
continue in treatment can enter a second stage that is
designed to promote semi-independent living and is a
preparatory stage before returning to the community.
The duration of the second stage is optional but nor-
mally lasts for eight weeks. The main elements of the
programme are described below.
Description of client group served
The programme is intended for adults who have diag-
nosed substance dependence (meeting DSM-IV criteria). 
Philosophy 
The programme recognizes that some people with com-
plex drug-abuse-related problems require respite and an
intense programme of support and care that cannot be
realistically delivered in a community or outpatient set-
ting.
Standards governance
The programme has a management body comprising a
mix of members of diverse background in terms of race,
gender and professional expertise. The membership of
the committee is open to election each year and an
annual meeting and its composition are subject to peri-
odic review. 
Core mission and strategic management
The mission of the programme is to facilitate the recov-
ery of people with substance use disorders and their
rehabilitation into mainstream society. The programme
has an internal core mission statement, a three- to five-
year strategic plan and an annual plan. 
Therapeutic approach
The programme adheres to a twelve-step philosophy
and approach, the core elements of which are as follows:
• Maintenance of abstinence from illicit drugs in a
controlled therapeutic environment;
• Communal living with other drug users in recovery;
• Emphasis on shared responsibility by peers and
group counselling;
• Counselling and support oriented towards relapse
prevention;
• Individual support and promotion of education,
training and vocational experience;
• Improved skills for activities of daily living;
• Housing advocacy and resettlement work.
Staffing
A multidisciplinary team delivers the therapeutic pro-
gramme and comprises the following posts:
• One co-coordinator/manager;
• Two administrators/secretaries;
• One clinical psychologist;
• Three social workers;
• One occupational therapist;
• Four drug workers/care workers;
• Three community psychiatric nurses.
The staff team has an appropriate compositional bal-
ance in terms of race and gender.
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Access and referral information
Access to the programme is made via the social services
department of the local government. The social services
team undertakes all initial screening and assessment
functions.
Assessment criteria 
All clients seeking treatment will be asked to complete a
comprehensive assessment with a member of the staff
team. That assessment looks at health, social, economic,
psychological, employment, family, relationship and
legal considerations. 
Care planning and review
For each client, a written care plan will be prepared,
specifying their needs, the ways in which those needs are
to be addressed by the service (and by other service
providers as required), and how the plan will be moni-
tored, evaluated and revised as necessary. All clients will
have a nominated key worker and receive a copy of their
written care plan. Dates for the review of the care plan
will be stated at the outset. 
Completing treatment 
Departure from the programme and onward referral will
be a planned element of the programme. The key 
worker will normally oversee those aspects, although
some providers may have dedicated workers who facili-
tate referral and aftercare support.
Human resource management and 
development
The programme has written staff recruitment, selection
and employment policies that comply with equal oppor-
tunity and employment rights legislation, as well as a
human resource management policy and a supervision
and appraisal system that monitors, motivates and sup-
ports performance.
Physical environment
The premises and other environmental resources meet
the requirements of standards and relevant registration
requirements including: health and safety legislation;
environmental health; and fire regulations. The premi-
ses are kept in good decorative order, with furniture
replaced as required and the environment maintained
safely, with repairs conducted promptly. Decor and fur-
niture are conducive to the needs of residents, and the
programme makes a concerted effort to appear and feel
like a comfortable home environment. 
Accommodation and food
All accommodation for clients provided under the pro-
gramme is comfortable and meets the needs of the resi-
dent in terms of his or her right to privacy, dignity,
respect and personal independence. Food and drink
provided to the users are nutritious and healthy. The
diet provided is varied and well balanced. 
Performance monitoring and quality
The programme has developed criteria and procedures
for documenting and reporting service outputs and out-
comes. Criteria have been agreed with commissioners
and other relevant external bodies. Output and outcome
monitoring reports are provided to the management
body and to relevant external audiences as specified
within contracts. 
Operational policies 
The core policies and procedures encompass:
• Client-related matters: 
— Rights statement;
— Working with special and priority groups 
(for example, children and young people; 
pregnant drug users; drug-using parents; and 
people with co-morbid psychiatric 
problems);
— Confidentiality;
— Complaints procedure;
— Procedures for the involvement of service 
users;
— Policy on visitors to the programme;
— Privacy policy for service users;
— Equal opportunities policy;
• Programme environment and personnel matters:
— Health and safety;
— Recruitment and employment procedures;
— Staff appraisal system;
— Grievance and disciplinary system;
— Redundancy policy;
— Staff training strategy; 
— Employment of people who have previously 
had substance-related problems; 
— Violence at work; 
— Procedure for working in the community 
(covering, for example, outreach and 
home visits).
All policies are dated and subject to regular review (for
example, annually). 
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The form below is presented as an example of the type of screening form used in the United Kingdom
Forename: ________________________  Surname: _______________________________________
Date of birth: _____________________   Case screening reference (if used): ____________________
Gender:  Male ❒ Female ❒ Age group:   17 or less ❒ 18-24 ❒ 25-29 ❒ 30 and over ❒
Client has childcare responsibilities:  yes ❒ no ❒
Usually resident in:   ____________________________________  [locality] 
Substance use in past 3 months
Used? Problem?* Ranked (1,2,3)
Opioids
Cocaine
Amphetamines
Sedatives/tranquillizers
Hallucinogens
Solvents/inhalants
Cannabis
Alcohol
*Problem defined as substance-related difficulties in one or more of the following areas: physical health; psychological health; family/relationships; housing;
work/employment; finances
Priority checklist
Client is pregnant  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❒
Children may be at risk  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❒
Client is currently injecting drugs  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❒
Client has physical health conditions/symptoms that are likely to require treatment  . . . . . . . . . . . . . . . . . . . . . ❒
Client has psychiatric problems that are likely to require treatment  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❒
There is concern about the client's risk of self-harm  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❒
There is concern that the client may represent a safety threat to others  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ❒
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Action
1.   Client is currently in treatment/contact with:
Specialist substance abuse service: ❒
GP ❒
Community mental health team ❒
Criminal justice programme ❒
Social services ❒
Other type of treatment ❒ (specify): _______________________________________________
Details of treatment/service: ___________________________________________________________________
2.   Referral priority
Substance abuse problems—circle
0 = No referral required (no identified drug problems requiring further assessment)
1 = Standard referral (substance problems requiring triage assessment by substance abuse service)
2 = Priority referral (substantial problems requiring priority assessment by substance abuse service)
3 = Immediate referral (acute, urgent problems requiring immediate assessment by substance abuse service)
Other medical/social problems—0, 1, 2, 3 
3.   Referred to:
Specialist substance abuse service  ❒ GP  ❒ Hospital Accident/ER Department  ❒
Social Services  ❒
Details: __________________________________________________________________________________
Screened by: _________________________________________________ Date: _________________________
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Referral details
Date screened (if relevant): ________________   Date of present assessment: _________________
Referring agency: _____________________________
Client information
Forename: _____________________ Surname: ______________________________________
Date of birth: __________________ Case screening reference (if used): __________________
Gender:   Male  ❒ Female  ❒
Age group:  17 or under  ❒ 18-24  ❒ 25-29  ❒ 30 and over  ❒
Ethnic category:  
White A-British,  B-Irish,  C-Other White
Mixed D-White and Black Caribbean,  E-White and Black African,  F-White and Asian,
G-Other mixed
Asian/Asian British H-Indian,  J-Pakistani,  K-Bangladeshi,  L-Other Asian
Black/Black British M-Caribbean,  N-African,  P-Other Black
Other-ethnic R-Chinese,  S-Any Other,  Z-Not stated
Client has childcare responsibilities:  yes  ❒ no  ❒
Usually resident in:   ____________________________________  [locality]
Employment status:  Employed  ❒ Casual work  ❒ Unemployed  ❒ Other  ❒ specify ___________________
Person to be contacted in an emergency: __________________________________________________________
Substance use involvement and problems
Substance Used No. of days Day of last use Is this Rank main
used in past 4 (1 = today; 2 = causing problem drug(s)
weeks yesterday; etc.) problems? [first three]
Alcohol
Amphetamines
Cannabis
Cocaine
Hallucinogens
Solvents/inhalants
Opioids
Sedatives/tranquillizers
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The form below is presented as an example of the type of triage form used in the United Kingdom.
Main problem substance: _____________________________
Details of any prescribed drug use in the past 4 weeks:
Dependence checklist
In the past 6 months
If yes score 1
(a) Have you needed to use more [main drug] to get the desired effect, or has taking your usual amount had
less of an effect than it used to?
(b) Have you felt sick or unwell when the effects of [main drug] have worn off, or have you taken more of
it, or a similar drug, to relieve or avoid feeling unwell?
(c) Have you used [main drug] in larger amounts or for a longer period of time than you intended?
(d) Have you had a persistent or strong desire to take [main drug] or have you had problems cutting down,
or controlling how often or how much you use?
(e) Have you spent a large amount of time obtaining, or using, or recovering from the effects of [main drug]?
(f ) Have you given up work, recreational, or social activities as a result of your [main drug] use?
(g) Have you continued to use [main drug] despite having physical or psychological problems as a result?
Total score = _______
If total score is 3 or more, dependence is diagnosed ❒
Specify if:
With physiological dependence:
evidence of tolerance or withdrawal (that is, either item (a) or item (b) is present) ❒
Without physiological dependence:
no evidence of tolerance or withdrawal (that is, neither item [a] or item [b] is present) ❒
If dependence is NOT diagnosed, assess for substance abuse
Abuse checklist
In the past 6 months
If yes score 1 
(a) Have you found that using [main drug] has led you to neglect things or caused problems socially, or at
home, or work?
(b) Have you used [main drug] in a risky or dangerous situation (for example driving a car when under
the effects, or operating machinery)?
(c) Have you been arrested or questioned by the police in connection with your use of [main drug]?
(d) Have you continued to use [main drug] despite having problems with it in your social life or in 
relationships?
Total score = _______
If total score is 1 or more, abuse for the main drug is diagnosed ❒
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Treatment history and criteria-based treatment assessment
Specialist substance abuse treatment
Treatment modality Ever Currently in Number of Month/year of Reason for 
received? treatment? episodes? most recent leaving
treatment most recent tx*
Inpatient detoxification
Community detoxification
Community prescribing
Residential 
Care planned 
Structured day 
*Code as follows: 1 = planned departure [completed care plan at the agency]; 2 = unplanned departure [client dropped out or otherwise stopped treatment]; 3 = transferred to
another agency/treatment; 4 = administrative/disciplinary discharge [non-compliance with treatment plan or rules of the service].
Mental health treatment
Treatment modality Ever Currently Number of Month/year of Reason for 
received? treatment? episodes? most recent leaving most
treatment recent 
treatment*
Inpatient treatment
Community mental health 
team
GP
Other (specify)
_______________
*Code as follows: 1 = planned departure [completed care plan at the agency]; 2 = unplanned departure [client dropped out or otherwise stopped treatment]; 3 =  transferred
to another agency/treatment; 4 = administrative/disciplinary discharge [non-compliance with treatment plan or rules of the service].
Current treatment readiness and perceived needs
Circle
Client is highly motivated to receive treatment as a priority
Client is reasonably well motivated to receive treatment but has some ambivalence
Client expressed no preference for any particular treatment modality, but is willing to participate in further assess-
ment arrangements
Client describes little motivation or readiness to accept treatment at this point
Client's preferred type of treatment
Inpatient treatment ❒
Community detoxification ❒
Community prescribing (specialist service, GP, GP shared care) ❒
Residential rehabilitation ❒
Structured day programmes ❒
No preference stated ❒
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Referral priority status  
Check all priority status items that apply to the client's situation:  
Pregnant
Client is HIV/Hepatitis-B/Hepatitis-C seropositive
Current drug injector
Has shared injection equipment in past 4 weeks
Combination depressant substance use (for example opioids; benzodiazepines; alcohol)
Existing medical (physical) conditions requiring monitoring/treatment
Client is a frequent offender
Client is in a situation of acute family/relationship crisis
The client has childcare problems
Total priority score
Risk assessment
Risk to self  
Score
0 = no indication of any risk to self
1 = low risk (occasional suicidal ideation and/or self-harm thoughts but likely to ameliorate in treatment) 
2 = moderate (frequent thoughts of suicide)
3 = high (active suicide risk)
Risk to others  
Score
0 = no indication of any risk to others
1 = low risk (occasional verbal aggression, but no history of violence) 
2 = moderate (some verbal and physical violence)
3 = high (evidence of recent violence, may pose a significant danger to staff and other clients)
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Addiction Severity Index—Lite
Items underscored are used for outcome assessment
1.    Medical status
M1. How many times in your life have you been hospitalized for medical problems? _____
M3. Do you have any chronic medical problems which continue to interfere with your life?
0. No 1. Yes—if yes specify: ________________________
M4. Are you taking any prescribed medication on a regular basis for a physical problem?
0. No 1. Yes—if yes specify: ________________________
M5. Do you receive a pension for a physical disability?
0. No 1. Yes—if yes specify: ________________________
M6. How many days have you experienced medical problems in the past 30 days? _____
M7. How troubled or bothered have you been by these medical problems in the past 30 days?
0. Not at all    1. Slightly    2. Moderately    3. Considerably    4. Extremely
M8. How important to you now is treatment for these medical problems?
0. Not at all    1. Slightly    2. Moderately    3. Considerably    4. Extremely
Confidence ratings
Is the above information significantly distorted by:
M10. Client's misrepresentation? 0. No 1. Yes
M11. Client's inability to understand? 0. No 1. Yes
Employment/support status
E1. Education completed:  Years ____  Months ____
E2. Training or technical education completed:  Years ____  Months ____
E4. Do you have a valid driver's license?   0.  No 1. Yes
E5. Do you have an automobile available? 0.  No 1. Yes
E7. Usual or last occupation? _______________________
E9. Does this constitute the majority of your support?    0.  No   1. Yes
E10. Usual employment pattern, past three years:
1. Full time (35+ hours) 2. Part time (regular hours)   3. Part time (irregular hours)
4. Student   5. Service   6. Retired/disability   7. Unemployed   8. In controlled environment
E11. How many days were you paid for working in the past 30 days? ____
E12. Employment (net or “take home” pay) ______________
E13. Unemployment compensation ____________________
E14. Welfare __________________________
E15. Pensions, benefits or Social Security ________________
E16. Mate, family or friends ____________________
E17. Illegal _______________________
E18. How many people depend on you for the majority of their food, shelter etc.? _____
E19. How many days have you experienced employment problems in the past 30? _____ 
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A version of the Addiction Severity Index—Lite is given below.
E20. How troubled or bothered have you been by these employment problems in the past 30 
days?   0. Not at all   1. Slightly   2. Moderately   3. Considerably   4. Extremely
E21. How important to you now is counselling for these employment problems?
0. Not at all   1.Slightly   2. Moderately   3. Considerably   4. Extremely
Confidence ratings
Is the above information significantly distorted by:
E23. Client's misrepresentation? 0. No 1. Yes
E24. Client's inability to understand? 0. No 1. Yes
Alcohol/drugs
Route of administration types:  1. Oral   2. Nasal   3. Smoking   4. Non-IV injection   5. IV
D1. Alcohol (any use at all): Past 30 days:  ____  Lifetime (years)   
D2. Alcohol (to intoxication): Past 30 days:  ____  Lifetime (years)   
D3. Heroin:   Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D4. Methadone: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D5. Other opiates/analgesics: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D6. Barbiturates: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D7. Sedatives/hypnotics: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D8. Cocaine: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D9. Amphetamines: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D10. Cannabis: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D11. Hallucinogens: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D12. Inhalants: Past 30 days:  ____  Lifetime (years)  ____  Route of Admin ____
D13. More than 1 substance per day (including alcohol):  Past 30 days:  ____  Lifetime (years)  _____ 
D17. How many times have you had alcohol delirium tremens?  _____
How many times have you been treated for
D19. Alcohol abuse?  ____
D20. Drug abuse?  ____
How many of these were detoxification only? 
D21. Alcohol abuse?  ____
D22. Drug abuse?  ____
How much money would you say you spent during the past 30 days? 
D23. Alcohol?  ____
D24. Drugs?  ____
D25. How many days have you been treated as an outpatient for alcohol or drugs in the past 30? ____
How many days in the past 30 have you experienced:
D26. Alcohol problems?  ____
D27. Drug problems?  ____
How troubled or bothered have you been in the past 30 days by these: 
D28. Alcohol problems:   0. Not at all   1. Slightly   2. Moderately   3. Considerably   4. Extremely
D29. Drug problems: 0. Not at all   1. Slightly   2. Moderately   3. Considerably   4. Extremely
How important to you now is treatment for these:
D30. Alcohol problems: 0. Not at all   1. Slightly   2. Moderately   3. Considerably   4. Extremely
D31. Drug problems: 0. Not at all   1. Slightly   2. Moderately   3. Considerably   4. Extremely
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Confidence ratings
Is the above information significantly distorted by:
D34. Client's misrepresentation? 0. No 1. Yes
D35. Client's inability to understand? 0. No 1. Yes
2.    Legal status
L1. Was this admission prompted or suggested by the criminal justice system?   0. No   1. Yes
L2. Are you on parole or probation?   0. No   1. Yes
How many times in your life have you been arrested and charged with the following:
L3. Shoplift/vandalism L10. Assault
L4. Parole/probation L11. Arson
L5. Drugs charges L12. Rape
L6. Forgery L13. Homicide/manslaughter
L7. Weapons offence L14. Prostitution
L8. Burglary/larceny/breaking and entering L15. Contempt of court
L9. Robbery L16. Other
L17. How many of those charges resulted in convictions? ____
How many times in your life have you been charged with the following:
L18. Disorderly conduct, vagrancy, public intoxication? ____
L19. Driving while intoxicated? ____
L20. Major driving violations? ____
L21. How many months were you incarcerated in your life? ____
L24. Are you presently awaiting charges, trial, or sentence?  0. No   1. Yes
L25. What for?  ____
L26. How many days in the past 30 were you detained or incarcerated?  ____
L27. How many days in the past 30 have you engaged in illegal activities for profit?  ____
L28. How serious do your feel your present legal problems are? 
0. Not at all   1. Slightly   2. Moderately   3. Considerably   4. Extremely
L29. How important to you now is counselling or referral for those legal problems?
0. Not at all   1. Slightly   2. Moderately   3. Considerably   4. Extremely
Confidence ratings
Is the above information significantly distorted by:
L31. Client's misrepresentation? 0. No 1. Yes
L32. Client's inability to understand? 0. No 1. Yes
3.   Family/social relationships
F1. Marital status:
1. Married   2. Remarried   3. Widowed   4. Separated   5. Divorced   6. Never married 
F3. Are you satisfied with that situation? 0. No   1. Indifferent   2. Yes
F4. Usual living arrangements (past 3 years)
1. With sexual partner and children   2. With sexual partner alone   3. With children alone
4. With parents   5. With family   6. With friends   7. Alone   8. Controlled environment
9. No stable arrangement
F6. Are you satisfied with that situation?    0. No   1. Indifferent   2. Yes
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F9. With whom do you spend most of your free time?  1. Family   2. Friends   3. Alone 
F10. Are you satisfied with spending your free time in that way?  0. No   1. Indifferent   2. Yes
Do you live with anyone who:
F7. Has a current alcohol problem? 0. No   1. Yes
F8. Uses non-prescribed drugs? 0. No   1. Yes
Have you had significant periods in which you have experienced serious problems getting along with: 0. No 1. Yes
Past 30 days In your life
F18. Mother   ____ ____
F19. Father   ____ ____ 
F20. Brother/Sister   ____ ____ 
F21. Sexual partner/Spouse ____ ____ 
F22. Children ____ ____ 
F23. Other significant family members ____ ____
F24. Close friends ____ ____ 
F25. Neighbours ____ ____ 
F26. Co-workers ____ ____
Did anyone abuse you
Past 30 days In your life
F28. Physically? ____ ____
F29. Sexually? ____ ____
How many days in the past 30 have you had serious conflicts:
F30. With your family?  ____
F31. With other people? ____
How troubled or bothered have you been in the past 30 days by:
F32. Family problems? 0. Not at all   1. Slightly   2. Moderately  3. Considerably   4. Extremely
F33. Social problems? 0. Not at all   1. Slightly   2. Moderately  3. Considerably   4. Extremely
How important to you now is treatment or counselling for those:
F34. Family problems? 0. Not at all   1. Slightly   2. Moderately  3. Considerably   4. Extremely
F35. Social problems? 0. Not at all   1. Slightly   2. Moderately  3. Considerably   4. Extremely
Confidence ratings
Is the above information significantly distorted by:
F37. Client's misrepresentation? 0. No   1. Yes
F38. Client's inability to understand? 0. No   1. Yes
Psychiatric status
How many times have you been treated for any psychological or emotional problems?
P1. In a hospital or inpatient setting?   ____
P2. Outpatient/private client?  ____
P3. Do you receive a pension for a psychiatric disability? 0. No    1. Yes
Have you had a significant period of time (that was not a direct result of alcohol/drug use) in which you have:
0. No    1. Yes
Past 30 days Lifetime
P4. Experienced serious depression-sadness, hopelessness, 
loss of interest, difficulty with any function? ____ ____
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P5. Experienced serious anxiety/tension-uptight, unreasonably
worried, inability to feel relaxed? ____ ____
P6. Experienced hallucinations-saw things or heard voices that
were not there? ____ ____
P7. Experienced trouble understanding, concentrating or 
remembering? ____ ____
P8. Experienced trouble controlling violent behaviour?
P9. Experienced serious thoughts of suicide? ____ ____
P10. Attempted suicide? ____ ____
P11. Been prescribed any medication for any psychological 
or emotional problems? ____ ____
P12. How many days in the past 30 have you experienced those
psychological or emotional problems? ____ ____
P13. How much have you been troubled or bothered by those 
psychological or emotional problems?
0. Not at all   1. Slightly    2. Moderately   3. Considerably   4. Extremely
P14. How important to you now is treatment for these problems?
0. Not at all   1. Slightly    2. Moderately   3. Considerably   4. Extremely
Confidence ratings
Is the above information significantly distorted by:
P22. Client's misrepresentation? 0. No 1. Yes
P23. Client's inability to understand? 0. No 1. Yes
Annex VI.5
Annex VI Addiction Severity Index—Lite

The purpose of the Treatment Demand Indicator (TDI) project is to generate consistent and comparable informa-
tion on clients seeking treatment in Europe. A panel of experts has developed a basic set of treatment contact,
sociodemographic and drug-related information about the characteristics of people presenting to treatment services.
The TDI is offered as a core set of information from which member States can gather additional information as
required. The TDI core set is as follows:
Treatment contact details
1. Treatment centre type
(1. Outpatient treatment centres    2. Inpatient treatment centres    3. Low- threshold/drop in/street agencies  
4. General practitioners  5. Treatment units in prison)
2. Date of treatment-month
3. Date of treatment-year
4. Ever previously treated-(1. Never 2. Previously treated 0. Not known)
5. Source of referral-(1. Self-referred  2. Family/friends  3. Other drug-treatment centre  4. General practitioner
5. Hospital/other medical source  6. Social services  7. Court/probation/police  8. Other  9. Not known)
Socio-demographic and basic epidemiological information
6. Gender (1. Male  2. Female  0. Not known)
7. Age
8. Year of birth
9. Living status (with whom)-(1. Alone   2. With parents   3. Alone with child   4. With partner (alone)   5. With
partner and child(ren)   6. With friends    7. Other   0. Not known)
10. Living status (past 30 days before starting treatment)—(1. Stable accommodation  2. Unstable accommoda-
tion  3. Institutions (prison, clinic)  0. Not known)
11. Nationality—(1. National of this country   2. EU national   3. National of another country   0. Not known)
12. Labour status—(1. Regular employment   2. Pupil/student   3. Economically inactive (pensioners, house-
wives/men, invalids)   4. Unemployed   5. Other   0. Not known)
13. Highest educational level completed—(1. Never went to school/never completed primary school   2. Primary
level of education   3. Secondary level of education   4. Higher level of education   0. Not known)
Drug-related information
14. Primary drug—(1. Opioids (heroin/methadone/other opioids)  2. Cocaine (cocaine/crack)  3. Stimulants
(amphetamines/MDMA and other derivatives/other stimulants)  4. Hypnotics and sedatives (barbiturates/
benzodiazepines/others)  5. Hallucinogens (LSD/others)  6. Volatile inhalants  7. Cannabis  8. Other substances)
15. Already receiving substitution treatment—(a) heroin (b) methadone (c) other opiates (d) other substances—
(1. Yes   2. No   0. Not known)
16. Usual route of administration (primary drug)—(1. Inject   2. Smoke/inhale   3. Eat/drink   4. Sniff   5. Others
0. Not known)
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17. Frequency of use (primary drug)—(1. Not used in past month (occasional)   2. Used once a week or less  
3. Used 2-6 days a week   4. Used daily   0. Not known)
18. Age at first use of primary drug
19. Other (= secondary) drugs currently used—see list in 14 above
20. Ever injected/currently injected (last 30 days) injecting—(1. Ever injected but not currently   2. Currently
injecting   3. Never injected   0. Not known)
For further information, go to:
http://www.emcdda.org/multimedia/project_reports/situation/treatment_indicator_report.pdf
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Maudsley Addiction Profile
A.   Management information
Incorporate standard details about client identification, demographics, referral source and treatment programme
descriptors as required.
B.   Substance use 
1.   Oral 2. Snort/sniff     3. Smoke/chase 4. Intravenous 5. Intramuscular
Days used (past 30) Amount used on Route
typical day
B1. Alcohol ____ ____ ____
B2. Heroin ____ ____ ____
B3. Illicit methadone ____ ____ ____
B4. Cocaine powder ____ ____ ____
B5. Crack cocaine ____ ____ ____
B6. Amphetamine ____ ____ ____
B7. Cannabis ____ ____ ____
B8. Other (specify) _________ ____ ____ ____
C.   Health risk behaviour
C1. Days injected drugs in the past 30 days ____
C2. Times injected on a typical day in the past 30 days ____
C3. Times injected with a needle/syringe already used by someone else ____
C4. Number of people had sex with and not used condom ____
C5. Total number of times had sex with and not used condom ____
D.   Health symptoms
D1. How often experienced the following physical health symptoms
0. Never 1. Rarely    2. Sometimes    3. Often    4. Always
(a) Poor appetite ___
(b) Tiredness/fatigue ___
(c) Nausea (feeling sick) ___
(d) Stomach pains ___
(e) Difficulty breathing ___
(f ) Chest pains ___
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(g) Joint/bone pains ___
(h) Muscle pains ___
(i) Numbness/tingling ___
(j) Tremors/shakes ___
D2. How often experienced the following emotional or psychological health symptoms
0. Never    1. Rarely    2. Sometimes     3. Often    4. Always
(a) Feeling tense ___
(b) Suddenly scared for no reason ___
(c) Feeling fearful ___
(d) Nervousness or shakiness inside ___
(e) Spells of terror or panic ___
(f ) Feeling hopeless about the future ___
(g) Feelings of worthlessness ___
(h) Feeling no interest in things ___
(i) Feeling lonely ___
(j) Thoughts of ending your life ___
E.   Personal and social functioning
Relationships
E1. Days had contact with partner in the past 30 days  ___
E2. Number of those days where there was conflict with partner ___
E3. Days had contact with relatives in the past 30 days ___
E4. Number of those days where there was conflict with relatives ___
E5. Days had contact with friends in the past 30 days ___
Employment
E7. Number of days of paid work in past 30 days ___
E8. Days missed from work because of sickness or unauthorised absence ___
E9. Days formally unemployed in the past 30 days ___
Crime
E10. Crimes committed in the past 30 days
Days Times/
typical day
(a) Selling drugs ___ ___
(b) Fraud/forgery ___ ___
(c) Shoplifting ___ ___
(d) Theft from a property ___ ___
(e) Theft from a vehicle ___ ___
(f ) Other crimes (list) ___ ___
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Abstinencea
The term refers to the act of refraining from alcohol or other
drug use, whether for health, personal, social, religious, moral,
legal or other reasons.
Someone who is currently abstinent may be called an “abstain-
er”, a “total abstainer”, or, an old-fashioned term relating only
to alcohol, a “teetotaller”. The term “current abstainer” is
sometimes used for research purposes and is usually defined as
a person who has not used drugs for a specified period of time,
for example, 3, 6 or 12 months. In some studies, persons who
drink or use other drugs only once or twice per year are also
classified as abstainers.
Abusea
A term in wide use but of varying meaning. In international
drug control conventions “abuse” refers to any consumption of
a controlled substance no matter how infrequent. In the
Diagnostic and Statistical Manual of Mental Disorders (DSM-
IV, American Psychiatric Association, 1994), “psychoactive
substance abuse” is defined as “a maladaptive pattern of sub-
stance use leading to clinically significant impairment or dis-
tress, as manifested by one (or more) of the following within a
12 month period: (1) recurrent substance use resulting in a fail-
ure to fulfil major role obligations at work, school or home; 
(2) recurrent substance use in situations in which it is physica-
lly hazardous; (3) recurrent substance-related legal problems; 
(4) continued substance use despite having persistent or recur-
rent social or interpersonal problems caused or exacerbated by
the effects of the substance”. It is a residual category, with
dependence taking precedence whenever applicable.
The term “abuse” is sometimes used disapprovingly to refer to
any use at all, in particular of illicit drugs. Because of its ambi-
guity, the term is only used in the ICD-10 Classification of
Mental and Behavioural Disorders: Clinical Descriptions and
Diagnostic Guidelines (WHO, 1992) for non-dependence-
producing substances. “Harmful” and “hazardous use” are the
equivalent terms in WHO usage, although they usually relate
only to effects on health and not to social consequences. The
term “abuse” is also discouraged by the Centre for Substance
Abuse Prevention in the United States, although the term
“substance abuse” remains in wide use and refers generally to
problems of psychoactive substance use. The term “drug
abuse” has also been criticized as being circular when it is used
without reference to specific problems arising from drug use.
See also: Drug abuse.
Accreditation
The process of recognition that a programme meets specific
operational and organizational standards that have been estab-
lished to ensure the quality of services within a particular
region or treatment system. Accreditation is usually awarded
by an external professional body on the basis of a review or
audit and is usually for a specific period.
Addictiona
One of the oldest and most commonly used terms to describe
and explain the phenomenon of long-standing drug abuse. In
some professional circles it has been replaced by the term “drug
dependence”. According to the WHO Lexicon of Alcohol and
Drug Terms, “addiction” is defined as: the repeated use of a psy-
choactive substance or substances, to the extent that the user
(referred to as an addict) is periodically or chronically intoxi-
cated, shows a compulsion to take the preferred substance (or
substances), has great difficulty in voluntarily ceasing or modi-
fying substance use, and exhibits determination to obtain psy-
choactive substances by almost any means.
Key indicators of “addiction” have traditionally been thought to
be tolerance and experience of a withdrawal syndrome, that is, it
is often equated with physical dependence. More recently, some
drug researchers have suggested that “compulsion to use drugs”
is a more central indicator of addiction. Addiction is otherwise
regarded by the self-help or “recovery” movement as a discrete
disease, a debilitating and progressive disorder rooted in the
pharmacological effects of the drug for which the only cure is
total abstinence. That view is most notably associated with the
“self-help” or “recovery” movement, for example, Narcotics
Anonymous and Alcoholics Anonymous. In the 1960s, WHO
recommended that the term “addiction” be abandoned in favour
of dependence, which can exist in various degrees of severity as
opposed to an “all or nothing” disease entity.
Addiction is not a diagnostic term in the ICD-10, but con-
tinues to be very widely employed by professionals and the
general public alike. 
See also: Dependence, Dependence syndrome.
Advice servicesa
The range of information and non-medical treatment services
which can variously provide drug information, details of serv-
ices available, referral to other agencies, and direct clinical
casework or psychotherapy. Services may be provided in a
direct face-to-face setting or indirectly by telephone to indi-
viduals, families, groups, other workers or agencies. The term
“advice” is usually reserved for the provision of factual infor-
mation on specific issues. It also incorporates brief and specif-
ic advice to change behaviour, for example in brief interven-
tions (see below). Advice is usually distinguished from “coun-
selling” where the emphasis is more on assisting individuals to
evaluate their own situation and reach their own decisions
about how to cope.
See also: Brief intervention, Counselling and psychotherapy,
Treatment.
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Aftercare
A broad range of community-based service supports designed
to maintain benefit when a structured treatment has been
completed. Aftercare may involve a continuation of individual
or group counselling and other supports, but usually at a
lower intensity and often by other agencies. Self-help groups
such as Narcotics Anonymous are an important provider of
aftercare. 
See also: Self-help group.
Agonista
A substance that acts on receptor sites to produce certain
responses; for example, both methadone and heroin are ago-
nists for opioid receptors.
AIDSa
The common abbreviation for a fatal viral condition known as
acquired immunodeficiency syndrome in which the immune
system is weakened and unable to combat infectious diseases.
The sharing of injecting equipment among injecting drug users
is a major route of transmission for human immunodeficiency
virus (HIV). That is the virus that causes AIDS, and in many
countries has led to programmes discouraging injecting and to
the establishment of programmes to make clean injecting
equipment more readily available for injecting drug users in
order to reduce the likelihood of transmission of the virus
through the sharing of used needles and other equipment.
See also: Harm reduction, Needle exchange, Risk reduction,
Safer use.
Antagonista
A substance that counteracts the effects of another agent.
Pharmacologically, an antagonist interacts with a neuronal
receptor to inhibit the action of agents (agonists) that produce
specific physiological or behavioural effects mediated by that
receptor.
Brief interventionb
A treatment strategy in which structured therapy of a limited
number of sessions (usually one to four) of short duration
(typically 5-30 minutes) is offered with the aim of assisting an
individual to cease or reduce the use of a psychoactive sub-
stance or (less commonly) to deal with other life issues. It is
designed, in particular, for general practitioners and other pri-
mary health care workers. 
Buprenorphinea
Buprenorphine is a mixed agonist/antagonist which can be
used in substitution treatment. It has been used extensively in
many countries for the short-term treatment of moderate to
severe pain. The mixed opioid-action/blocking-action appears
to make buprenorphine safe in overdose and possibly less 
likely to be diverted than pure opioids. It may also provide an
easier withdrawal phase, and due to a longer action, may allow
for alternate day dosing. It is apparent from the research 
conducted to date that buprenorphine is at least as effective as
methadone as a maintenance agent. 
See also: Drug substitution, Methadone.
Capture recapture method
Capture recapture method (CRM) is an epidemiological tech-
nique which is used to estimate the prevalence of a specific
behaviour within a defined population (for example, the
number of injecting drug users in a specified geographic area).
CRM uses the overlap between two or more samples or regis-
ters of people to derive an estimate of the total population. 
Care coordination
The process of oversight and practical management of patients
within a particular treatment and across different treatments
over time. For a particular patient, care coordination can
involve assessment, referral, progress monitoring and review
activities. In some treatment systems, the care coordinator has
some degree of authority over the system that pays for the
treatment of patients. 
Client satisfaction
A broad concept that refers to whether a treatment meets the
expectations and needs of a particular client (patient). Client
satisfaction is usually assessed by a self-report questionnaire
during or at completion of treatment. Client satisfaction is
sometimes used as an outcome measure alongside primary
clinical, social and economic outcome assessments.
Cognitive-behavioural techniques
A type of psychotherapy that stresses that the way in which
people think about a problem is instrumental in causing feel-
ings and behaviours that are unwanted. Cognitive-behavioural
techniques (CBT) therefore aims to help a patient replace those
unhelpful thoughts with others that lead to more desirable reac-
tions. In the substance abuse field the CBT therapist helps a
patient to acquire new skills to alter or maintain changes in
their behaviour. In that respect, relapse prevention programmes
may contain a CBT element to help patients resist urges to use
substances.
Annex IX.4
Drug Abuse Treatment and Rehabilitation A Practical Planning and Implementation Guide
b Lexicon of Alcohol and Drug Terms (Geneva, World Health Organization, 1994).
Community-based treatment
Any treatment that is based in a non-residential setting.
Outpatient treatments (day attendance-based services provi-
ded from a hospital) are often bracketed with community-
based treatments. Examples of community-based treatments
are opioid substitution programmes; counselling programmes
and aftercare services.
Community empowermenta
Interventions which encourage a community (for example,
people in a locality, drug injectors, sex workers) to develop
collective ownership and control over health-related choices
and activities. To achieve that result, the community may also
need to gain collective control of the wider social, political
and economic factors which influence their access to health.
“Empowerment” is a process of increasing personal, interper-
sonal or political power so that individuals can take action to
improve their lives.
Co-morbidity
See: Dual diagnosis.
Correctional system
The organization of police, judiciary and penal structures that
operate in a particular State. The terms “correctional system”
and “criminal justice system” are synonymous.
Counselling and psychotherapya
Counselling is an intensive interpersonal process concerned
with assisting normal people to achieve their goals or function
more effectively. Psychotherapy is generally a longer-term
process concerned with reconstruction of the person and 
larger changes in more fundamental psychological attributes
such as personality structure. Psychotherapy is often restricted
in conception to those with pathological problems.
Court diversiona
A programme of treatment, re-education or community serv-
ice for individuals referred from criminal courts (criminal
diversion) after being charged with driving under the influence
of alcohol (drinking-driver diversion) or another drug, with
the sale or use of drugs (drug diversion), or with another
crime. Individuals are assigned to diversion programmes in
lieu of prosecution, which is usually held in abeyance pending
successful completion of the diversion programme. Pre-charge
diversion refers to the systematic referral of those detected 
by the police to an alternative programme without arrest. In
some countries, the term “custody diversion” is used to make
explicit that in many diversion schemes the individual may
attend court but be diverted away from custody into a 
programme of treatment or re-education.
Custody diversion
See: Court diversion.
Dependence, dependence syndromea
According to the WHO Lexicon of Alcohol and Drug Terms,
“dependence, dependence syndrome” is defined as follows: as
applied to alcohol and other drugs, a need for repeated doses
of the drug to feel good or to avoid feeling bad.
The terms “dependence” and “dependence syndrome” have
gained favour with WHO and in other circles as alternatives
to addiction since the 1960s.
In the DSM-IV, dependence is defined as “a cluster of cogni-
tive, behavioural and physiological symptoms indicating that
the individual continues use of the substance despite signifi-
cant substance-related problems”. 
See also: Addiction.
Detoxification
The process by which a person who is dependent on a psy-
choactive substance ceases use, in such a way that minimizes
the symptoms of withdrawal and risk of harm. While the term
“detoxification” literally implies a removal of toxic effects from
an episode of drug use, in fact it has come to be used to refer
to the management of rebound symptoms of neuroadapta-
tion, that is, withdrawal and any associated physical and men-
tal health problems.
Drug abuse
Current international drug control treaties do not define drug
abuse but make reference to a variety of terms, including
abuse, misuse and illicit use. In the context of international
drug control, drug abuse constitutes the use of any substance
under international control for purposes other than medical
and scientific, including use without prescription, in excessive
dose levels, or over an unjustified period of time.
Drug substitutiona
Treatment of drug dependence by prescription of a substitute
drug for which cross-dependence and cross-tolerance exist.
The term is sometimes used in reference to a less hazardous
form of the same drug used in the treatment. The goals of
drug substitution are to eliminate or reduce use of a particu-
lar substance, especially if it is illegal, or to reduce harm from
a particular method of administration, the attendant dangers
to health (for example, from needle sharing), and the social
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consequences. Drug substitution is often accompanied by
psychological and other treatment.
DSM-IV
The Diagnostic and Statistical Manual of Mental Disorders is
the standard classification of mental disorders used by mental
health professionals in the United States. It is also widely used
in other parts of the world. It is intended to be applicable in a
wide array of contexts and used by clinicians and researchers
of many different orientations (for example, biological, psy-
chodynamic, cognitive, behavioural, interpersonal, family/sys-
tems). DSM-IV (fourth edition), compiled and published by
the American Psychiatric Association in 1994, was designed
for use across settings. It is also a tool for collecting and com-
municating accurate public health statistics. The DSM con-
sists of three major components: the diagnostic classification,
the diagnostic criteria sets and the descriptive text.
See also: Abuse.
Dual diagnosis
A person diagnosed as having an alcohol or drug abuse prob-
lem in addition to some other diagnosis, usually psychiatric, for
example, mood disorder, schizophrenia. Making differential
diagnoses is often complicated by overlapping signs and symp-
toms of dependence and diagnostic entries, for example, anxi-
ety is a prominent feature of drug withdrawal. A further com-
plication is with shared or reciprocal casual processes, for exam-
ple, a mild disorder of mood leads to some drug use which
eventually leads to an exacerbation of the mood disturbance, to
further drug use, dependence and severe mood disturbance.
Early interventionb
A therapeutic strategy that combines early detection of haz-
ardous or harmful substance use and treatment of those
involved. Treatment is offered or provided before such time as
patients might present of their own volition and in many cases
before they are aware that their substance use might cause
problems. It is directed in particular at individuals who have
not developed physical dependence or major psychosocial
complications.
Eligibility criteria
A set of medical, social and psychological conditions that are
used to judge the appropriateness of a treatment for a partic-
ular individual. Eligibility criteria usually take into account
the severity of patients' problems, their personal motivations
or readiness for treatment, and the nature and extent of their
social supports and stressors in terms of their suitability for a
particular treatment. Use of eligibility criteria is part of a com-
mitment to matching patients to the best or more appropriate
treatment in the context of two or more alternatives.
Evaluationc
The systematic and scientific process of determining the
extent to which an action or sets of actions were successful in
the achievement of predetermined objectives. It involves
measurement of adequacy, effectiveness and efficiency of pro-
grammes or services. Evaluation is to be distinguished from
assessment and appraisal: both terms are used as more general
terms than evaluation, connoting the drawing of conclusions
from the examination of a situation or its elements.
Evaluation, then, is a particular type of assessment.
Evaluation instrument
An interviewer or patient self-report questionnaire that is used
to record past behaviours and/or perceptions that assess the
impact of a treatment. Ratings on an evaluation instrument
for a recall period before treatment are commonly contrasted
with ratings on the same measures during treatment and/or
after treatment has ended.
Family liaison worker
A professional counsellor, social worker or nurse whose role is
to support the family (dependants and carer(s) of a patient).
The worker assists family members who are affected by a sub-
stance abuse problem and may provide information, support-
ive counselling and referral services. Helping the family
understand and provide support to a member with a sub-
stance abuse problem is a core function.
Focus group
A discussion-based, qualitative research data gathering
method designed to explore a topic of interest and generate a
range of opinions. A small number of members of a particu-
lar group meet together and their discussion is facilitated by a
researcher known as a “moderator”. 
Generic service
A social, welfare or health care service that does not have as its
primary function the treatment of substance abuse problems
but may in the course of its work come into contact with peo-
ple who are affected. Generic services may develop expertise in
screening, assessing and treating substance abuse problems (so
that the boundary between generic and speciality services may
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be difficult to draw) and may also have formal referral links
with specialist substance abuse services.
Half-way housea
Often, a place of residence that acts as an intermediate stage
between an inpatient or residential therapeutic programme
and fully independent living in the community. The term
applies to accommodation for alcohol- or drug-dependent
individuals endeavouring to maintain their sobriety (compare
therapeutic community). There are also half-way houses for
individuals with psychiatric disorders and for individuals who
are leaving prison.
Harm reductiona
In the context of alcohol or other drugs, harm reduction refers
to policies or programmes that focus directly on reducing the
harm resulting from the use of alcohol or other drugs, both to
the individual and the larger community. The term is used in
particular for policies or programmes that aim to reduce the
harm without necessarily requiring abstinence. Some harm
reduction strategies designed to achieve safer drug use may,
however, precede subsequent efforts to achieve total absti-
nence. Examples of harm reduction include needle/syringe
exchanges to reduce rates of needle sharing among injecting
drug users.
Harmful usea
According to the WHO Lexicon of Alcohol and Drug Terms,
“harmful use” is defined as follows: a pattern of psychoactive
substance use that is causing damage to the health of the drug
user. The damage may be physical (for example, hepatitis fol-
lowing injection of drugs) or mental (for example, depressive
episodes secondary to heavy alcohol intake). Harmful use gen-
erally has adverse social consequences as well.
The term was introduced in the ICD-10 and supplanted “non-
dependent use” as a diagnostic term. The closest equivalent in
other diagnostic systems (for example, in the DSM-IV) is sub-
stance abuse, which usually includes social consequences. 
ICD-10
The Tenth Revision of the International Statistical
Classification of Diseases and Related Health Problems is the
latest in a series that was formalized in 1893 as the Bertillon
Classification or International List of Causes of Death. While
the title has been amended to make clearer the context and
purpose and to reflect the progressive extension of the scope of
the classification beyond diseases and injuries, the familiar
abbreviation “ICD” has been retained. ICD was developed by
the World Health Organization (WHO) and is designed to
promote international comparability in the collection, process-
ing, classification, and presentation of morbidity and mortality
statistics. The reported conditions are translated into medical
codes through use of the classification structure and the selec-
tion and modification rules contained in the application of
ICD. The tenth revision (ICD-10) was published in 1992.
Impact evaluation
Impact evaluation is a form of outcome evaluation that assess-
es the net effect of a programme by comparing programme
outcomes with an estimate of what would have happened in
the absence of the programme. The time horizon for impact
evaluations are often in the medium or longer term.
Incidencea
The rate at which a condition or illness occur, often expressed
in terms of the number of cases per 10,000 people per year.
Integrated care pathways
A description of the nature and anticipated course of sub-
stance abuse treatment. An integrated care pathway describes
a predetermined plan of treatment for a particular patient
group entering structured treatment and the anticipated out-
comes that are expected. The pathway may relate to several
treatment components to be delivered by a single agency pro-
gramme or it may include several treatments delivered by two
or more agencies. Integrated care pathways form part of the
set of documents and protocols that describe what a treatment
programme intends to do as well as the intended results.
Integrated treatment system
An integrated treatment system is one that contains several
treatment services, both specialist and generic, that operate in a
structured and organized way. Most integrated treatment sys-
tems will contain community-based and residential services and
have established referral and patient transfer arrangements.
Intoxicationa
According to the WHO Lexicon of Alcohol and Drug Terms,
“intoxication” is defined as follows: a condition that follows
the administration of a sufficient amount of a psychoactive
substance and which results in disturbances in the level of
consciousness, cognition, perception, judgement, affect,
behaviour, or other psychophysiological functions and
responses. The disturbances are related to the acute pharma-
cological effects of, and learned responses to, the substance
and resolve with time, with complete recovery, except where
tissue damage or other complications have arisen. The term is
most commonly used with regard to alcohol use.
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LAAMa
From the chemical name levo-alpha-acetylmethadol, LAAM
is a synthetic pure opioid agonist (related to methadone) of
the morphine type. It was extensively investigated in the
1970s as a pharmacological alternative to methadone, its chief
advantage being that it has a longer half-life and consequent-
ly patients can be dosed every 48 to 72 hours rather than every
24 hours as is required with methadone. 
See also: Drug substitution, Methadone, Opiate, Opioid.
Maintenance therapy
See: Drug substitution.
Mandated treatment
A characterization of treatment, sometimes called coercive treat-
ment, that is organized by the criminal justice system. Typically,
a court (or other criminal justice body) orders that an individ-
ual enters a therapeutic programme (sometimes as an alternative
to a custodial sentence). Treatment is mandated in the sense that
failure to enter the programme or comply with its rules and reg-
ulations may result in the individual receiving the criminal jus-
tice penalty that would normally be invoked.
Matrix model
The matrix model is a multi-component framework treatment
for managing substance abusers, in particular stimulant
abusers in treatment and helping them achieve abstinence.
The model addresses the needs of stimulant abusers in a sys-
tematic way, separating the problem areas into distinct cate-
gories. The chosen categories are: behavioural, cognitive, emo-
tional and relationships. The treatment focuses on particular
issues in each of those areas which emerge in the “stages of
recovery” encountered by recovering clients during the first
year of stimulant abstinence. The model emphasizes individ-
ual therapist contact and education about drug abuse, relapse
prevention, social support, 12-step participation and focuses
on issues critical to addiction and relapse. The programme
includes educational sessions focusing on skills required to
maintain abstinence and promoting recovery. Family mem-
bers are encouraged to attend support and discussion groups
and are provided with support as required.
Methadoneb
A synthetic opiate drug used in maintenance therapy for those
dependent on opioids. It has a long half-life, and can be given
orally once daily with supervision. It is the most widely used
treatment for opioid dependence in the developed world.
When given in an adequate dose to opioid dependent indi-
viduals, methadone tends to reduce desire to use heroin and
other opiates, eliminates opioid withdrawal, and blocks the
euphoric effects of the other opioid drugs. 
See also: Buprenorphine, Drug substitution, LAAM, Opiate,
Opioid.
Minimal interventiona
Usually used as a synonym for brief intervention. However,
some authorities suggest that minimal intervention as a term
should be restricted to person-to-person interventions lasting
between 30 minutes and 3 hours, that is, somewhat longer
than “brief intervention”.
See also: Brief intervention, Early intervention, Prevention.
Modality
A categorization of a specific type of drug abuse treatment. A
given treatment modality can be described in terms of its spe-
cific therapeutic approach or philosophy and purpose. In the
United Kingdom, for example, the following treatment
modalities are available: residential rehabilitation; inpatient
stabilization and detoxification; community specialist pre-
scribing; community general practitioners prescribing; struc-
tured counselling and structured day services.
Motivational interviewinga
A counselling and assessment technique which essentially fol-
lows a non-confrontational approach to questioning people
about difficult issues like alcohol and other drug use and assist-
ing them to make positive decisions to reduce or stop their drug
use altogether. The underlying philosophy is closely linked with
the Stages of Change Model which posits the view that deci-
sion-making about behavioural change proceeds through
defined stages termed pre-contemplation, contemplation,
preparation, action and maintenance. Motivational interview-
ing comprises a set of techniques designed to move the drug
user, smoker or drinker through those stages by assisting them
to make an accurate appraisal of the benefits and drawbacks of
their behaviour in a non-judgemental interview.
See also: Counselling and psychotherapy.
Mutual-help group
A group in which participants support each other in recover-
ing or maintaining recovery from personal problems. Those
groups are often associated with alcohol and other drug
dependence problems; however, they also operate in the con-
text of other issues such as depression and various compulsive
behaviours. Membership is usually established on a voluntary
and confidential basis, with meetings organized with a pre-
scribed format and time.
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Naloxonea
Naloxone is a narcotic antagonist which reverses the respira-
tory, sedative and hypotensive effects of heroin overdose. It
can be injected intramuscularly, intravenously or subcuta-
neously. A nasal spray preparation is now also available in
some countries. It is an opioid receptor blocker that antago-
nizes the actions of opioid drugs. It reverses the features of
opiate intoxication and is prescribed for the treatment of over-
dose with that group of drugs. 
See also: Antagonist, Naltrexone.
Naltrexonea
A drug that antagonizes the effects of opioid drugs. Its effects are
similar to those of naloxone, but it is more potent and has longer
duration of action. It is used in various ways in the treatment of
opioid dependence and also alcohol dependence. The most
widely adopted use is to prescribe at a dose that will block the
psychoactive effects of all opioid drugs. The idea is that while the
drug needs to be taken daily to maintain that blockade, it will
minimize the chance of impulsive decisions to relapse.
See also: Antagonist, Drug substitution, Naloxone.
Narcotics Anonymous (NA)
See: Self-help group, Twelve-step group.
Narcotic druga, b
A chemical agent that can induce stupor, coma, or insensibil-
ity to pain. The term usually refers to opiates or opioids,
which are called narcotic analgesics. In common parlance and
legal usage it is often used imprecisely to mean illicit drugs,
irrespective of their pharmacology. For example, narcotics
control legislation in Canada, the United States and several
other countries includes cocaine and cannabis as well as opi-
oids. It is also a term adopted by the Single Convention on
Narcotic Drugs, 1961.
Needle exchangea
Provision to reduce the transmission of infectious diseases by
the repeated use and sharing of needles in order to reduce the
transmission of blood-borne viruses. It was first developed in
response to the advent of HIV/AIDS and quickly spread to
many countries in which injecting drug use was experienced
as a problem. The concept involves the provision of clean nee-
dles in exchange for used needles which are then safely dis-
posed of. In practice, an “exchange” is not always required and
clean injecting equipment is provided on demand, sometimes
for a small payment.
See also: AIDS, Harm reduction. 
Needs assessment
A systematic approach to determining the nature and extent
of substance abuse problems in a target population or com-
munity that seeks to identify which (or how many) specific
interventions should be made available to specific groups of
people or how existing interventions and services can be bet-
ter provided.
Non-governmental organizationa
A service agency which is independent of government and
operates in a broad social field. As most of them are non-profit,
non-governmental organizations (NGOs) can be funded by
Governments, public institutions and/or private donations.
Often, such agencies have a mix of paid staff and voluntary
workers and they have traditionally provided services in sec-
tors where it would not be possible to provide funding for
fully-paid staff.
Open access services
Substance abuse services that can be used by any member of a
community without a formal specialist referral.
Opiate
According to the WHO Lexicon of Alcohol and Drug Terms,
“opiate” is defined as follows: one of a group of alkaloids
derived from the opium poppy (Papaver somniferum) with the
ability to induce analgesia, euphoria, and, in higher doses, stu-
por, coma and respiratory depression. The term opiate
excludes synthetic opioids such as heroin and methadone.
See also: Heroin, Opioid, Opium.
Opioida
According to the WHO Lexicon of Alcohol and Drug Terms, “opi-
oid” is defined as follows: the generic term applied to alkaloids
from the opium poppy (Papaver somniferum), their synthetic
analogues, and compounds synthesized in the body, which inter-
act with the same specific receptors in the brain, have the capac-
ity to relieve pain, and produce a sense of well-being (euphoria).
The opium alkaloids and their synthetic analogues also cause
stupor, coma and respiratory depression in high doses.
See also: Narcotic drug, Opiate.
Opioid agonist
See: Agonist.
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Opioid antagonist 
See: Antagonist.
Outcome evaluation
Outcome evaluation measures the extent to which a pro-
gramme achieves its immediate objectives. It focuses on out-
puts and outcomes, including unintended effects, to judge the
programme effectiveness. It may also assess the programme
process to understand how the outcomes are produced. For
UNDCP, outcome evaluations often address the effectiveness
of immediate project objectives and the process through
which they are achieved. The time horizon for outcome eval-
uation is usually with the life of the programme or project.
Outcome measure
A direct or indirect observation or record that concerns a spe-
cific patient's behaviour or cognition that is relevant to their
problems and to the objectives of a treatment or rehabilitation
programme. Outcome measures are usually drawn from a set
of domains spanning substance abuse behaviours and cogni-
tions; physical and psychological health symptoms and condi-
tions and various aspects of personal, social and economic
functioning, including relationship difficulties, housing and
accommodation problems; education, training and employ-
ment problems; and illegal activities. Commonly, outcome
measures are recorded for a suitable period immediately prior
to a patient commencing treatment and recorded again at one
or more follow-up points and changes in scores on the pairs of
measures and then attributed to the treatment provided. 
Outcome monitoring
The recording, communication and application of informa-
tion about the impact or benefit of treatment that is used to
judge the value of the intervention and for the purpose of
improving its operation and effectiveness. 
Outreacha
A community-based activity with the overall aim of facilitat-
ing improvement in health and reduction of drug-related risk
or harm for individuals and groups not effectively reached by
existing services or through traditional health education chan-
nels. Outreach can be “detached”, “peripatetic”, or “domicil-
iary” or “peer”. Detached outreach takes place outside of an
agency or organizational setting in public places such as the
streets, public transport stations, nightclubs, hotels and cafes.
Peripatetic outreach focuses on organizations (for example,
half-way houses, needle exchanges, youth clubs, schools and
prisons) rather than individuals. Domiciliary outreach takes
place in people's homes. Peer (or indigenous) outreach pro-
jects use current and former members of the target group
(such as injecting drug users) as volunteers and paid staff.
Overdose
According to the WHO Lexicon of Alcohol and Drug Terms,
“overdose” is defined as follows: the use of any drug in such an
amount that acute adverse physical or mental effects are pro-
duced. Deliberate overdose is a common means of suicide and
attempted suicide. 
Overdose may produce transient or lasting effects, or death;
the lethal dose of a particular drug varies with the individual
and with circumstances. 
See also: Intoxication.
Peer intervention
Essentially, a treatment that is delivered by a trained individ-
ual who is close in gender or age group or other socio-eco-
nomic category to the target group. Peer interventions are
usually, but not always, brief in duration and target individu-
als at risk of substance abuse problems or who have problems
of moderate severity.
Peer supporta
At one level, one of the components of a peer outreach rela-
tionship where the outreach worker provides some form of assis-
tance to a peer. The assistance is usually ongoing rather than a
single discrete episode. Examples include support provided by
peer carers of people living with AIDS who may be unwell. The
term “peer support group” is used to describe collectives or self-
organizations of members of a community for the purpose of
representing their shared interests at a socio-political level.
Examples include the “Junkiebonden” in the Netherlands and
other drug abuse groups which are found in many countries.
Performance indicator
A measure that is used to assess the progress of a drug supply
or demand strategy.
Performance monitoring
The measurement and communication of the results of strategic
plans and treatment services designed to tackle substance abuse.
See also: Strategic plan.
Prevalencea
A measure of the extent of a particular condition or illness
usually expressed in terms of the numbers of cases per 10,000
people in a given population. 
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Prevention 
An intervention designed to avoid or substantially reduce risk
for the acquisition or further development of adverse health
and interpersonal problems. Drug abuse prevention pro-
grammes vary widely in content and philosophy. The most
effective programmes are multidimensional and contain a
mixture of straight-talking education sessions about drugs and
drug abuse; skills to deal with stress and personal and rela-
tionship problems; and drug resistance skills. The specific
content of a programme can be specifically adapted to the
nature and needs of the target population.
Primary health-care workers
The doctors, nurses, psychologists and support personnel who
work from community locations and who essentially provide
general health-care services to the local population.
Priority groups
Identified groups of people in a country or community that
have a particular set of substance-related risks and/or prob-
lems that require treatment (for example, children and young
people; people with substance abuse and psychiatric co-mor-
bidity; and those in the criminal justice system).
Process evaluation 
An evaluation to determine the degree to which programme
procedures were followed according to a written programme
plan: How much of the intervention was provided to whom,
when, and by whom? A process evaluation can also be called
a quality assurance review.
Psychoactive substancea
According to the WHO Lexicon of Alcohol and Drug Terms,
“psychoactive substance” is defined as follows: a substance
that, when ingested, alters mental processes, that is, thinking
or emotion. That term and its equivalent, psychotropic drug,
are the most neutral and descriptive terms for the whole class
of substances, licit and illicit, of interest to drug policy.
“Psychoactive” does not necessarily imply dependence-pro-
ducing.
See also: Psychotropic drug.
Psychological dependencea
A term for a largely discredited concept but which is still used
in some quarters. It refers to dependence upon a drug in the
absence of the development of either tolerance or withdrawal
symptoms. Most modern uses of the term “dependence” avoid
a strict distinction between “psychological” and “physical”
dependence. If that phenomenon exists at all, it is likely to be
a characteristic of the user and not a property of the drug.
See also: Dependence, Dependence syndrome.
Psychosocial treatment
Interventions based on psychological principles and methods
involving individual and group counselling and therapy
designed to modify problematic substance-related cognitions
and behaviours.
Psychotropic druga
In the context of international drug control, “psychotropic
substance” refers to a substance controlled by the 1971
Convention on Psychotropic Substances. According to the
WHO Lexicon of Alcohol and Drug Terms, “psychotropic” is in
its most general sense a term with the same meaning as “psy-
chotropic”, that is, affecting the mind or mental processes.
Strictly speaking, a psychotropic drug is any chemical agent
whose primary or significant effects are on the central nervous
system. Some writers apply the term to drugs whose primary
use is in the treatment of mental disorders-anxiolytic seda-
tives, antidepressants, antimanic agents and neuroleptics.
Others use the term to refer to substances with a high abuse
liability because of their effects on mood, consciousness, or
both-stimulants, hallucinogens, opioids and sedatives/hyp-
notics (including alcohol).
Quality assurance and improvement
A systematic approach to the organization, delivery and devel-
opment of treatment based on a shared staff commitment to
addressing the needs of patients/clients through appropriate
and good quality services. 
Rapid assessmenta
A variety of methods for rapid or focused data collection
which since the early 1980s have grown out of a sense of
urgency for social science input in disease control pro-
grammes. Both UNDCP and WHO have developed guide-
lines for conducting such assessments. Rapid assessment
methods can be used as an evaluation tool or in order to gen-
erate baseline data. Methods include knowledge, attitude and
behaviour surveys; community diagnosis; rapid rural analysis
used in agriculture; rapid epidemiological assessments; and
those rapid assessment procedures which use ethnographic
methods. Rapid assessment methods may involve either quan-
titative or qualitative methods, but often involve both.
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Rehabilitationa
According to the WHO Lexicon of Alcohol and Drug Terms,
“rehabilitation” is defined as follows: in the field of substance
use, the process by which an individual with a drug-related
problem achieves an optimal state of health, psychological
functioning and social well-being.
Rehabilitation typically follows an initial phase of treatment
in which detoxification and, if required, other medical and
psychiatric treatment occurs. It encompasses a variety of
approaches including group therapy, specific behaviour thera-
pies to prevent relapse, involvement with a mutual-help
group, residence in a therapeutic community or half-way
house, vocational training, and work experience. There is an
expectation of social reintegration into the wider community.
See also: Recovery, Treatment.
Relapsea
According to the WHO Lexicon of Alcohol and Drug Terms,
“relapse” is defined as follows: a return to drinking or other
drug use after a period of abstinence, often accompanied by
reinstatement of dependence symptoms. Some writers distin-
guish between relapse and lapse ("slip"), with the latter denot-
ing an isolated occasion of alcohol or drug use.
The rapidity with which signs of dependence return is
thought to be a key indicator of the degree of drug depend-
ence.
See also: Relapse prevention.
Relapse preventiona
According to the WHO Lexicon of Alcohol and Drug Terms,
“relapse prevention” is defined as follows: a set of therapeutic
procedures employed in cases of alcohol or other drug prob-
lems to help individuals avoid or cope with lapses or relapses
to uncontrolled substance use. The procedures may be used
with treatment based on either moderation or abstinence, and
in conjunction with other therapeutic approaches. Patients are
taught coping strategies that can be used to avoid situations
considered dangerous precipitants of relapse, and shown,
through mental rehearsal and other techniques, how to mini-
mize substance use once a relapse has occurred. 
See also: Relapse.
Research evidence base
The extant published research literature that describes the
nature and strength of clinical, social and economic benefits
associated with a particular treatment modality. To say that a
treatment has a “research evidence base” is to state that its ben-
efit has been demonstrated by a number of published out-
come studies. The research evidence base is generally seen as
relating only to reports published in scientific peer-reviewed
journals, where the quality of the research undertaken can be
assured. Systematic reviews of the evidence base for a particu-
lar treatment are also published in scientific journals and by
the Cochrane Collaboration. Caution needs to be exercised
when considering the published research on a particular treat-
ment—in particular when studies vary by nation, method and
the populations treated. 
Residential treatment
Programmes that provide ancillary residential services on the
same site as treatment services. The programmes generally
strive to provide an environment free of substance abuse, with
an expectation for compliance in a number of activities such
as detoxification, assessment, information/education, coun-
selling, group work, and the development or recovery of social
and life skills.
Risk reductiona
Risk reduction describes policies or programmes that focus on
reducing the risk of harm from alcohol or other drug use. Risk
reduction strategies have some practical advantages in that
risky behaviours are usually more immediate and easier to
objectively measure than harms, in particular those harms
which have a low prevalence. For example, it may be more
practical to measure reduced sharing of needles and other
injecting equipment than indices of harm such as the inci-
dence of HIV.
See also: Harm reduction, Safer use.
Risky behavioura
In relation to drug use, risky behaviour refers to behaviours
that place persons at risk of some drug-related harm.
Although most often used in relation to behaviours, such as
sharing needles or other injecting equipment (spoon, water,
tourniquet, etc.) which place drug injectors at risk of trans-
mission of blood-borne viruses such as HIV or hepatitis C,
the term can be applied to any drug and to any risk of harm
to livelihood, relationships, legal sanctions, or health.
Safer usea
Most drugs may be used in a way in which risk of adverse con-
sequences is reduced by means of a combination of safer
preparation, low dose, safer route of administration and in
safer settings. For example, the risk of adverse consequences
from using heroin, or the extent to which a drug use episode
is life threatening, is greatly determined by whether injecting
equipment is shared; whether a new batch of heroin is tested
first in a small dose in case it is unusually pure; or whether it
is used concomitantly with other central nervous system
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depressants such as benzodiazepines and alcohol. In most
cases it is possible to identify drug-using practices which
reduce, though usually not eliminate, the risk of serious
adverse consequences.
See also: Harm reduction, Risk reduction.
Screening
A rapid procedure designed to detect individuals who have a
substance abuse problem.
Self-help group
Groups that offer programmes of recovery on a voluntary
basis principally through a twelve-step process for personal
change. Those programmes often include participation in
meetings to share histories of problems, obtain help and sup-
port from other members in dealing with challenges that have
led to relapses, and seeking a member who will serve as a
sponsor or mentor to provide help in times of crisis.
Alcoholics Anonymous (AA) and Narcotics Anonymous (NA)
make up a significant sector of the self-help groups concerned
with substance dependence, while Al-anon, Alateen and Adult
Children of Alcoholics (ACOA) attract family members try-
ing to reconcile and resolve current or past personal problems
associated with substance abuse in the family. Numerous
other groups also operate in a similar fashion within and out-
side the field of substance abuse.
Service accreditation
A system within quality assurance that indicates that a treat-
ment service or programme meets a set of organizational,
operational, clinical and professional performance standards
and relevant legal requirements for its operation. There are
currently no internationally agreed standards for service
accreditation, but a wide range of countries have developed
national standards and accreditation processes.
Shared care
A formal arrangement or cooperation between one or more
generic services (usually primary health care) and a specialist
substance abuse treatment service for the management of
patients. Shared care arrangements usually involve the transfer
of a patient receiving continuing treatment from a specialist
service to a generic service and vice versa. 
Specialist service
A social, welfare or health-care service that has the treatment of
people with substance abuse problems as its primary purpose.
Stakeholders
The set of individuals in a community with an investment or
expectation in the efficient and effective operation of a treat-
ment service or system. That can include patients, carers/fam-
ily members, treatment providers, planners and those provid-
ing financial support for service costs.
Strategic framework
A formal government policy that describes the national vision
and goals for tackling substance supply and demand. The
strategic framework provides a summary description of the dif-
ferent agencies or bodies involved, how they will operate joint-
ly and singly, the nature of resources that have been allocated
and the specific actions and objectives that are sought.
Strategic plan
An overall framework prepared at a national (and usually sub-
national) level that characterizes the nature of substance abuse
problems, the vision underpinning demand reduction and other
prevention efforts, the agencies and resources to be committed
to tacking the problem and the specific time-based goals and
objectives sought. Effective plans place considerable value on
consultation and open communication with the community
and target populations. Most strategic plans are published open-
access documents and can be accessed via the Internet.
Structured treatment
Structured treatment describes a programme of therapeutic
care that has several components that are organized in a logi-
cal or sequential way and are based on an initial patient
assessment, and personalized treatment plan. Those compo-
nents may include short and longer stay residential care and
community/outpatient settings and involve the provision of
medical and/or psychosocial interventions and/or aftercare.
Naturally, there is variation in the intensity and duration of
the components and their goals and objectives.
Substance abused
A maladaptive pattern of substance use manifested by recur-
rent and significant adverse consequences related to the
repeated use of substances. There may be repeated failure to
fulfil major role obligations, repeated use in situations in
which it is physically hazardous, multiple legal problems, and
recurrent social and interpersonal problems. 
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d Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-
IV) (Washington, D.C., American Psychiatric Association, 1994).
Substance dependenced
A cluster of cognitive, behavioural and physiological symp-
toms indicating that the individual continues use of the sub-
stance despite significant substance-related problems. There is
a pattern of repeated self-administration that usually results in
tolerance, withdrawal and compulsive drug-taking behaviour.
Substance use disordera, e
A generic term used in international systems (DSM-IV and
ICD-10) for classifying diseases for various conditions and ill-
nesses associated with the use of any psychotropic drug. It
includes both problematic and dependent drug use.
Any mental or behavioural disorder resulting from the use of
one or more psychoactive substances, whether or not med-
ically prescribed. The substances specified are alcohol, opi-
oids, cannabinoids, sedatives or hypnotics, cocaine, other
stimulants (including caffeine), hallucinogens, tobacco, and
volatile solvents. The clinical states that may occur include
acute intoxication, harmful use, dependence syndrome, with-
drawal state, withdrawal state with delirium, psychotic disor-
der, late-onset psychotic disorder and amnesic syndrome.
Substitution treatment
See: Drug substitution.
Synthetic estimation
A set of indirect methods used to determine the prevalence of
substance abuse for a specified locality using results from
existing prevalence estimates and other demographic informa-
tion for specified segments of the population.
Syringe exchange
See: Needle exchange.
Target groupsa
Groups or categories of people who are selected for special
attention by a programme or policy, for example, indigenous
peoples, single mothers, persons aged 14 to 19.
Targeted programmea
A programme designed to reach particular high-risk groups in
society, such as unemployed youth, street children and prisoners.
Therapeutic communitya
A structured environment in which individuals with drug-
related problems live while undergoing rehabilitation. Such
communities are often specifically designed for drug-depend-
ent people; they operate under strict rules, are run mainly by
people who have recovered from dependence, and are often
geographically isolated. Therapeutic communities are also
used for management of patients with psychotic disorders and
anti-social personalities. Therapeutic communities are charac-
terized by a combination of “reality testing” (through con-
frontation of the individual's drug problem) and support for
recovery from staff and peers. They are usually closely aligned
with mutual-help groups such as Narcotics Anonymous.
Tolerancea
A term for the well established phenomenon of reduced drug
effects following repeated drug administrations. Tolerance
develops fastest with more frequent episodes of use and with
larger amounts per occasion. It is useful to distinguish between
metabolic tolerance and functional tolerance. Metabolic toler-
ance arises usually as a consequence of an induction of liver
enzymes which result in the faster metabolism of a given drug
dose, thereby reducing the level and duration of blood-drug
levels. Functional tolerance refers to diminished effects of a
given blood-drug level. That is thought to occur both by virtue
of neuroadaptation, as well as by the user learning to anticipate
and accommodate intoxicating effects.
Treatmenta
According to WHO (WHO Expert Committee on Drug
Dependence Thirtieth Report, Technical Report Series) the term
“treatment” refers to “the process that begins when psychoac-
tive substance abusers come into contact with a health
provider or any other community service and may continue
through a succession of specific interventions until the high-
est attainable level of health and well being is reached”. More
specifically, treatment may be defined “… as a comprehensive
approach to the identification, assistance, ... (and) ... health
care ... with regard to persons presenting problems caused by
the use of any psychoactive substance”.
Essentially, by providing persons, who are experiencing prob-
lems caused by their use of psychoactive substances, with a
range of treatment services and opportunities which maximize
their physical, mental and social abilities those persons can be
assisted to attain the ultimate goal of freedom from drug
dependence and to achieve full social reintegration. Treatment
services and opportunities can include detoxification, substi-
tution/maintenance therapy and/or psychosocial therapies
and counselling.
Additionally, treatment aims at reducing the dependence on
psychoactive substances, as well as reducing the negative
health and social consequences caused by, or associated with,
the use of such substances.
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e Lexicon of Psychiatric and Mental Health Terms (Geneva, World Health
Organization, 1994).
Treatment protocol
A document that is a complete description of the nature of the
patients that are to be treated, the operational and organiza-
tional elements of the treatment to be provided, the staffing
and clinical methods and procedures to be followed.
Triage
The process of priority allocation or assignment of an indi-
vidual to an intervention, needed by services providing treat-
ment for substance abuse problems. 
Twelve-step groupb
A mutual-help group organized around the twelve-step pro-
gramme of Alcoholics Anonymous (AA) or a close adaptation
of that programme. AA's programme of twelve steps involves
admitting one is powerless over one's drinking and over one's
life because of drinking, turning one's life over to a “higher
power”, making a moral inventory and amends for past
wrongs, and offering to help other alcoholics. 
Urinalysisa
Analysis of urine samples to detect the presence of substances a
person may have ingested, or for other medical or diagnostic
purposes. Different drugs can be detected in the urine for dif-
ferent time periods. Heroin and amphetamines can only be
detected in the urine at most within a few days of last ingestion,
while cannabis can be detected up to several weeks after last
ingestion in persons who have been long-term heavy users. In
recent years, the analysis of saliva, blood, sweat and hair strands
has also become available for the detection of past drug use.
Vocational traininga
Training in a particular field of potential employment (for
example, computer skills) with the aim of helping clients to
improve their chances of employment and/or a better income.
Voluntary organization 
An agency whose human resources largely or wholly consist of
staff who are not paid but provide their labour or services for
free. They have tended to be agencies outside the government
sector. 
See also: Non-governmental organization.
Welfare neta
A general term to describe the constellation of social welfare,
economic supports, public health and housing services which
are available in a certain country, jurisdiction, or locality
which aim to protect people from poor health and economic
and social destruction. Usually seen as comprising health and
welfare benefits, such as health care and unemployment ben-
efit schemes, as well as government and non-government
health and welfare agencies. Often used in the context of peo-
ple who may have “fallen through the welfare net” in the sense
that they have not been “caught” by the existing government
services and schemes.
Withdrawala
A term used to refer to either the individual symptoms of, or
the overall state (or syndrome), which may result when a per-
son ceases use of a particular psychoactive drug upon which
they have become dependent or after a period of repeated
exposure. The level of central nervous system arousal and the
accompanying mood state is usually directly opposite to the
direct action of the drug.
See also: Withdrawal syndrome, Dependence syndrome.
Withdrawal syndromea
According to the WHO Lexicon of Alcohol and Drug Terms,
“withdrawal syndrome” is defined as follows: a group of symp-
toms of variable severity which occur on cessation or reduc-
tion of drug use after a prolonged period of use and/or in high
doses. The syndrome may be accompanied by signs of both
psychological and physiological disturbance.
A withdrawal syndrome is one of the indicators of a depend-
ence syndrome. It is also the defining characteristic of the nar-
rower psycho-pharmacological meaning of dependence.
See also: Withdrawal, Dependence syndrome.
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Please give us your OVERALL EVALUATION of the Guide.
Strongly Disagree Unsure Agree Strongly 
disagree agree
1.   The Guide is clearly written. ■ ■ ■ ■ ■
2.   The language style is too 
technical. ■ ■ ■ ■ ■
3.   The Guide is well-structured. ■ ■ ■ ■ ■
4.   The format is “user-friendly”. ■ ■ ■ ■ ■
5.   The material is of practical 
value. ■ ■ ■ ■ ■
6.   The Guide is relevant to 
practical work on treatment 
planning. ■ ■ ■ ■ ■
Dear readers, 
This Guide aims at offering practical, step-by-step advice for the establishment of treatment services. It is intended to
be a practical “how to” resource for all those involved in the planning, delivery, monitoring and evaluation of treat-
ment services.
Your experience in using this Guide is a very important source of feedback for refining it in the future. Please return
this feedback form to the Demand Reduction Section, UNODC.
Thank you very much in advance for your cooperation.
FEEDBACK FORM
Please mail to:
Juana Tomás-Rosselló
Treatment Adviser
Demand Reduction Section, UNODC
Vienna International Centre 
P.O. Box 500
A-1400 Vienna, Austria
PLEASE FEEL FREE TO ADD ANY COMMENTS THAT YOU WOULD LIKE TO SHARE WITH US.
General comments
Strengths
Weaknesses
Issues that require further clarification or elaboration/Additional material
Suggestions for making the Guide more practically oriented and useful
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